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ABSTRACT 
  
 Recurrent miscarriage (RM) is stressful.  One reason for this is because no 
causes can be found for the pregnancy loss in the majority of cases.  Focus has been 
on the endometrium which undergoes decidualisation in preparation for 
implantation.  Any problems in the finely organised interactions between the 
endometrium and invading trophoblast cells may contribute towards a miscarriage.  
Immunological mechanisms are thought to be one of the pathways involved as there 
is the need of maternal adaptation of her immune response to the semi-allogenic 
developing embryo.  Uterine natural killer (uNK) cells are the most abundant in the 
endometrium during the window of implantation.  They interact with trophoblast 
cells, and are involved in vascular remodelling, an important step in implantation.  
Hence, they have a biological plausibility of playing a major role in RM.  
Both peripheral NK (pNK) and uNK cells tests have been developed as assessments 
of immunological causes of RM.  A systematic review performed showed inadequate 
evidence for both pNK and uNK cells tests as markers for adverse pregnancy 
outcomes.  There were only twelve studies, with 446 patients reporting pregnancy 
outcomes. There was no accepted consensus of normality and methodology for 
analysing NK cells.  The conclusion was the need for well-designed studies to assess 
the role of NK cell tests as a clinically useful marker for screening. 
 This led to the conduct of the pilot phase of a RCT of prednisolone in early 
pregnancy in women with idiopathic RM and raised uNK cells density.  The main 
aim of this trial was to assess feasibility of recruitment and tolerability of 
prednisolone.  Secondary clinical outcomes included live birth, types of miscarriage, 
miscarriage karyotype, gestational age at delivery, birthweight and pregnancy 
complications (eg: pre-eclampsia, gestational diabetes, fetal abnormality, stillbirth, 
IUGR).  160 women were screened for uNK cells density and 40 were randomised, 
despite the majority (85%) desiring prednisolone if given a choice.  There was a 
trend towards improved live birth rate with prednisolone treatment but this was not 
significant.  There were equal numbers of biochemical, sac and fetal pregnancy 
losses in both groups.  All completed treatment with main reported side effects in the 
prednisolone group of insomnia.  There were no pregnancy complications.  The 
analysis of uNK cells was found to be very time consuming.  To accommodate 
potentially large numbers who will be screened in the definitive trial, an alternative, 
quicker and equally accurate method of analysing uNK cells was developed using 
the colour deconvolution and area measurement plug-ins of a public domain image 
analysis package, Image J.   
 Women supported this trial.  Randomisation was acceptable.  The 
prednisolone was safe.  UNK cell density is a valid biomarker of severe outcomes.  
There was a trend towards improvement in live birth rates.  This trial paves the way 
for the development of an endometrial based test to screen for the subgroup of 
women with RM that could potentially benefit from individualised treatment. 
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CHAPTER 1 – INTRODUCTION 
 
1.1 Background 
Miscarriage is the most common complication in human pregnancy.  
Recurrent miscarriage (RM), historically defined as the loss of three or more 
consecutive pregnancies before 24 weeks gestation, occurs in about 1% of fertile 
women trying to conceive, and is associated with significant psychological 
morbidity
1
.  This definition is recommended by the European Society of Human 
Reproduction and Embryology (ESHRE), but is not accepted universally
2
.  The 
definition should ideally be based on the knowledge of risk for a subsequent 
miscarriage and the probability of finding a treatable factor for the disorder after 
evaluation.  The prevalence of aetiological factors was found to be similar in those 
after two or three miscarriages, suggesting that investigations should be initiated 
after two miscarriages, challenging the classical definition of RM
3
.  The American 
Society of Reproductive Medicine (ASRM) defines RM as the loss of two or more 
pregnancies consecutively
4
.  However, this definition would increase the prevalence 
of RM to 5%, and significantly impact on the numbers that need to be evaluated. 
This heterogenous condition is associated with many pathologies, but yet 
none are found in more than 50% of couples after numerous investigations
5
.  
Recognized associations of RM include parental and foetal chromosomal 
abnormalities
6, 7
, certain structural uterine abnormalities
8
, antiphospholipid syndrome 
(APS)
9
, some thrombophilia
10
 and endocrinological disorders such as polycystic 
ovarian syndrome (PCOS)
11
.   
In cases where no known associations are diagnosed, women are termed to 
have idiopathic RM.  This is frustrating for both patients and clinicians alike, as an 
incidence of 1% is higher than the calculated incidence of a spontaneous miscarriage 
(15%
12
) occurring 3 times consecutively due to chance alone (15%
3
 = 0.3%), 
suggesting that there may be an underlying pathology for the miscarriages.  Different 
aetiologies have been proposed, with the trial of various empirical treatments, in an 
attempt to prevent the occurrence of another miscarriage.  However, research studies 
are compromised due to the inconsistencies in the definition of RM, leading to 
3 
 
variability in the initiating of evaluation and potential treatment across studies, 
creating heterogeneity. 
An immune-based aetiology is one of the proposed theories, although the 
exact mechanisms are still not fully understood.  The placenta and fetus are 
genetically different from the host mother.  This would be expected to lead to 
immune incompatibility.  Yet, in a normal pregnancy this developing ‘unit’ is 
protected from the maternal immune system.  This led to the use of numerous 
immune-modulating therapies in women with RM, without high quality evidence of 
benefit.  This thesis will focus on uterine natural killer (uNK) cells, the most 
abundant leucocytes found in the endometrium during the window of implantation.  
We will examine the feasibility of assessing the benefit of prednisolone, an 
immunosuppressive drug, to improve live birth rates in women with abnormal levels 
of uNK cells and no other recognised pathology associated with RM in a randomised 
controlled trial (RCT).  
Initially, an overview of the recognised associations of RM, and evidence on 
the available management options for these women is discussed, followed by a 
discussion on idiopathic RM.  The subsequent chapters will consider the immune 
system in the endometrium, the association of NK cells and reproductive problems, 
the pilot phase of the RCT to assess the use of prednisolone in women with 
idiopathic RM and abnormal levels of uNK cells, and an alternative method of 
quantifying uNK cells for screening in the definitive trial. 
 
 
1.2 Structural genetic defects 
1.2.1 Fetal chromosomal abnormality 
Chromosomal abnormality such as trisomy, polyploidy or monosomy in the 
miscarried pregnancy is the most common cause of pregnancy loss.  This especially 
holds true for women in the older reproductive age group.  Chromosomal anomalies 
account for up to 70% of early pregnancy losses (<12 weeks gestation), falling to 
20% when the pregnancy is lost between 13 and 20 weeks gestation
7
.  For this 
4 
 
reason, products of conception ought to be sent for karyotyping, as an abnormal fetal 
karyotype is diagnostic for the cause of miscarriage, and is an important prognostic 
factor, suggesting a successful outcome of more than 75% in the next pregnancies
7
.      
 
1.2.2 Parental chromosomal abnormalities 
Parental chromosomal abnormalities are found in about 2% of women with 
RM, with the most common being a balanced reciprocal translocation
13
.  They could 
be referred to a clinical geneticist for counselling when an abnormality is found, and 
offered prenatal diagnosis.  It is common practice to routinely perform karyotype on 
all couples with RM.  However, large case series of couples with RM and balanced 
translocation have found the risk of unbalanced translocation in the offspring to be 
less than 1%, which is less than the miscarriage rate of normal pregnancies after 
invasive prenatal diagnosis
14
.  Furthermore, these couples, if evaluated and treated 
for other related problems and offered supportive care
15
, have encouraging 
pregnancy outcomes of over 70% live birth rates in the subsequent pregnancy.  This 
is similar to couples with RM, but without chromosomal abnormalities.  Thus, 
conservative management, may be optimal, especially if women are not keen to 
undergo invasive prenatal diagnosis
13
.    
There were expectations that preimplantation genetic diagnosis (PGD) and 
assisted reproductive techniques (ART) would further improve the live birth rate for 
women with RM and balanced translocations.  However, the pregnancy rate and live 
birth rate from PGD-ART were found to be lower than natural conception
14, 16
.  
Natural conception involves the selection of normal oocytes, then the selection of 
normal pregnancy, allowing genetically abnormal pregnancies to miscarry 
inherently.  These natural selection steps are circumvented in PGD-ART, creating 
large numbers of abnormal embryos.  Furthermore, PGD is not completely accurate 
at predicting the pregnancy karyotype as not all the cells in a 4 or 8 cells embryo are 
genetically identical.  Although ART with or without PGD is not recommended in 
couples with normal karyotype
17
, consideration should be given for PGD in a 
situation if ART is needed, as observational studies show PGD-ART have better 
pregnancy outcomes, and shorter time to a successful pregnancy compared to ART 
without PGD
16
.   
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1.3  Structural uterine abnormalities 
1.3.1  Congenital uterine anomaly 
The exact contribution of congenital uterine anomaly in causing RM is 
difficult to assess, due to the vast difference in criteria and techniques for diagnosing 
abnormal uterine morphology.  However, the prevalence of congenital uterine 
anomaly, such as bicornuate, septate or arcuate uterus in women with RM is 16.7%, 
much higher compared to the general population at 6.7%
18
.  The commonest of these 
is arcuate uterine anomaly.  Advances in hysteroscopic surgery mean that these 
malformations can be corrected using a resectoscope, and laparotomy is avoided, 
reducing operative morbidity.  Observational studies have indicated that surgery 
(hysteroscopic metroplasty) reduces subsequent miscarriages and improves 
pregnancy outcomes
19-21
.  Furthermore, a systematic review of 17 observational 
studies (N=1501) assessing hysteroscopic metroplasty or septoplasty in women with 
reproductive problems (RM, 2
nd
 trimester miscarriage, infertility or pre-term labour) 
showed a pooled pregnancy rate of 60% and LB rate of 45% overall, and appears 
safe with a complication rate of only 1.9%
22
.  Thus, surgery could be considered 
after individualised counselling.  However, the women in many of these studies 
served as their own controls.  Therefore, the results of The Randomised Uterine 
Septum Transsection (TRUST) RCT evaluating the value of surgical treatment 
which was recruiting in Netherlands are awaited which may direct future 
management of congenital uterine anomalies (Netherlands Trial Register: NTR1676, 
Date of registration 18/2/2009). 
 
1.3.2 Acquired uterine anomaly 
Fibroids and intrauterine adhesions (Asherman’s syndrome), are also 
associated with RM
8
.  Observational studies of pregnancy outcomes after 
myomectomies have shown improvement in post-operative pregnancy rates, which is 
not significantly influenced by the location, size and number of fibroids
8, 23, 24
.  
Nonetheless, patients need to be adequately counselled regarding potential 
complications from surgical intervention.  In Asherman’s syndrome, surgical 
treatment is only considered after comprehensive counseling, as the benefit of 
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hysteroscopic adhesiolysis is uncertain.  Some observational studies report similar 
pregnancy loss rate in women with Asherman’s syndrome and the general 
population
25
.  Furthermore, there is the risk of adhesions reforming after treatment.   
 
 
1.4  Antiphospholipid syndrome 
RM is one of the clinical components for the diagnosis of antiphospholipid 
syndrome (APS), which is prevalent in about 15% of women with RM
9, 26
.  Even 
with adequate treatment, these are high risk pregnancies and should be monitored for 
complications in all three trimesters
27
.  Low dose aspirin (LDA), heparin, 
prednisolone and intravenous immunoglobulin (IVIG) have all been investigated as 
treatment options for this condition.  A systematic review showed that prednisolone 
and IVIG do not improve pregnancy outcomes and are associated with increased risk 
of diabetes and premature birth, but a combination of LDA and unfractionated 
heparin (UFH) reduced a subsequent pregnancy loss by 54%
28
.  Thus, LDA and 
heparin became the recommended treatment for women with RM and APS
27
.  
However, in clinical practice, low molecular weight heparins (LMWH) are preferred 
as they have reduced risk of thombocytopaenia, only need once a day administration 
and levels do not need to be monitored.  But, LMWH may not have the same effect 
compared to UFH in reducing risks of miscarriage in APS
28
.  Two RCTs have shown 
similar live birth rates of 79% in both groups, in women treated with LDA and 
LMWH, compared with LDA alone
29, 30
.  Therefore, the role of heparin in the 
treatment of APS in women with RM needs to be further investigated by looking 
into differences between UFH and LMWH to optimise treatment regimes.   
 
 
1.5  Thrombophilia 
A large group of conditions are included under the definitions of acquired 
and inherited thrombophilia, which predispose patients to thromboembolic events.  
This may partially explain the association of some of these conditions with RM.  A 
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meta-analysis of 25 studies on early pregnancy loss showed that factor V Leiden 
(FVL) mutation, activated protein C resistance (APCR) and prothombin gene 
G20210A mutation were significantly associated with RM
10
.  Treatment with LDA, 
with or without LMWH has been proposed as thromboprophylaxis to prevent 
putative placental infarcts or vascular thrombosis.  Initial studies suggest there may 
be beneficial effects of improved live birth rates for women with thrombophilia and 
RM
31
.  However, more recently, high quality, large RCTs failed to substantiate this
29, 
32
.  Thus, the evidence to support the use of LDA and LMWH treatment in women 
with thrombophilia associated RM for the sole purpose of improving pregnancy 
outcomes was weakened.  However, anticoagulant treatment could be considered if 
there was high risk of a thromboembolic event, for example in women homozygous 
for FVL mutation.  As there is still controversy about the prognostic implications of 
positive tests, and the lack of evidence based treatment, it is uncertain if all women 
with RM should be screened for thrombophilia
33
. 
 
 
1.6  Endocrine Disorders 
1.6.1  Polycystic ovarian syndrome 
The association of PCOS and RM is possibly through mechanisms of 
hyperandrogenism, obesity and insulin resistance
11
.  But, the huge variation in 
criteria for diagnosing PCOS before the availability of the Rotterdam diagnostic 
criteria makes it difficult to assess the importance and prognostic value of this 
condition in relation to RM
4
.  Small studies suggest there may be a role for 
metformin, now regarded as having low risks during pregnancy, in reducing 
miscarriage rates especially in the presence of abnormal glucose tolerance test
11, 34
.  
However, a RCT in infertile women indicated that clomiphene is superior to 
metformin in achieving live births
35
.  Whether or not this trial can be extrapolated to 
women with RM is debatable, especially if ovulation is not a problem.  Similarly, the 
benefit of ovarian drilling to improve pregnancy outcome is uncertain in the absence 
of anovulation
11
.  Nevertheless, a simple, safe and cheap way to reduce subsequent 
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pregnancy loss in obese women with PCOS is weight loss, and should be 
recommended to all
36
.   
 
1.6.2  Thyroid and glucose metabolism abnormalities 
Well controlled thyroid disorders and diabetes are not risk factors for RM.  
Thus, national guidelines do not recommend routine screening in the absence of 
symptoms
27
.  However, these are easily treatable conditions with a potential to 
improve pregnancy outcome, and therefore have been commonly requested for in 
many hospitals as part of the investigations for RM.  The association with thyroid 
antibodies is discussed later in the chapter. 
 
 
1.7  Idiopathic Recurrent Miscarriage 
Women are classified as ‘idiopathic’ or have ‘unexplained’ RM when none 
of the ‘conventional’ associations of RM are found after a series of investigations.  
This occurs in more than half of the women diagnosed with RM
3, 5
.  They have an 
excellent prognosis, up to 75% success of a live birth in future pregnancies with 
supportive care of regular ultrasound scans for reassurance, and psychological 
support in a dedicated early pregnancy assessment unit (EPAU)
37
.  There is still a 
lack of explanation for their recurring miscarriages and lack of treatment to prevent 
further miscarriages.   
This has led to the development of different theories of potential pathways 
leading to a miscarriage.  Various treatment options based on these theories have 
been attempted.  They broadly fall into categories of thrombotic, endocrinological or 
immunological factors.  The associations of these factors with RM are controversial 
as studies have shown contradictory results of association, and it is unclear if these 
relationships are causal or casual.  Similarly, treatment options addressing these 
factors are still being examined, and there is the lack of unequivocal evidence of 
benefit in reducing the risk of miscarriage in a subsequent pregnancy. 
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1.7.1  Thrombotic factors 
An explanation for the process leading to a miscarriage could possibly be of 
inflammation or thrombosis in the placental bed.  This led to the empirical use of 
aspirin and/or heparin for their anti-inflammatory and antithrombotic properties.  
Although LDA was commonly prescribed for women with idiopathic RM, there is 
currently no evidence for its use.  A recent systematic review and RCT both showed 
no benefit of LDA in improving live birth rates
32, 38
.  Similarly for heparin, a 
systematic review of five studies concluded insufficient evidence to recommend this 
treatment, even in the presence of thrombophilia, to improve live birth rates
39
.  This 
is consistent with the recent published results of two multicentre RCTs reporting that 
LMWH was not of therapeutic benefit in this group of women
32, 40
.   
 Thromboelastography (TEG), a test of whole blood haemostasis, may 
identify a subgroup of women with idiopathic RM with thrombotic abnormalities.  A 
prospective study showed that women with RM had abnormal TEG results, 
compared with parous controls, and were at an increased risk of subsequent 
miscarriage
41
.  But, it is still unclear if correcting these TEG parameters with 
antiplatelet agents will improve live birth rate and needs to be investigated in a 
prospective placebo-controlled trial. 
 
1.7.2  Endocrinological factors 
Another potential factor is the malfunction of hormones, such as 
progesterone and human chorionic gonadotrophin (hCG), which are thought to create 
a suitable endometrial environment for implantation to occur.  A condition known as 
luteal phase deficiency, diagnosed when two timed endometrial biopsy in 
consecutive cycles is ‘out of phase’ to the expected morphology of the endometrium, 
may be the result of this problem.  The process may relate to either decreased 
progesterone production by the corpus luteum, abnormal luteanising hormone (LH) 
secretion, or poor response of the endometrium to available progesterone
42
.  In view 
of this, progesterone has been empirically prescribed.  A systematic review however 
showed that progesterone treatment did not significantly reduce the risk of 
miscarriage, though a subgroup analysis of 3 small studies on women with RM 
10 
 
showed a significant decrease in the miscarriage rate
43
.  A large scale, multicentre 
RCT (Progesterone in Recurrent Miscarriages - PROMISE study) investigating 
women with idiopathic RM, to ascertain whether progesterone supplementation is 
beneficial in preventing subsequent miscarriages has recently completed recruitment 
and results are awaited
44
 (ISRCTN Number: 92644181). 
Treatments with clomiphene, with or without gonadotrophins and hCG 
injections, have also been attempted but there are no completed RCTs that have 
shown treatment efficacy
42
.  A small RCT of hCG injections found no overall 
benefit, but a subgroup analysis found an improved live birth rate with hCG in 
women with oligomenorrhoea
45
. 
High levels of prolactin may inhibit progesterone secretion and lead to 
endometrial defects
42
.  However, the role of hyperprolactinaemia in RM is unclear.  
One study showed no association of RM with hyperprolactinaemia
46
 whereas the 
only small RCT published an improved pregnancy success when women with 
hyperprolactinemia were treated with bromocriptine
47
.  So, it may be important to 
maintain normal levels of prolactin prior to pregnancy.   
 
 
1.7.3  Immunological factors 
Immunological mechanisms have been thought to play a role in RM as a 
successful pregnancy involves maternal adaptation of the immune response to the 
semi-allogenic developing embryo.  Currently, the exact mechanisms of how the 
fetus is protected from the maternal immune system during pregnancy are unknown, 
but potential defects in the immune system have been investigated.   
One aspect investigated is autoantibodies.  Autoantibodies that have been 
studied in the RM population include antiphospholipid antibodies (primarily 
anticardiolipin antibodies (ACA) and lupus anticoagulant (LA), collectively known 
as APS), antithyroid antibodies, antinuclear antibodies (ANA), and anti-DNA 
antibodies
48
.  However, the associations of most autoantibodies are weak apart for 
APS, which has been discussed earlier in the chapter.   
11 
 
Antithyroid antibodies (thyroglobulin Ab, thyroid peroxidase Ab) are more 
prevalent in women with RM compared to controls
49
.  They potentially play a role 
which could be explained by mechanisms such as an underlying maternal 
autoimmune pathology or mild thyroid failure
42
.  A systematic review of 12,126 
women showed that the presence of maternal thyroid autoantibodies is strongly 
associated with miscarriage, and there is evidence that treatment with levothyroxine 
can attenuate the risk
50
.  The results of the multicentre Randomised Controlled Trial 
of the Efficacy and Mechanism of Levothyroxine Treatment on Pregnancy and 
Neonatal Outcomes in Women with Thyroid Antibodies (TABLET RCT, ISRCTN 
Number: 15948785) evaluating the efficacy of levothyroxine treatment are awaited.  
Although the TABLET trial does not solely include women with RM, it may provide 
an indication whether treatment could improve pregnancy outcomes in women with 
antithyroid antibodies and previous miscarriages. 
Alloimmune factors such as human leucocyte antigens (HLA) compatibility 
of couples, the maternal leucocytotoxic antibodies, or maternal blocking antibodies 
have also been postulated to play a role in RM.  However, the correlation is 
controversial, and no definite associations to pregnancy outcomes have been found
51
.  
Yet, different immuno-modulatory therapies have been developed and tried on 
women with idiopathic RM, including steroids, IVIG and leucocyte immunization 
therapy (either paternal or third party donor).  A systematic review of twenty trials of 
various immunotherapies, showed no significant beneficial effect over placebo in 
improving live birth rates
52
. 
A specialized immune system is thought to exist in the endometrium, hosting 
many immune cells such as T cells, macrophages and uNK cells, and a range of 
cytokines are produced by these cells
53, 54
.  There has been significant interest in the 
interactions and functions of these cells and cytokines as potential contributing 
factors in the aetiology of RM, which will be discussed in further detail in the next 
chapter.  
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1.8  Conclusion 
 After reviewing all the recognised and potential associations of RM, it can be 
concluded that only fetal chromosomal abnormalities and APS have an established 
causal link with RM.  Observational studies of other associations with RM such as 
uterine abnormalities, thrombophilia, and PCOS have shown contradictory results.  It 
is also disappointing that more than 50% of women with RM continue to be termed 
‘idiopathic’, although it is likely that there is an underlying pathology to their 
condition.   
Ideally, assessment and investigation of a couple with RM would have the 
aim of guiding management options by finding contributory factors to the 
miscarriages, providing prognostic value in the subsequent pregnancy and directing 
treatment of proven benefit to improve live birth rates.  However, there are only few 
observational studies that give prognostic implications for positive tests for 
conditions associated with RM.  There are even fewer high quality, large scale RCTs 
that show unequivocal proven benefit of a reduction in risk of miscarriage in a 
subsequent pregnancy following treatment.   
In women with idiopathic RM, there are numerous factors, as described 
above that could potentially play a role leading to a miscarriage.  RM is a 
heterogeneous disorder.  All these factors may relate to each other, contributing in 
different mechanisms to the miscarriage.  At present, there is no conclusive 
evidence-based treatment to offer these women, and supportive care is all that can be 
recommended.  The challenge is, to develop a prognostic test that predicts pregnancy 
outcome for one of these potential associations, and can be used as a screening tool 
or marker to identify the subgroup of women with idiopathic RM, who will respond 
to treatment, and benefit from it in preventing the recurrence of another miscarriage.   
We aimed to achieve this goal by investigating the role of the endometrium, 
in the population of women with idiopathic RM.  The endometrium is very important 
as it plays the key role for the establishment and maintenance of the pregnancy.  All 
the factors discussed above may influence the growth and development of the 
endometrium, either in the pre-pregnancy phase when it decidualises and prepares 
for implantation, or in early pregnancy, when fetal trophoblast invasion occurs for 
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the establishment and nourishment of the pregnancy.  I have focused on uNK cells, 
the most abundant leucocyte found in the window of implantation and early 
pregnancy, and their potential role in RM, which is described in detail in the next 
chapter. 
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CHAPTER 2 – THE ENDOMETRIUM AND RECURRENT 
MISCARRIAGE 
 
2.1 Introduction 
A receptive endometrium is required for the implantation of the embryo, 
nurturing of the developing fetus and the success of a pregnancy.  Although the exact 
pathways are still not fully understood, the implantation process involves a series of 
finely organised and regulated interactions between immune cells in the 
endometrium and the invading trophoblast cells of fetal origin (Figure 2.1).  
Defective implantation leading to inappropriate development of the feto-placental 
unit and miscarriage may partly be explained by some of the many associations of 
RM as discussed in the previous chapter, including an immune-based aetiology.  The 
endometrium hosts a number of immune cells, and there is considerable evidence for 
the presence of a specialized immune system within the maternal part of the placenta 
which may play a role in regulating implantation
54-57
.   
 
Figure 2.1.  The endometrial trophoblast interface 
Various immune cells and cytokines in 
the uterine endometrium
Cell-cell interactions 
Invading trophoblast
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The selection failure hypothesis also exists. According to this hypothesis,  
there is the ‘failure of prevention of poor quality embryos implanting, allowing 
embryos that are destined to fail to implant and present clinically as RM’58.  
Examples include embryos with lethal genetic or chromosomal abnormalities that 
implanted too easily into the endometrium.  Therefore, a miscarriage can occur as a 
result of either an error in the implantation processes and developing feto-placental 
unit in the endometrium, rendering it ‘too hostile’, or ‘too receptive’. 
This chapter will discuss the association of the endometrium and RM from an 
immunological perspective, with emphasis on uNK cells, the most abundant 
leucocyte in the endometrium during the window of implantation. 
 
 
2.2 Methods of Endometrial Investigations  
It is difficult to study the endometrium as tissue is not easily accessible, 
especially in an ongoing pregnancy.  Thus many studies are done on animals and 
there is a tendency to extrapolate results of these studies where knowledge of the 
process is incomplete, onto humans.  There are important differences in the 
implantation process between mice, where most studies are carried out, and humans, 
and so careful interpretation of animal findings are needed.  Attention is also needed 
on certain aspects of investigating the endometrium, as detailed below. 
 
2.2.1  Timing of endometrial sampling 
 The endometrial structure and function regularly changes throughout the 
menstrual cycle
59
.  This makes chronological dating of the endometrium very 
important when it is sampled for investigations and interpretation of any findings 
needs to be correlated to the cycle.  Traditionally, the onset of menstruation was used 
as the reference point, but it is now known that a more precise reference point is 
either
60
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-  the LH surge, established by daily monitoring of LH levels through 
plasma or urine samples, or  
- follicular rupture, detected by daily follicle scanning   
The period of interest in the menstrual cycle in investigations of women with 
RM is the ‘window of implantation’, also known as the mid-secretary phase.  This is 
commonly taken as day 6 to day 9 after the LH surge
61
.   
 
2.2.2  Analysis of the endometrium 
 The endometrial sample for analysis is obtained either with a Pipelle 
endometrial sampler, or endometrial curettage.  Pipelle endometrial sampling is more 
comfortable for women, but is a ‘blind’ procedure using an inner plunger to create a 
vacuum to suction out a sample of the endometrium
62
.  The benefit of using 
curettage is knowing the exact site in the uterine cavity where the endometrial 
sample was taken from.  However,  no differences were observed in the 
endometrium sampled with a curette from different sites
61
.  Hence, Pipelle 
endometrial sampling is acceptable in acquiring tissue for investigations.  
Different techniques are available in the analysis of endometrium in women 
with RM such as morphological studies and quantitative studies through 
immunohistochemical, flow cytometric or enzyme-linked immunosorbent assay 
(ELISA) methods.  Morphological studies on the endometrium are widely based on 
the dating criteria described by Noyes et al
59
.  There are characteristic differences in 
the glands and stromal cells in the endometrium during the proliferative or secretory 
phase, timed to the menstrual cycle or LH surge
59, 60
.  This method used in studies 
has shown that some women with RM have a delay in the maturation of the 
endometrium, also known as luteal phase defect described previously
46, 63
.  
Quantitative methods employing immunohistochemical staining or flow 
cytometry of the constituents of the endometrium have also been used to investigate 
women with RM.  These methods are commonly used to quantify the leucocytes or 
expression of cytokines in the endometrium.  Leucocytes in the endometrium of 
women with RM examined with immunohistochemical staining and two-colour flow 
cytometric analysis after enzymatic digestion of the endometrium were found to 
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have a different population when compared to women with normal reproductive 
histories
64, 65
.  Immunohistochemistry is more time consuming, but it reveals the 
exact location of cells
66
.  Analysis using flow cytometry is faster, but involves 
digesting the tissue, and thereby potentially losing cells and antigens.  Furthermore, 
it needs a large sample of endometrium that may be difficult to obtain in some 
women. 
Cytokines became of interest as murine models demonstrated that pregnancy 
rejection was mediated by Th1 cytokines such as interferon (IFN)-, interleukin (IL)-
2, IL-12 and tumour necrosis factor (TNF)-β, while Th2 cytokines such as IL-4, IL-
6, and IL-10 was important for successful implantation and pregnancy
67
.  Cytokine 
profiling is commonly done using ELISA and studies have found different levels of 
cytokines in women with RM compared with fertile controls
68, 69
.  The endometrium 
is cytokine rich, produced by the array of endometrial leucocytes, but the exact 
mechanism of their involvement in RM is still not fully understood
55
.    
 
 
2.3 Endometrial leucocytes and cytokines 
 The population of leucocytes in the endometrium has been extensively 
studied and differences were found between endometrium of women with RM and 
control women with normal reproductive histories
64, 65
.  The majority consists of 
three cell types, T cells, macrophages and uNK cells, with very few neutrophils, and 
hardly any B cells.  These cells vary in number and proportions throughout the 
menstrual cycle
70
.  In the proliferative phase, leucocytes make up <10% of the 
stromal cells but they increase in numbers to comprise >20% of stromal cells 
towards the late secretory phase and to >30% in early pregnancy
66
.  This observation 
of the large increase in numbers during the window of implantation is one of the 
reasons for implicating endometrial leucocytes in playing a key role in the 
implantation process and immunological maintenance of a pregnancy.  Cells that are 
found and investigated in a non-pregnant cycle are commonly termed ‘endometrial’, 
while cells that are investigated in pregnancy are termed ‘decidual’.   
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 The three major endometrial cell types will be described, with the emphasis 
on uNK cells.  Uterine NK cells have the most dramatic rise in numbers to become 
the predominant leucocyte in the window of implantation and early pregnancy, and 
express receptors for the invading extravillous trophoblastic (EVT) tissue, with 
evidence of cell-cell interaction.  Thus, of these three, we investigated the role of 
uNK cells in RM in the thesis.  
 
2.3.1  T cells 
 T cells, all CD3
+
, comprise about 40% of leucocytes in the proliferative 
endometrium
66
.  The cell numbers remain fairly constant through the menstrual 
cycle, but there is a relative decrease in proportion due to the remarkable rise in uNK 
cells numbers in the secretory phase
66, 70
.  The numbers also hardly vary throughout 
pregnancy
71
.     
T cells express either the CD8 or CD4 antigen
71
.  CD8+ T cells are cytotoxic 
while CD4+ T cells are more cytokine producing.  CD4+ T cells are further divided 
into Th1 or Th2 type cells depending on the cytokines production profile (Figure 
2.2).  T cells are also classified according to their receptor expression, αβ+ or γδ+.  
Human endometrial T cells are mostly αβ+, where only 5-10% are γδ+71.   
Although studies in mice have shown important roles for T cells in the 
maintenance of pregnancy
67, 72
, evidence for this is not as apparent in humans
55, 73
.  
There appears to be no difference in the absolute number of T cells in the 
endometrium between women with RM and control women
64, 65
 in early pregnancy, 
deciduas between women with RM and women with normal fertility
74
, and in 
deciduas of normal pregnancies and after spontaneous miscarriage
73
.  It may be 
possible that the difference in the ratio of T cell subtypes, CD8 and CD4, or the 
balance of Th1 and Th2 cytokines that are produced by these cells, which play a role 
in the initiation or maintenance of a pregnancy. 
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Figure 2.2  Classification of T cells 
CD3+
CD 8
CD 4
T Cells
TH 1 type 
cytokines
TH 2 type 
cytokines
CD8+ cytotoxic
T cells
 
   
2.3.2  Macrophages 
 Macrophages, identified either by CD14
+
 or CD68
+
, also account for a 
substantial proportion of endometrial leucocytes
66
.  They appear to increase in 
numbers during the secretory phase and further rise in early pregnancy, although to a 
lesser extent compared to uNK cells
66
.  They are present in both 
endometrium/decidua and myometrium, and are found near spiral arteries, glands 
and extravillous trophoblast
75
. 
Functional studies have proposed a role of phagocytosis of cell debris during 
the implantation process
76
 and of immunosuppression by preventing maternal T cell 
activation in pregnancy
77
.  Endometrial macrophages also produce Th2 type 
cytokines such as IL-10, TNF-α and IL-1β, which may play a role in the regulation 
of trophoblast invasion
77
.    
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A difference in macrophage populations have been found in the endometrium 
of studies comparing women with RM and controls.  More macrophages were found 
in women with RM who subsequently miscarried compared to those who 
subsequently have a live birth
64
.  However, no differences in macrophages were 
found in deciduas of women with RM compared to controls
74
, although a trend of 
increased macrophages was found in deciduas of women with sporadic 
miscarriages
78
.   
 
2.3.3  Uterine NK cells 
Uterine NK cells form the largest group of leucocytes in the endometrium 
and are characterised by the cytoplasmic granules.  They previously had many 
names, including ‘granular endometrial stromal cell’, ‘endometrial granulocytes’, ‘K 
cells’, and ‘large granulated lymphocyte’79.  The name ‘uterine Natural Killer’ has 
been adopted as these cells share similar properties with NK cells in the peripheral 
blood, part of the innate immune system
79
.  But, they are a unique subset of NK cells 
with its own distinct antigenic features.  To date,  similar cells have not been found 
in large numbers in other organs
54
. 
All uNK cells express the CD56 antigen.  It is the intensity of CD56, and the 
lack of CD16 and CD57 antigens, typical NK cell markers that differentiate uterine 
from peripheral blood NK (pNK) cells
80
.  The density of CD56 on uNK cells is 20 
times that of the majority of pNK cells, and 80% of uNK cells are CD56
bright
CD16
-
 
80
.  Despite their name, uNK cells display only weak cytotoxic capabilities against 
target cells and probably exert their function by producing high levels of angiogenic 
growth factors (VEGF-C, placental growth factor, angiopoietin-1 (Ang-1), Ang-2 
and TGF-) and cytokines such as granulocyte-macrophage colony stimulating 
factor (GM-CSF), colony stimulating factor (CSF)-1, TNF-α, IFN-, transforming 
growth factor (TGF)-β1, leukemia-inhibitory factor (LIF) and IL-281, 82.  
There is a well-described fluctuation of uNK cells throughout the menstrual 
cycle.  In the proliferative phase, both T cells and uNK cells are scanty and of equal 
proportion, about 40% each of all leucocytes (<10% of stromal cells).  However, 
uNK cells, which are predominantly found in the stratum functionalis of the 
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endometrium, start to increase in numbers after ovulation, to encompass about 60% 
of leukocytes towards the late secretory phase, forming aggregates around spiral 
arteries and glands.  They continue to peak to >75% of leukocytes (about 30-40% of 
all stromal cells) in early pregnancy when implantation occurs
66
 (Figure 2.3).  This 
fluctuation of numbers according to the menstrual cycle suggests that their existence 
depends on hormonal regulation
53
.  In pregnancy, uNK cells are found in highest 
numbers in the decidua basalis, closest to the invading EVT at implantation.  The 
level of uNK cells in the second trimester of pregnancy is not certain as there is 
difficulty in obtaining tissue for analysis of uNK cells in this gestation, but is still 
thought to form the majority of leucocyte population
79
.  In the third trimester, uNK 
cell numbers generally decreases drastically but a substantial number remains in both 
deciduas basalis and parietalis
79
.   
 
 
Figure 2.3  Population of endometrial leucocytes in the menstrual cycle 
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The rise in uNK cells begin in the early secretary phase, regardless of the 
presence of trophoblast and before decidualisation occurs. UNK cells have been 
found to co-exist with decidua in normal pregnancy and also in ‘ectopic decidua’ in 
fallopian tube, cervix, ovary or foci of endometriosis
83
.  Furthermore, persistent 
infiltration of uNK cells was also seen in pseudo-decidualised endometrium 
associated with levonorgestrel intra-uterine devices
84
, implicating a hormonally 
regulated function of uNK cells in the initiation of the decidualisation process.  
Although exact pathways are not clear, uNK cells play important roles in early 
pregnancy of decidualisation, implantation and placentation (discussed further in 
2.3.3.2).   
There is also a role for uNK cells when implantation does not occur and the 
functional layer of the endometrium is shed at menstruation.  UNK cells undergo 
characteristic nuclear changes of apoptosis before other morphological features of 
endometrial breakdown such as neutrophil infiltration, clumping of stromal cells and 
interstitial haemorrhage.  These changes are only seen in late-secretory endometrium 
and not in normal deciduas.  Therefore the death of uNK cells could be the initial 
triggering event for mucosal breakdown and menstruation
53
.  This menstrual cycle is 
a tightly regulated ongoing process of growth and breakdown, and any changes to 
numbers or angiogenic growth factors and cytokines produced by endometrial 
immune cells, including uNK cells, can lead to benign endometrial disease such as 
menorrhagia and endometriosis
85
.   
 
2.3.3.1 Source of Uterine NK cells 
The process of how uNK cells arrive in large numbers into the endometrium 
during the late secretory phase of the menstrual cycle is still uncertain, but two main 
theories exists: 
- In-utero proliferation and differentiation of stem cells or indigenous NK 
cells in the endometrium, or 
- Recruitment of haematopoietic stem cells or NK cells from peripheral 
blood which subsequently differentiate in the uterine microenvironment 
into uNK cells phenotype   
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In-utero proliferation and differentiation 
Though CD56
bright
 cells are few in the proliferative phase, they are still 
present.  Therefore, there could be local proliferation of residual uNK cells present in 
the stratum basalis that is not shed during menstruation
79
.  Furthermore, there is an 
increase in the expression of Ki-67, a proliferative marker on uNK cells in both 
secretory phase endometrium and decidua of early pregnancy which supports this 
theory
80
.  When comparing both tissue types, maximum proliferation was seen in 
secretory phase endometrium and there was a downward trend of proliferation in 
deciduas as gestation proceeds
80
.  Although the exact pathways are unknown, 
prolactin and IL-15, under the influence of progesterone, are thought to regulate 
uNK cells proliferation and maturation in the endometrium
86
. 
The endometrium sheds every month and thus is highly regenerative.  There 
is emerging evidence for both the presence and potential functional capability of 
endometrial stem cells
87
.  Although the exact markers and roles of these stem cells 
are still under investigations, there is potential for these cells to differentiate and 
proliferate into uNK cells in the uterus.   
 
Trafficking from peripheral blood 
The alternate theory proposes the recruitment of peripheral blood cells into 
the endometrium through hormonally regulated methods via chemokines and 
cytokines.  This theory is supported by population of uNK cells that are commonly 
found to form aggregates in large numbers around spiral arteries and glands
66
.  Once 
peripheral cells are recruited, they could then differentiate into uNK cells. 
The precise mechanism of recruitment of cells from peripheral blood is still 
unknown.  UNK cells express estrogen receptor (ER)-β1 and glucocorticoid 
receptors but not progesterone receptors
88
, which is the main hormone during the 
secretory phase of the menstrual cycle.  Thus, recruitment could be potentially 
mediated directly through actions of oestrogen via the existing ER-1 receptor, 
directly through action of progesterone via yet an unidentified receptor, or through 
progesterone action on endometrial T cells and stromal cells via cytokines and 
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chemokines such as IL-15, macrophage inflammatory protein-1 (MIP-1β), vascular 
endothelial growth factor (VEGF) or CXCL10 and CXCL11
79, 86
.   
For example, IL-15, secreted by endometrial stromal cells, are distinctly 
expressed in the vascular and perivascular areas in the secretory phase endometrium 
at a higher concentration compared to the proliferative phase, and thus may serve as 
chemoattractants for recruitment of peripheral cells
89
.  There is also a strong 
correlation between cytokine levels and the number of uNK cells
89
.  Once recruited, 
IL-15 can continue to assist in its proliferation and differentiation into unique uNK 
cells
89
.  There is also a possibility that precursor immature NK cells are recruited 
from the peripheral circulation and subsequently differentiate into uNK cells in the 
endometrium
90
.    
 
2.3.3.2 Functions of Uterine NK cells 
Despite extensive studies into uNK cells, their exact roles remain undefined.  
Their temporal distribution may indicate a function in the establishment and 
maintenance of early pregnancy, as uNK cells peak during the window of 
implantation.  Human species have an invasive placenta.  When implantation occurs, 
there needs to be adequate invasion of the trophoblast to allow for good maternal 
blood supply to support the developing fetal-placental unit
53
.  There is evidence to 
imply that uNK cells play an important role in initiating decidualisation and 
regulating trophoblast invasion.  These cells are hormonally dependant and 
accumulate as a dense infiltrate at the implantation site near stromal cells, glands, 
blood vessels and trophoblast cells in early pregnancy
80
. 
 
Regulation of trophoblast invasion and growth though direct cell-cell interactions 
Trophoblast cells (consisting of syncytiotrophoblast and cytotrophoblast 
layers) constitute the fetal side of the interface between fetal and maternal tissue, and 
mediate the implantation of the embryo into the endometrium.   In-vitro studies have 
shown that EVT and uNK cells interactions occur and may regulate the maternal 
immune response to the fetal allograft
56
.   
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Both syncytiotrophoblast (outermost layer implanting into maternal tissue) 
and cytotrophoblast (inner layer of trophoblast) cells do not express classical class I 
major histocompatibility complex (MHC) alloantigens HLA-A and HLA-B, or class 
II HLA-DP, HLA-DQ and HLA-DR involved in graft rejection.  Instead, the 
invasive EVT cells express an unusual combination of non-classical class I MHC 
HLA-E and HLA-G with low expression of HLA-C
56
.  Uterine NK cells are found to 
express receptors such as killer-cell immunoglobulin-like receptors (KIR), 
immunoglobin-like transcripts (ILT), NKp and CD94/NKG2 proteins, belonging to 
two main families, the NKC (NK complex of lectin-related genes) (CD94/NKG2) 
and the LRC (leukocyte receptor complex of immunoglobulin-related genes) (KIR, 
ILT, NKp) families, which recognise all these non-classical MHC molecules 
expressed by EVT cells
56
 (Figure 2.4).  Thus, there are potential molecular 
interactions for maternal recognition of trophoblast, which results in either activating 
or inhibitory mechanisms.   
 
Figure 2.4  Activating and inhibitory receptors on uNK cells 
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The receptors on uNK cells for HLA-C are members of the KIR multigene 
family.  All women express KIRs for both group of HLA-C alleles and because 
HLA-C is polymorphic, maternal uNK cells can encounter paternal (non-self) HLA-
C alleles on trophoblast.  Each pregnancy may present a different combination of 
KIRs and HLA-C
91
.  The percentage of KIR expressed and the density of receptor 
expression also differs between individuals.  This interaction plays a physiological 
role related to immune regulation and placental development.  Obvious differences 
were observed with different combinations of polymorphic ligand-receptor pairs and 
have been associated with pre-eclampsia, a condition that is known to be secondary 
to poor trophoblast invasion
92
.  These specific fetal HLA-C/maternal KIR genotype 
combinations have also been identified in RM
93
.  
HLA-E has high affinity for CD94/NKG2 dimers on uNK cells.  The overall 
effect is inhibition of cytolysis of either maternal or fetal tissues by uNK cells
56
.  
However, uNK cells are unable to kill trophoblast even when these receptors were 
blocked by antibodies, which suggest that this interaction may regulate other 
functions besides cytolysis during implantation.  It could be that other inhibitory 
pathways exist or trophoblast lacks specific surface molecules to initiate killing
56
.   
The expression of HLA-G is almost entirely by EVT cells.  Although specific 
receptors for it are yet to be defined, HLA-G is recognised by CD94/NKG2 via co-
expression with HLA-E or by ILT-2
56
.  HLA-G has also been shown to bind to 
KIR2DL4, ILT 2 and ILT4 receptors
94
, and potentially lead to decreased sensitivity 
to NK cell mediated cytotoxicity
55, 95
.  Three polymorphisms of HLA-G have been 
investigated and found to be associated with women with RM
55
.  HLA-G interaction 
has also been shown to stimulate proliferation of uNK cells and increased production 
of IFN- and VEGF96.  Although there is evidence for uNK cells and EVT 
interaction through these MHC molecules and receptors, the final consequences of 
these interactions are still unclear. 
  
Regulation of trophoblast invasion and growth though cytokine production 
 Control of trophoblast invasion was initially thought to be via cell-mediated 
cytotoxicty as uNK cells were capable of cytolysis, although at a lesser extent than 
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their peripheral equivalent
81
.  However, as previously described, trophoblast cells are 
resistant to lysis by uNK cells.  They express non-classical HLA class I antigen, 
unless stimulated by IL-2, which is not present in the endometrium in large amounts 
in normal pregnancy.  Thus, a different mechanism had been proposed, where uNK 
cells and EVT interactions alter the profile of cytokine production, ultimately 
resulting in a change in the invasive behaviour of trophoblast
53
.  
Uterine NK cells are known to produce many cytokines such as GM-CSF, 
CSF-1, TNF-α, IFN-, TGF-β1, LIF, IL-2, and IL-10, some of which trophoblast 
cells have receptors for
82, 97
.  Thus, there could be a role for these uNK cell derived 
cytokines on trophoblast growth and differentiation, or apoptosis and defective 
invasion of the endometrium.  For example, GM-CSF has been shown to stimulate 
DNA synthesis in culture of murine trophoblast and CSF-1 increases production of 
hCG and human placental lactogen (hPL) by trophoblast.  Both these cytokines have 
also been shown to cause placental cell proliferation in mouse models
86
.  Similarly, 
IL-4, IL-6 and LIF stimulate hCG secretion by trophoblast cells
55
.  Another cytokine, 
macrophage migration inhibitory factor (MIF), produced by uNK cells and expressed 
highly in endometrium and human placenta, reduces the cytolytic capabilities of 
uNK cells
98
. 
On the other hand, IFN- has been shown to inhibit EVT invasion within 
early human pregnancy decidua both by increased EVT apoptosis and reduced levels 
of active proteases
99
.  Similarly, TNF-α impairs trophoblast invasion through 
elevation of plasminogen activator inhibitor-1 (PAI-1)
100
.  TGF-β is also known to 
affect growth and differentiation of first trimester trophoblast by inhibiting intergrin 
expression, hPL and hCG secretion
101
.  Some of these cytokines also regulate 
production of matrix metalloproteinases (MMP) -2 and MMP-9 that plays a role in 
trophoblast invasion
102
.  A recent study demonstrated that granulysin, a cytotoxic 
granule protein produced by uNK cells causes apoptosis of EVT and granulysin-
positive uNK cells can attack EVT
103
.  Therefore, any alternations in the production 
of cytokines could contribute to the imbalance of this unique fetal-maternal interface 
immune phenomena leading to abnormal implantation and the clinical presentation 
of a miscarriage. 
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In addition to direct effects of individual cytokines on trophoblast invasion, 
the patterns of cytokine release may be important.  Animal models have provided 
evidence that Th2 cytokines are favourable to pregnancy, and Th1 cytokines are 
detrimental to implantation
67
.  Although studies in humans have proved that this is 
true in normal pregnancy, the mechanisms leading to a miscarriage are more 
complicated than a simple shift in the Th1-Th2 cytokines balance
55
.  In our unit, 
when peripheral cytokines were examined before the miscarriage occurred, a lack of 
Th1-Th2 switch was not found to predict miscarriage
69
. 
 
Regulation of angiogenesis and decidual vascular remodelling 
 High numbers of uNK cells are found around blood vessels.  Whether their 
location is a reflection of trafficking cells from peripheral circulation or due to the 
possible function of uNK cells in development and remodelling of uterine spiral 
arteries is still not known.  However, early structural changes that occur in decidual 
spiral arteries, including dilatation and disorganisation, happen at the time when 
uNK cells are present, and are generally completed after 20 weeks gestation when 
uNK cells reduce in number.  The variation in numbers and time line implicate uNK 
cells function in vascular remodelling
79
. 
Uterine NK cells are found to secrete high levels of angiogenic growth 
factors important for vascular remodelling, such as VEGF-C, placental growth 
factor, angiopoietin-1 (Ang-1), Ang-2 and TGF-, in both non-pregnant 
endometrium and early pregnancy deciduas
104, 105
.  Their roles include mediating 
spiral artery transformation and destabilisation of vessel structure.  The modulation 
of vascular growth in early pregnancy is a fine interaction between these angiogenic 
growth factors and other cytokines, such as IFN-, also secreted by uNK cells105.  
Studies in mice models, where a lot of evidence for uNK cells’ involvement in spiral 
artery transformation has come from, show that mice deficient in uNK cells or IFN- 
signalling have implantation site abnormalities and failure of decidual artery 
remodelling
106
.  Uterine NK cells density was also positively correlated with the 
formation of blood vessels, lymphatics, spiral arterial smooth muscle differentiation 
and endometrial oedema in humans
107
.   
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2.3.4  Uterine NK cells and Recurrent Miscarriage 
As discussed above, it is likely that uNK cells are essential for 
decidualisation, implantation and the maintenance of pregnancy and it may be 
changes in their numbers or function that results in miscarriages.  The association 
between high uNK cell density and RM has been repeatedly reported in pre-
pregnancy endometrium
64, 108, 109
, with a further association of higher density in 
women with RM of severe phenotype
110
.  A likely function of uNK cells was 
controlling angiogenesis, and their density was found to be positively correlated with 
endometrial angiogenesis and uterine artery blood flow in women with RM
79,
 
107
.  
Similarly, sub-endometrial vascular flow was also shown to increase with higher 
uNK cells density in women with unexplained recurrent failure of IVF
111
.  Embryo 
implantation and early pregnancy development occur in a relatively hypoxic 
environment (2-3% O2)
112
.  Therefore, inappropriate blood flow to the intervillous 
space could be associated with oxidative stress damage to the developing placenta
113
.  
One theory is that increased uNK cell density is associated with increased number of 
spiral arteries which may lead to inappropriate blood flow to the developing foetal-
placental unit, causing oxidative stress and consequent miscarriage
107
. 
Studies comparing normal and miscarried early pregnancy decidua have also 
implicated uNK cells in the aetiology of miscarriage by being phenotypically 
different in these 2 groups
74, 114, 115
.  Uterine NK cells were found to be more 
numerous in the decidua of chromosomally abnormal miscarriages compared with 
chromosomally normal miscarriages
115
.  This may be due to uNK cells facilitating 
implantation of abnormal blastocysts (‘selection failure’ theory), and leading to the 
clinical presentation of miscarriage
58
.   
Although an increased density of uNK cells in pre-implantation endometrium 
has been found in women with RM compared to fertile controls
64, 108-110
, there are 
also studies that have shown no difference in the population of uNK cells in women 
with RM and controls.  However these included women with only 2 consecutive 
miscarriages
116, 117
.  It has been suggested that the significantly decreased number of 
uNK cells in controls who all have had previous live births were due to the effect of 
a previous term normal pregnancy as pregnancy and birth involved extensive 
changes in size and vascularisation of the uterus.  However, a study in our unit 
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showed that five women who had a previous birth had high uNK cells density, 
excluding the possibility that a live birth reduces uNK cells to a normal range in all 
women
110
. 
The endometrium is shed every cycle and these observations of increased 
uNK cells density were seen in one menstrual cycle.  It is uncertain if the elevated 
result is a transient or persistent phenomenon, and there is currently only one study 
which has investigated the cycle to cycle variability of uNK cells density
118
.  
Although they investigated only 10 women with reproductive problems, they found 
an overall poor agreement of uNK cells density (=0.348) in repeated endometrial 
samples.  However, there was an agreement in the classification of abnormal uNK 
results (high or low) of repeated endometrial samples 70% of the time.  This 
significant variation in different menstrual cycles needs further investigation and is a 
factor to be considered when the test is done.    
Furthermore, numbers of uNK cells may not correlate directly to function and 
the significance of these observations are still not known.  Whether high uNK cells 
density is indeed harmful to the invading trophoblast is still uncertain.  Abnormal 
uNK cells density may however serve as a marker of a reproductive pathology that is 
yet to be identified.  There is one study which suggested that high density of uNK 
cells in the mid-luteal phase predict subsequent miscarriage
64
 but a slightly larger 
study refuted this
109
.  This relationship was further explored in a systematic review 
of NK cells and pregnancy outcomes in the next chapter. 
 
 
2.4  Immunolodulation Therapy for Immunological Endometrial 
Pathology 
2.4.1  Glucocorticoids   
Glucocorticoids may influence several aspects of implantation through its 
effect on endometrial cellular proliferation, apoptosis, remodelling and trophoblast 
invasion
119
.  The subgroup analysis of a Cochrane review of peri-implantation 
steroid use in women undergoing standard in-vitro fertilisation (IVF) suggested that 
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pregnancy outcomes were improved
120
.  There have also been published case reports 
of live births after treatment with steroids in women with RM.  In Japan, a patient 
with 10 previous miscarriages had a live birth after receiving preconceptual 
steroids
121
.  In our unit, a patient with 19 previous miscarriages, and found to have 
high uNK cells density, had a successful live birth after steroid therapy
122
.   
Although uNK cells are found in high numbers during a progesterone rich 
environment for decidualisation in the late secretary phase, progesterone receptors 
have not been found on uNK cells.  Instead, uNK cells express ER-β1, and 
glucocorticoid receptors which could be directly pharmacologically manipulated 
with estrogen or steroid treatment, such as prednisolone
88
.  Indirectly, progesterone 
has been reported to exert effects on uNK cells by modulating their cytokine 
production via the glucocorticoid receptor
123
.  This is important for further 
understanding the role of uNK cells and potential treatment mechanisms during the 
implantation window.  Progesterone has also been postulated to exert its effect on 
uNK cell function through the cytokines such as IL-15, or stromal cells.    
A prospective study using 20mg prednisolone from day 1 to day 21 of the 
menstrual cycle demonstrated a reduction in uNK cells in preimplantation 
endometrium of patients with RM
110
.  In addition to reducing uNK cell numbers, 
prednisolone has been shown to reduce the degree of blood vessels maturation, 
which could be advantageous for the implanting embryo that favours a low oxygen 
environment
124
.  In the same study, prednisolone also decreased some angiogenic 
growth factor expression, important for angiogenesis, a vital process in 
decidualisation and implantation.   
The effect of glucocorticoids on uNK cells may not only be regulated by 
glucocorticoid receptors but also by the expression of steroid metabolising enzymes 
such as the 11-β hydroxyl steroid dehydrogenase (HSD) family88.  Recently, 
laboratory studies have shown defective decidualisation correlating with high uNK 
cells and a lack of 11-β hydroxyl steroid dehydrogenase type 1 in stromal cells125.  
11-β hydroxyl steroid dehydrogenase type 1 activates cortisol.  Hence, 
administration of prednisolone may overcome this deficit.  Prednisolone could exert 
its therapeutic effect through either one or a combination of the mechanisms 
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discussed and modify the endometrial environment to one more favourable for 
maintaining a pregnancy. 
It is however unclear, if reducing uNK cells density to normality with steroid 
therapy will improve pregnancy outcomes.  This could be examined in a double 
blinded, placebo controlled, randomised trial.  We described a pilot trial of this 
nature in detail in Chapter 4 of this thesis.   
 
2.4.2  Intravenous Immunoglobulin (IVIG)  
IVIG is a costly treatment of fractionated blood product of pooled 
immunoglobulin (Ig) G extracted from plasma of blood donors, which has in the 
recent decade been used to treat women with reproductive problems, including RM.  
Although the exact mechanisms of action are unknown, IVIG is thought to suppress 
and neutralize autoantibodies, reduce NK cell activity, modify cytokine production 
and inhibit complement binding and activation
126
.  A few systematic reviews have 
been performed to assess the beneficial effect of IVIG treatment in improving live 
birth rates.  Although one of the systematic reviews demonstrated a significant 
benefit in improving subsequent live births in women with secondary RM
127
, a larger 
RCT carried out thereafter challenged this conclusion as the trial found no benefit of 
IVIG treatment in idiopathic secondary RM
128
.  This was further confirmed by the 
latest systematic review addressing this topic
129
.  Thus, consideration should be 
given to seek out a marker to identify the subgroup of women with RM and 
immunological pathology, where the efficacy of IVIG treatment in these women 
subgroups can be further assessed through RCTs.  Although there are potentially 
significant side effects such as sepsis and venous thromboembolism from this 
treatment, the reviews have shown a good safety profile of its use. 
 
2.4.3  Other immunomodulation therapies 
Therapies such as 3rd party donor cell immunization, paternal cell 
immunization and trophoblast membrane infusion have previously been proposed 
and used on women with RM.  However, there is conflicting evidence as to their 
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efficacy.  A meta-analysis of trials comparing these immunotherapies has found no 
evidence of a beneficial effect over placebo in preventing further miscarriages
52
.  
These treatments are less commonly prescribed now, with the availability of newer 
treatments such as IVIG, described above, and intralipid.  
Intralipid fat emulsion infusion is a standard component of parenteral 
nutrition.  A number of studies have reported that intralipid infusion can modulate 
the immune system through suppression of NK cells cytotoxicity and pro-
inflammatory cytokines formation, and has been shown to reduce abnormal NK cells 
activity
130
.  This has led to its empiric use to improve pregnancy outcomes for 
women with abnormal NK cell parameters and reproductive problems.  It is 
considerably cheaper, and thought to be safer than IVIG as it is not a blood product.  
However, its use is still in the experimental state and there is minimal evidence about 
its efficacy in recent literature. 
 
 
2.5  Conclusion 
There is considerable evidence for a specialized immune system in the 
endometrium that potentially plays a major role in the initiation and maintenance of 
a successful pregnancy.  Uterine NK cells are the predominant immune cells during 
the window of implantation and early pregnancy, implicating an importance in the 
implantation process.  This is further strengthened by evidence of cell-cell 
interactions between uNK cells and EVT, and possible functions of uNK cells that 
play direct important roles in the process of implantation.  Alternately, uNK cell 
density may serve as a marker of an underlying endometrial or immunological 
phenomenon that leads to miscarriage.   
Immunotherapy has been empirically prescribed in an attempt to improve 
pregnancy outcomes in women with RM but systematic reviews of its efficacy have 
not shown significant benefit.  It is possible that the apparent absence of an effect of 
immunotherapy reflects the lack of a screening test to identify the subgroup of 
women that may benefit from immunotherapy.  Immunomodulation may not be a 
suitable treatment for all women with idiopathic RM.  In-vitro and in-vivo studies 
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have shown these therapies to normalise NK cell density and function.  Therefore, 
NK testing may be a suitable screening tool.   
There are studies investigating peripheral blood NK (pNK) cell and 
endometrium NK cell density and function in relation to reproductive problems as 
both have been associated with RM.  The next chapter will discuss the association of 
both pNK and uNK cells and subsequent pregnancy outcomes in women with 
reproductive problems using the method of a systematic review, to assess if a NK 
cell test can be utilized as a screening tool for poor pregnancy outcomes. 
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CHAPTER 3:  NATURAL KILLER CELLS AND PREGNANCY 
OUTCOMES IN WOMEN WITH RECURRENT MISCARRIAGE 
AND INFERTILITY: A SYSTEMATIC REVIEW 
 
3.1 Introduction 
There are two types of NK cells.  One found in the endometrium, known as 
uNK cells, has been extensively discussed, and the other is found in peripheral 
blood, known as pNK cells.  Although both pNK and uNK cells express the surface 
antigen CD56, there are significant differences between them and thus should be 
considered separate entities
86
 (Figure 3.1).  90% of pNK cells are CD56
dim
 and 
CD16
+
, while 80% of uNK cells are CD56
bright
 and CD16
-
.  PNK cells have been 
demonstrated to show significant cytotoxic activity with well established anti-viral 
and anti-neoplastic functions.  In contrast, the exact functions of uNK cells are still 
under investigations as described in detail in the previous chapter. 
Reproductive failure includes women with RM or infertility and both may 
have similar underlying pathology with endometrial receptivity.  In general, only 
30% of conceptions result in live births.  Of the other 70% where pregnancy losses 
occur, about 30% are loss before implantation, another 30% after implantation but 
before a missed period, and 10% is loss after a missed period
131
.  Pregnancy losses 
before a missed period are often not known.  It is thus possible that couples who are 
thought to be infertile have repeated conceptions lost prior to missing a period, either 
before or after implantation.  A non-receptive endometrium, manifesting as infertility 
could be one end of the spectrum of reproductive failure, compared to implantation 
then miscarrying consecutively, manifesting as RM.  Hence, both RM and infertility 
have been investigated for their association with NK cells. 
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Figure 3.1  Differences in uterine NK (uNK) and peripheral blood NK (pNK) cells 
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3.1.1  Association of NK cells and reproductive failure 
The association of NK cells and women with reproductive problems is 
complex as some studies show elevated NK cells number and activity in women with 
reproductive problems
64, 108-110, 132-137
 while others do not
116, 117, 138-142
.  There have 
been a series of case-controlled studies reporting an association between pNK cells 
number
132-134
 and activity
135, 136
 with RM and some studies that showed no difference 
in pNK cells parameters between RM and controls
138-140
.  Similarly, there have been 
case-controlled studies reporting an association between uNK cells and RM
64, 108-110
, 
but others that included women with only two miscarriages failed to find this 
association
116, 117
.    
There is also inconsistency in the association of pNK cells and uNK cells 
with infertility.  Some groups found an association of pNK cells and infertility
133, 143, 
144
 while some did not
141
.  Likewise for uNK cells, one group reported an association 
with infertility
137
 and another found no difference
142
.   
 
3.1.2  The rationale for pNK and uNK tests 
Tests examining both pNK and uNK cells number and activity have been 
offered to women with reproductive failure, occasionally as a screening method to 
identify women who may benefit from manipulation of their immune system, 
although the association between pNK and uNK cells and reproductive failure has 
not been conclusive.  
Peripheral NK cells may not reflect the condition of the endometrium where 
implantation occurs and the mechanism of how these cells can be associated with 
miscarriage is unclear.  However, how large numbers of uNK cells appear in the 
mid-secretory phase is still not known.  There are two theories: recruitment from 
pNK cells which subsequently differentiate in the uterine microenvironment into 
uNK cell phenotype through a series of organised processes; or in-utero proliferation 
and differentiation of stem cells or endogenous NK cells in the endometrium
79, 145
.  
The former is the rationale for testing pNK cells.   
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In contrast, uNK cells are resident in the endometrium and constitute 70% of 
endometrial leucocytes during the time of implantation and early pregnancy
66
.  They 
are adjacent to fetal trophoblast cells in the maternal-fetal interface and express 
receptors that recognise antigens on trophoblast cells, where cell-cell interactions 
occur
56
.  Thus, there is a biological plausibility for the role of uNK cells in 
reproductive failure. 
The strength of the association between NK cells test and reproductive 
problems would be considerably improved if the tests of pre-pregnancy NK cells 
number or activity correlate to subsequent pregnancy outcome.  Thus, we performed 
a systematic review of the current literature to ascertain the relationship of pre-
pregnancy NK cell tests results and outcomes of miscarriage, live births and 
implantation failure in women with RM and those undergoing ART.     
 
3.2 Methods 
3.2.1 Search criteria 
We searched the electronic MEDLINE database through OvidSP from 1950 
to April 2010 for published literature in all languages (Appendix 1).  The MeSH 
terms ‘Natural Killer cells’, ‘Reproduction’, and ‘Pregnancy Complications’ were 
exploded.  To identify citations relevant to NK cells, we used terms ‘CD56’, 
‘uterus’, ‘uterine’, ‘endometrial’, ‘decidual’ and ‘peripheral’.  Search terms such as 
‘abortion/miscarriage’, ‘ectopic pregnancy’, ‘fetal death’, ‘fertilisation’, 
‘insemination’, ‘livebirth’, ‘pregnancy’, ‘pregnancy outcome’ and ‘stillbirth’, in 
relation to pregnancy outcomes were under the MeSH tree of ‘Reproduction’ and 
‘Pregnancy Complications’, to retrieve all papers relevant to NK cells and 
reproductive outcomes.  The search was then limited to humans and females.  
Advice was sought from the trials search coordinator in the Cochrane Collaboration 
Pregnancy and Childbirth Group with regards to the development of the search 
strategy protocol, who advised on the terminology and methods of searching.  The 
trials search co-ordinator was not involved in the study selection of the articles, or 
data extraction. 
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The abstracts for all the citations were retrieved and assessed for their 
suitability for inclusion.  Papers that were published in other languages all had 
abstracts in English.  Original articles for abstracts that identified NK cells using the 
CD56 marker, either CD56
+
, CD56
bright
 or CD56
dim
, CD69 activation marker and NK 
cells activity measured by 
51
Chromium release cytotoxicity assay, in women with 
RM (defined as two or more consecutive miscarriages) and women with infertility 
seeking ART, and for those where relevance could not be judged from the abstract 
alone were obtained for analysis.  Additionally, the reference lists of these 
publications identified were examined for possible studies not included in the initial 
search.  The search was updated in March 2014 and the findings discussed in section 
3.6. 
 
3.2.2 Study Selection 
Inclusion criteria were studies that identified NK cells using the CD56 
marker, either CD56
+
, CD56
bright
 or CD56
dim
, CD69 activation marker and NK cells 
activity measured by 
51
Chromium release cytotoxicity assay, and investigated 
women with RM (defined as two or more consecutive miscarriages) and women with 
infertility seeking ART.   
Review articles, letters, and studies with no pregnancy outcomes reported 
were excluded after reading the abstracts by myself.  The list of publications for 
inclusion and exclusion were then reviewed by one of my supervisor SQ.  We also 
excluded studies that reported on treating women with immunotherapy such as 
prednisolone or IVIG as prednisolone reduces both uNK
110
 and  pNK
146
 cells and 
IVIG alters pNK cell parameters
147
, which may either positively or negatively affect 
the pregnancy outcome, and distort the results of this review.  Furthermore, these 
treatments are still experimental without evidence from methodologically sound 
RCTs.   
All the papers selected for detailed evaluation were read and analysed by 
myself and SQ.  Study quality was assessed using The Guidelines Manual 2009 
published by National Institute for Health and Clinical Excellence (NICE)
148
.  
Information was obtained for the inclusion and exclusion criteria of women in the 
42 
 
study, the source and method of analysing NK cells, the percentage/number and 
activity levels of NK cells, the level of normality of NK cells in the unit, and 
pregnancy outcomes. 
Publications were divided into four groups according to the source of NK 
cells and type of reproductive failure:  
- pNK cells test in RM,  
- pNK cells test in infertility,  
- uNK cells test in RM, and  
- uNK cells test in infertility.   
Pregnancy outcomes assessed were: 
- failure to get pregnant (defined as no positive pregnancy test after ART)  
- miscarriage <24 weeks gestation,  
- livebirths 
- implantation success leading to either miscarriage of <24 weeks gestation 
- implantation success leading to livebirths  
Data were extracted from texts, tables and graphs of each of the included 
studies.  Original data in our unit were reexamined by classifying the pregnancy 
outcomes according to the cut-off of 5% published in a later article
110
.  When 
appropriate, meta-analyses were performed using Review Manager (RevMan) 
Version 5.0 (Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration 2008) on studies reporting pregnancy outcomes according to pre-
determined cut-offs for normality of NK cell parameters in similar patient groups.  
Odds ratio were used to present the results of meta-analyses as this is the common 
statistical method used for systematic reviews.  In the presence of significant 
heterogeneity, random effects were used to pool the results.  The random effect 
model would take into account that the effects being estimated in each study were 
not identical and would consider these effects as if they were random.  Heterogeneity 
was evaluated statistically using I
2
, and the causes for these explored from the aspect 
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of population studied, methods of NK cells testing and outcomes measured.  We also 
wrote to the authors of the studies in an attempt to obtain data that were not 
published.  The results were reported according to the Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) Guidelines
149
. 
 
 
3.3  Results 
There were altogether 783 citations identified (Figure 3.2).  780 were from 
the search terms mentioned above, and three were from the assessment of reference 
lists of these publications.  There were no non-English language publications that 
were found to be relevant to this review.  After reading the abstracts, 756 articles 
were excluded, and 27 full text articles regarding pNK and uNK cells were retrieved.  
After detailed analysis, fifteen publications were excluded: three were letters, six did 
not report relevant outcomes
133, 134, 142, 150-152
, four reported on studies using the same 
group of women for slightly different aspects of NK cells
153-156
 and two reported 
immunotherapy use in some women
143, 157
.  A total of twelve publications met the 
criteria for analysis.  There were seven studies reporting on pNK cells (Table 3.1), 
six studies reporting on uNK cells (Table 3.2), as one study investigated both pNK 
and uNK cells.  Five publications reporting on pNK cells and two publications on 
uNK cells presented pregnancy outcomes, dichotomized into groups of high and 
normal levels of NK cell parameters, established from controls as described in the 
tables. 
Only three studies
64, 65, 109
, all investigating uNK cells, fit the definition of 
idiopathic RM where women were included after three consecutive miscarriages 
with no causes for the miscarriages found after routine investigations in their 
hospital.  Three studies on pNK cells
132, 136, 140
 and one study on uNK cells
117
 
included women after only two miscarriages, and one
132
 included women with 
known associations of RM such as endocrine disorders, APS and thrombophilia.  
The group for infertility included all women who underwent IVF treatment, 
regardless of the cause for infertility apart from one study
137
 which included women 
after three cycles of implantation failure. 
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Figure 3.2  Flow chart of the selection process of publications included in this 
review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant citations on pNK 
and uNK cells identified and screened 
for retrieval                                             
N = 783 
Studies excluded after screening as 
being unsuitable                                     
N = 756 
Full text articles retrieved for indepth 
analysis and assessed for inclusion in 
the review                                               
N = 27 
Studies excluded for these reasons: 
- Letters (N=3) 
- Did not report relevant outcomes 
(N=6) 
- Duplicated patient groups (N=4) 
- Reported immunotherapy use in 
some patients (N=2) 
Studies included in the review                
N = 12                                        
Peripheral NK cells (N=7),                            
Uterine NK cells (N=6)                                           
(1 study investigated borth pNK and uNK cells) 
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Table 3.1  Included studies investigating peripheral NK cells (7 studies) 
 
Study N Inclusion 
criteria 
Method of 
analysis 
Results 
Recurrent Miscarriage 
Aoki et al 
(1995)  
68  ≥2 
miscarriages; 
idiopathic 
RM 
  
51
Cr release 
assay  
Higher % NK activity in patients 
who miscarried 
 
Normal range – <41.8% NK 
activity determined by the mean 
+1 SD of 47 healthy controls with 
no history of miscarriages with 
pregnancy outcomes reported 
according to normal range 
 
Emmer et 
al (2000)  
142  
 
≥2 
miscarriages; 
idiopathic 
RM 
 
 
Flow 
cytometry,  
51
Cr release 
assay  
Normal range – <12% NK cells 
taken from publications by other 
groups and <322 lytic units for 
NK cells activity (no mention of 
how this was obtained) with 
pregnancy outcomes reported 
according to normal range 
 
Yamada et 
al (2003)  
113  
 
≥2 
miscarriages; 
all RM 
 
Flow 
cytometry,  
51
Cr release 
assay  
  
Higher % NK cells in miscarriage 
of normal karyotype and 
biochemical pregnancy compared 
with live birth 
 
Normal range – <16.4% CD56+ 
cells and <46% NK activity 
determined by ROC curve for 
optimal discrimination between 
miscarriage (normal karyotype or 
biochemical pregnancy) and live 
birth   
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Infertility 
Fukui et 
al (1999)  
85 NK 
cells  
 
297  
NK 
activity 
 
Patients 
undergoing 
IVF 
 
Flow 
cytometry  
  
51
Cr release 
assay  
% NK cells 
Pre-IVF cycle – No difference in 
% NK cell and subpopulation in 
women with infertility who failed 
to get pregnant and those who 
became pregnant after ART  
% NK cell activity 
Pre-IVF cycle – No difference in 
% NK cell activity in women with 
infertility who failed to get 
pregnant and those who became 
pregnant after ART; and between 
miscarriage and LB in those who 
were pregnant  
 
No normal range reported 
 
Thum et 
al (2005)  
138  
 
Patients 
undergoing 
IVF 
Flow 
cytometry  
No difference in % NK cell and 
NK cell subpopulation in women 
with infertility who failed to get 
pregnant and those who became 
pregnant after ART, and between 
miscarriage and LB in those who 
were pregnant  
 
Normal range – <12%  taken from 
publications by other groups with 
pregnancy outcome reported 
according to this normal range 
 
Matsubay
ashi et al 
(2005)  
94  
 
Patients 
undergoing 
IVF 
51
Cr release 
assay  
Higher % NK cell activity in 
women with infertility who failed 
to get pregnant and those who 
became pregnant after ART  
No difference in % NK cell 
activity between miscarriage and 
LB in those who were pregnant  
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Normal range – <44% as 
determined by the mean +1 SD of 
94 healthy, age-matched controls 
with pregnancy outcomes 
reported according to normal 
range 
 
Baczkow
ski et al 
(2007)  
58  
 
Patients 
undergoing 
IVF 
Flow 
cytometry 
 
No difference in % NK cell in 
women with infertility who failed 
to get pregnant and those who 
became pregnant after ART  
 
No normal range reported 
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Table 3.2  Included studies investigating uterine NK cells (6 studies) 
 
Study N Inclusion 
criteria 
Method of 
analysis 
Results 
Recurrent Miscarriage 
LaChapelle 
et al (1996)  
20  
 
≥3 
miscarriages; 
idiopathic 
RM  
Flow cytometry   
 
No difference in % total NK 
cells in women with 
miscarriage and ongoing 
pregnancy  
 
No normal range reported 
 
Quenby et al 
(1999)  
 
22  
 
≥3 
miscarriages; 
idiopathic 
RM 
Immuno-
histochemistry  
 
Higher % NK cells in women 
with miscarriage compared 
with LB  
 
Normal range – <5% 
determined by 75
th
 percentile 
of 18 control women who were 
attending for sterilization with 
two or more pregnancies and 
no miscarriages 
 
Michimata et 
al (2002)  
17  
 
≥2 
miscarriages; 
idiopathic 
RM 
 
Immuno-
histochemistry  
No difference in number of 
NK cells/10 high power fields 
in women with miscarriage 
and LB  
 
No normal range reported 
 
Tuckerman 
et al (2007)  
87 
 
≥3 
miscarriages; 
idiopathic 
RM  
Immuno-
histochemistry   
 
No difference in % NK cells in 
women with miscarriage and 
LB  
 
Normal range – <13.8% 
determined by the 90
th
 centile 
of 10 control women with 
regular menstrual cycle not on 
hormonal contraception 
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Infertility 
Fukui et al 
(1999)  
76  
 
Patients 
undergoing 
IVF 
Flow cytometry  No difference in % NK cells in 
women with infertility who 
failed to get pregnant and 
those who became pregnant 
after ART; and between 
miscarriage and LB in those 
who were pregnant  
Higher subpopulation of 
%CD56
bright
 NK cells in 
women who had LB compared 
to miscarriage  
 
No normal range reported 
 
Ledee-
Bataille et al 
(2004)  
15  ≥3 IVF 
cycles 
failures 
Immuno- 
histochemistry  
No difference in number of 
NK cells/100x fields in natural 
IVF cycle in women with 
infertility who failed to get 
pregnant and those who 
became pregnant after ART  
 
No normal range reported 
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3.3.1  Peripheral NK cells in reproductive failure 
All studies on pNK cells used flow cytometry to investigate the number of 
pNK cells as a percentage of lymphocytes or leucocytes depending on the panel of 
monoclonal antibodies used to identify these cells, and 
51
Cr release cytotoxicity 
assay to assess NK cell activity.   
There were three studies
132, 136, 140
 investigating pNK cells (number and 
activity) in women with RM, but only two studies included women with idiopathic 
RM
136, 140
.  Emmer et al
140
 reported pregnancy outcomes in relation to both number 
and activity of NK cells.  It is likely that the same women were tested for both 
parameters, and therefore, the results were not pooled to avoid double counting.  In 
addition, both tests are significantly different in the laboratory where cell numbers 
alone may not reflect the function or activity of pNK cells.  There was significant 
heterogeneity between the studies of pNK cell activity with I
2
=85%.  Therefore, 
random effects were used.  High pNK cells number or activity did not predict 
miscarriage in a subsequent pregnancy in women with idiopathic RM as the meta-
analysis of these studies did not reach statistical significance, although positive OR 
were found (n=22, OR 17, 95% CI 0.82-350.60; n=92, OR 2.51, 95% CI 0.16-40.29) 
(Figure 3.3).   
 
Figure 3.3  Odds of miscarriage with high pre-pregnancy peripheral NK cell 
parameters in women with idiopathic RM 
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Of the four studies
158-161
 that investigated pNK cells in women with 
infertility, only two
159, 161
 reported outcomes of implantation failure after ART, 
dichotomized into high and normal levels of pNK cells, but used different 
parameters of pNK cells number and activity.  The effect of high pNK cells number 
and activity on subsequent implantation failure is unclear (n=126, OR 0.63, 95% CI 
0.30-1.33; n=77, OR 3.13, 95% CI 1.12-8.69) (Figure 3.4).  The same two studies
159, 
161
 also reported outcomes of miscarriage after implantation success, and abnormal 
pNK cell test results did not predict subsequent miscarriage after implantation 
success (n=51, OR 1.31, 95% CI 0.37-4.68; n=28, OR 7.13, 95% CI 0.88-57.55) 
(Figure 3.5).  Results were not pooled due to the differences in techniques used to 
obtain the pNK cells test result.   
 
Figure 3.4  Odds of implantation failure after ART with high levels of pre-
pregnancy peripheral NK cell numbers and activity in women with infertility  
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Figure 3.5  Odds of miscarriage (after implantation success from ART) with high 
levels of pre-pregnancy pNK cell parameters in women with infertility  
 
 
 
Of all the studies investigating pNK cell parameters, two studies
158, 160
 did 
not report pregnancy outcomes according to a pre-determined cut-off of normality.  
Both were investigating women with infertility.  Fukui et al
158
 reported no difference 
in pre-pregnancy pNK cells number and activity between women who failed to get 
pregnant and those who became pregnant after ART, and between miscarriage and 
live birth in those who were pregnant after ART.  Baczkowski et al
160
 also found no 
difference in percentage pNK cells in these two groups of women 
 
3.3.2  Uterine NK cells in reproductive failure 
All the samples in the studies were timed from the LH surge and thus 
examined the endometrium in the implantation window of a non-conception cycle.  
Four studies
64, 109, 117, 162
 investigating uNK cells used immunohistochemistry of 
frozen or paraffin fixed sections with antibodies to CD56 to identify NK cells 
staining, and two studies
65, 158
 used enzymatic digestion of endometrium and then 
flow cytometry to identify C56
bright or dim 
cells.  Uterine NK cells results were 
presented either as an absolute count of NK cells per three
162
 and ten high power 
fields
117
 or as a percentage of total stromal cells
64, 109
.  There were no studies that 
reported pregnancy outcomes according to uNK cell activity. 
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There were four studies investigating uNK cells in women with idiopathic 
RM but only two
64, 109
 reported pregnancy outcomes according to high and normal 
levels of uNK cells.  A meta-analysis, with high heterogeneity (I
2
=69%) did not 
provide adequate evidence that high levels of uNK cells was correlated to subsequent 
miscarriage in women with RM (n=72, OR 1.33, 95% CI 0.16-11.11) (Figure 3.6).  
The two studies that did not report dichotomized pregnancy outcomes found no 
differences in mean percentage of uNK cells in women who subsequently miscarry 
and those who had live births. 
 
Figure 3.6  Odds of miscarriage with high levels of pre-pregnancy uterine NK cell 
numbers in women with idiopathic RM 
 
 
 
Two studies
158, 162
, differing in methodology to each other, investigated uNK 
cells in women with infertility.  Both did not report pregnancy outcomes according 
to a pre-determined cut-off of normality.  One included women who underwent IVF 
treatment reported NK cells as a percentage of lymphocytes.  The other included 
women with implantation failure after three cycles of IVF and reported NK cells as 
mean absolute numbers in three 100x fields.  Both reported no differences in uNK 
cells between women who failed to get pregnant and who became pregnant after 
ART.  However, the study by Fukui et al
158
 which analysed NK cells by flow 
cytometry showed a higher percentage of the subpopulation CD56
bright
 NK cells in 
women who had live births compared with women who miscarried. 
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3.4  Discussion   
This systematic review did not demonstrate sufficient evidence for the 
association of abnormal pNK and uNK cell parameters of numbers and activity with 
adverse pregnancy outcomes of miscarriage or implantation failure, in women with 
RM and infertility.   The observational studies were individually and collectively 
underpowered to answer this important question.  Assuming that, irrespective of the 
reason for NK testing, women with a normal NK cell count have a miscarriage rate 
of around 30%, one would expect an increase in miscarriage rate by at least 10% 
(33% miscarriage) when NK cells are high.  At least 376 women per group would 
have to be followed until delivery (752 in total) to test this hypothesis with 80% 
power (α=5%).  This is considerably more than the largest individual study available, 
which investigated 126 women
159
.  
It was possible that only studies suggesting an association of NK cells testing 
and poor pregnancy outcomes were published as this was the indication for offering 
these tests to women with reproductive disorders, leading to publication bias.  
However, NK cells testing were only carried out regularly in a few centres, and we 
addressed this by writing to all the authors of published literature, asking for further 
information of unpublished data.  Unfortunately, there were no replies from these 
requests.  It was not possible to carry out a funnel plot analysis to assess for 
publication or related bias in view of the small number of studies.  However, it was 
unlikely there were any unpublished research that would significantly change the 
findings of this review as a recent review published last year on this subject reported 
similar conclusions
163
. 
Odds ratio from individual studies were analysed using a random effects 
model.  In this situation, the use of either risk ratio or odds ratio, and random or 
fixed effects model would result in the same findings due to the small effect size and 
small number of studies.  However, we need to be cautious when interpreting odds 
ratio as they could overestimate or underestimate an effect size, especially when the 
effect is large.    
There was significant heterogeneity between studies in terms of variation in 
the inclusion criteria, methodology of NK cells analysis, and outcome 
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measurements.  As discussed in the introduction, there is inconsistency in the 
definition of RM, leading to differences in study population.  There were some 
studies that included women after two miscarriages and some included women after 
three miscarriages.  Similarly for infertility, there were studies that included all 
women undergoing ART, while some included women after three implantation 
failures.  Heterogeneity could also be explained by differences in NK cells analysis, 
which could be by flow cytometry or immunohistochemistry.  Furthermore, every 
study had a different cut-off of normality for NK cells as discussed further below.  
There were also variations in the outcomes measured with differences in definition 
of implantation failure and miscarriages which led to the high heterogeneity.     
 
3.4.1  Peripheral NK cells 
It has been postulated that uNK cells originate from pNK cells, which 
subsequently differentiate in the uterine microenvironment into uNK cell 
phenotype
145
.  Testing for pNK cells involves venous blood sampling at any time 
during the menstrual cycle as they have not been shown to fluctuate throughout the 
cycle
164
, or with sampling in pregnancy.  All studies used flow cytometry, the best 
method to analyse and quantify lymphocyte subsets
86
.  Investigations have been 
reported in the pre-pregnancy period, during pregnancy or on the day of embryo 
transfer in infertility patients undergoing ART.  However, only results from 
investigations done prior to pregnancy were analysed in this study as the pre-
specified aim was to assess the association of pre-pregnancy NK testing and 
subsequent pregnancy outcomes.  Further studies were planned to determine if there 
was a potential for using NK cell tests as a pre-conception screening test to identify 
and select a subgroup of women with reproductive problems for treatment.   
All three studies of pNK cells and RM included women after only two 
miscarriages which do not fit the ESHRE definition of RM
2
.  Yamada et al
132
 and 
Emmer et al
140
 investigated both pNK cells number and activity, while Aoki et al
136
 
only studied pNK activity.  Emmer et al
140
 and Aoki et al
136
 both studied women 
with idiopathic RM whereas Yamada et al
132
, the study with the largest sample size, 
included women with known associations of RM such as endocrine disorders, APS 
and thrombophilia.  Although they reported that high pNK cells number and activity 
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predicted subsequent biochemical miscarriage and miscarriage of normal karyotype, 
more than half of the women investigated had another contributing factor to their 
miscarriage, creating potential bias in the results. 
There is significant heterogeneity between studies which is not surprising 
given potentially important differences in the analysis and interpretation.  The 
determination for the cut-off of normality in different studies was through different 
methods with different control groups.  Emmer et al
140
 used <12% pNK cells 
number as normal range set by Beer et al
143
 with no explanation of how this level 
was calculated.  Yamada et al
132
 used <16.4% pNK cells number and <46% pNK 
cell activity as the normal range determined by ROC curve for optimal 
discrimination between miscarriage (normal karyotype or biochemical pregnancy) 
and live birth.  However, Aoki et al
136
 set <41.8% pNK cell activity measurement as 
normal range determined by the mean +1 SD of 47 healthy controls with no history 
of miscarriage and Emmer et al
140
 set <322 lytic unit as normal with no mention of 
how this was obtained.  The inconsistency was also seen in studies of women with 
infertility where Matsubayashi et al
161
 determined <44% pNK activity as normal 
range with controls, although age-matched, not all of proven fertility whilst Thum et 
al
159
 used <12% pNK cells number as set by Beer et al
143
.  Therefore, it is clear that 
there is lack of a commonly accepted normal range for pNK cells number and 
activity, or generally accepted type of pNK cells testing.  In addition, there were also 
differences in IVF protocols in different units and the definition for implantation 
failure or success was not mentioned in some studies
160, 161
.     
Peripheral NK cells are phenotypically and functionally different from uNK 
cells and less than 10% of pNK cells resemble uNK cells
56
.  Thus, pNK cells tests to 
gauge the state of endometrium is questionable as it may not reflect the condition of 
the endometrium where implantation occurs, and the mechanism of how these cells 
can be associated with miscarriage remains unclear.  Two recent studies have 
attempted to answer these by studying pNK and uNK cells at the same in the same 
women.  However, the results were contradictory.  The study by Park et al 
investigated pNK cells and NK cells in miscarried endometrium (decidua) in 22 
women with two miscarriages
165
.  They reported a correlation (r=0.5) between pNK 
cells and decidual NK cells.  In contrast, the other study by Laird et al
166
 
investigating 25 women with three or more miscarriages did not show a correlation 
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between pNK and uNK cells number.  Therefore, the correlation of pNK and uNK 
cells is still contentious.  With the low numbers investigated in these studies, it is 
difficult to draw meaningful conclusions. 
It is also known that pNK cells increase significantly with stress and exercise 
and this was not taken into account when blood was taken for investigation
167, 168
.  
Furthermore, the value of an abnormal test for pNK cells activity is also unknown as 
it may be a reflection of a transient stress response at the time of blood withdrawal, 
or a representation of the response to other stresses in daily life
169
.  It is unclear if 
these phenomena exist for uNK cells.  Hence, more studies investigating pNK cell 
population and function in women with reproductive problems, including pregnancy 
outcomes, are needed to assess the utility of pNK cells tests.  Currently, pNK cells 
tests should not be used to identify women for treatment except in a well-designed 
study.  
 
3.4.2  Uterine NK cells 
Uterine NK cells constitute 70% of endometrial leucocytes during the 
window of implantation in the menstrual cycle and are thought to play a role in the 
regulation of trophoblast invasion and angiogenesis
56, 79
.  Testing of uNK cells 
involves an endometrial biopsy that can only be carried out in the pre-pregnancy 
period.  All the samples in the studies were timed from the luteinizing hormone (LH) 
surge as the number of uNK cells vary through the menstrual cycle.  They are scanty 
in the proliferative phase, increasing in numbers after ovulation and through the 
secretory phase
79
.  Thus, the mid-luteal biopsy examines the endometrium in the 
implantation window, of a non-conception cycle.  Immunohistochemistry was the 
method used in most of the studies of uNK cells.  This is more time consuming than 
flow cytometry but it reveals the location of the uNK cells
66
.  Analysis using flow 
cytometry involves digesting the tissue, and thereby potentially losing cells and 
antigens.  Furthermore, it needs a large sample of endometrium that may be difficult 
to obtain in some women.    
The evidence for the association between uNK cells and adverse outcomes in 
a subsequent pregnancy is limited as two studies reported no difference in uNK cells 
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between outcomes of miscarriage and live births while the other two studies which 
reported pregnancy outcomes according to high and normal uNK cells had 
contradictory results
64, 109
.  The studies that reported no difference in uNK cell 
numbers were different to each other and are not comparable.  Michimata et al
117
 
included women after two miscarriages and used immunohistochemistry for analysis 
while LaChapelle et al
65
 included women with three miscarriages and analysed NK 
cells using flow cytometry.  Although a recent study did show a significant 
correlation (r=0.497, p=0.026) between measurements of uNK cells by methods of 
immunohistochemistry and flow cytometry, the percentages are only comparable if 
measurements of CD56+ cells by flow cytometry are expressed as a percentage of 
CD45+ cells, and not a percentage of all cells
166
.    
There was again considerable heterogeneity between the two studies that 
reported dichotomized pregnancy outcomes.  Similarly to pNK cell parameters, the 
normal ranges were obtained with different control women.  Quenby et al
64, 110
 used 
<5% uNK cells as a normal range based on the 75
th
 percentile of 18 control women 
while Tuckerman et al
109
 defined <13.8% as normal determined by the 90
th
 
percentile of ten control women.  For analysis, Quenby et al
64
 used frozen sections 
while Tuckerman et al
109
 used waxed embedded specimens with possibly different 
methods of counting the stained sections.  Uterine NK cells are not evenly 
distributed through the tissues.  Hence their density varies depending on where the 
cells are counted, either along the epithelial edge or deeper into the section, and 
whether they are assessed near to or away from glands and blood vessels.   
 Both studies investigating uNK cells in women with infertility reported no 
difference in uNK cell numbers and percentage between women who failed to get 
pregnant and those who became pregnant after ART.  However, the women included  
in the studies were different as Fukui et al
158
 included all women undergoing ART 
while Ledee-Bataille et al
162
 included women without pregnancies after three cycles 
of ART.  In addition, the method of analysis was different where one employed flow 
cytometry and the other immunohistochemistry.  Thus, the studies are not 
comparable enough to draw conclusions about the implications of uNK cells tests in 
women with infertility.  
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There is a biological plausibility for a role for uNK cells in reproductive 
failure as discussed in the previous chapter.  Uterine NK cells are most numerous in 
the implantation window and in early pregnancy
79
, they are adjacent to and interact 
with EVT cells by expressing antigens that are recognized by the receptors of these 
cells
56
 and different uNK cells population have been described in deciduas of normal 
and miscarried early pregnancy
74
.  Furthermore, uNK cells have been shown to 
regulate angiogenesis
107
, an important factor in implantation.  Hence, the rationale 
for testing uNK cell numbers.  There is controversy about the origin of uNK cells as 
some suggest they are recruited from peripheral blood.  However, a study by Park et 
al
165
 investigated chemoattractants CCL3 and CXCL12 for NK cells in the decidua 
and reported that staining intensity for these cells were not correlated to the number 
of decidual NK cells, thereby suggesting that the origin of uNK cells are not solely 
from peripheral blood.   
 
 
3.5  Conclusion 
 This review suggests that the prognostic value of measuring pNK and uNK 
cells number or activity remains uncertain as these parameters have not been shown 
to be associated with subsequent pregnancy outcome.  This finding is similar to that 
of the many conditions that have been associated with RM such as thrombophilia 
and structural uterine anomalies, none of which have been shown to clearly relate to 
pregnancy outcome.   
This may be because of the disappointingly small number of studies reporting 
clinical outcomes, on small number of women.  The inclusion criteria were also 
inappropriate in studies that investigated women after only two miscarriages.  
Furthermore, there is still no consensus on what an abnormal NK cell test result is, as 
the normal ranges in different studies are derived from different controls.    There is 
a need for more studies to investigate pNK and uNK cells population and function, 
to assess these tests as clinically useful markers in screening women with 
reproductive problems.  Ideally, future studies should be prospective, with 
appropriate inclusion criteria and have a standard methodology of analyzing and 
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reporting pNK and uNK tests results.  Sample size should also be calculated to avoid 
lack of power in the study.        
Before the availability of the results from these larger, more 
methodologically sound evaluation of prognostic value, or RCT of therapeutic 
modalities on specifically selected women with potential immunological pathology, 
women with reproductive problems should not be routinely offered NK testing
170
.  
The Cochrane review on immunotherapy for RM quotes ‘a specific assay to 
diagnose immune-mediated early pregnancy loss and a reliable method to determine 
which women might benefit from manipulation of the maternal immune system are 
urgently needed’52.   
Although the review showed that the role of uNK cells testing was uncertain, 
there were biological plausibility for a role of uNK cells in RM as discussed in 
chapter 2, and the aim of the thesis was to investigate the endometrium in women 
with RM.  Furthermore, in some units, empirical treatment was being prescribed for 
women with RM according to NK cells test results without evidence from RCTs.   
Thus, we carried out the pilot phase of a RCT investigating the value of prednisolone 
therapy in women with idiopathic RM and found to have high levels of uNK cells, to 
further assess the role of uNK cells in RM, and to explore the feasibility of a screen 
and treat trial of this nature in women with RM.  This is described in the next 
chapter.  
 
 
3.6  Updated literature review 
The updated search to March 2014 found another 241 citations.  After 
reading the abstracts, four full text articles, which investigated on pNK cells were 
analysed in detailed
171-174
.  They were no abstracts on uNK cells which were 
relevant.  After reading the full text of the four publications, one was excluded as it 
did not report pregnancy outcomes
173
 and three were found to be relevant.  Of these, 
two reported on women with infertility and one was on RM.   
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Zhou J et al
171
 investigated women underdoing ART treatment and reported 
on the numbers of a subset of pNK cells called NKT cells.  They concluded that high 
NKT cell numbers were associated with favourable pregnancy outcomes of increased 
implantation rate and live birth rate, contradicting previous reports of poor obstetric 
outcomes in abnormally high results.  The other relevant article by Chernyshov et al 
reported that high pNK cell activity (cytotoxicity) was associated with poor 
pregnancy outcomes of miscarriage
174
.  When meta-analysed together with the study 
by Matsubayashi et al, high pNK cells activity is significantly associated with the 
poor pregnancy outcome of miscarriage in women with infertility (n=86, OR 4.48, 
95% CI 1.67-12.01) (Figure 3.7).  The only report on RM was the largest study of 
this nature which investigated 552 women with idiopathic RM
172
.  Of these, 124 
(22%) women miscarried and they concluded that there was no linear relationship 
between pNK cell activity and adverse pregnancy outcomes.   
    
Figure 3.7  Odds of miscarriage (after implantation success from ART) with high 
levels of pre-pregnancy pNK cell parameters in women with infertility including 
updated study  
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 The updated search showed that measurements of pNK cells activity could 
possibly be an important marker of adverse outcomes in women undergoing ART 
and thus should be an area of important research.  There remains a scarcity of studies 
of uNK cells in women with RM in the published literature.  It is admirable that 
there was a large study (N=552) of pNK cells in women with RM which gives a 
stronger conclusion that pNK cells analysis is unlikely to have a role as a marker of 
poor outcome for women with RM.  A study of similar size should be carried out for 
uNK cells to ascertain any utility for this test. 
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CHAPTER 4 – A PILOT RANDOMISED CONTROLLED TRIAL OF 
PREDNISOLONE FOR WOMEN WITH IDIOPATHIC RECURRENT 
MISCARRIAGE AND HIGH LEVELS OF NK CELLS IN THE 
ENDOMETRIUM 
 
4.1  Introduction 
Immunomodulation therapies such as steroids, IVIG, 3rd party donor cell 
immunization, paternal cell immunization and trophoblast membrane infusion have 
been proposed as treatment for women with idiopathic RM.  However, evidence of 
their efficacies has been conflicting as previously described.  It may be the lack of a 
test that selects the subgroup of women with RM that could benefit from such 
treatment. 
From discussions in previous chapters, uNK cells may possibly play a direct 
role in the pathophysiology of RM.  The systematic review carried out to assess the 
prognostic value of uNK cells tests in RM found only four studies where two studies 
reported no difference in uNK cells between outcomes of miscarriage and live births, 
and the other two studies which reported pregnancy outcomes according to high and 
normal uNK cells had contradictory results
64, 109
.  There is a need for more studies 
assessing uNK cells as clinically useful markers in screening women with 
reproductive problems for initiating treatment.   
 
4.1.1  The effect of prednisolone on uNK cells 
Steroids were chosen as the immunomodulator agent as uNK cells express 
both glucocorticoid and ER-β receptors88 and therapeutic manipulation of these cells 
is possible.  IVIG were not considered as a systematic review has shown that this 
treatment is not beneficial in improving live births in women with RM
129
.  Although 
intralipid is also known to modulate NK cells function, they are only available as an 
infusion
130
, which is not as convenient.  Prednisolone was chosen as the steroid of 
choice as it is metabolised by the placenta to inactive prednisone and thus very little 
of the active drug (only about 10%) reaches the fetus
175
.  Prednisolone is thought to 
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be safe as it has been commonly used to treat medical conditions in pregnancy and 
has been given in the first trimester to women with asthma
176
, rheumatoid arthritis
177
 
and hyperemesis gravidarum
178
 with minimal side effects.  Although there are 
concerns of possible complications of intrauterine growth restriction and an 
association with cleft palate from animal studies, more recent studies, even with 
postnatal follow-up, have not shown such complications with prednisolone use
178, 179
.  
Furthermore, prednisolone is orally available. 
There were also case reports of prednisolone use in the situation of RM and 
yielding successful pregnancies.  A team in Japan reported prednisolone use directly 
in the uterine cavity in a woman with 10 idiopathic RM, and achieved a successful 
pregnancy
121
.  In Liverpool, one woman with 17 miscarriages was found to have 
significantly raised uNK cells.  She was given 5 mg of prednisolone pre-
conceptually.  Unfortunately, she had a further 2 miscarriages.  Subsequently, she 
was prescribed 20 mgs of prednisolone once a day both pre-conceptually and in early 
pregnancy.  On this regimen, she had a live birth
122
.   
This led to the preliminary study which assessed the normal range of uNK 
cells, and the effect of prednisolone on uNK cells
110
.  This study carried out 7 years 
ago investigated 85 women with RM and 18 women with 2 or more normal 
pregnancies (controls) for uNK cells density via a mid-luteal phase endometrial 
biopsy.  The normal range of uNK cells was defined using the upper end of the inter-
quartile range for the 18 control women.  Thus, women with more than 5% uNK 
cells were considered to have high levels.  32 (38%) women with RM had high 
levels of uNK cells.  29 agreed to take 20mg prednisolone from day 1 to day 21 of 
the menstrual cycle for 3 weeks and have a second biopsy.   In 23 (79%) women, the 
number of uNK cells decreased.  The reduction in uNK cells density was significant 
with a mean level of 14% before treatment to 9% after treatment (p=0.0004, CI 2.3-
12).  Furthermore, 3 women requested a third biopsy after a further month of 
prednisolone and in each case, the uNK cells level had fallen further suggesting that 
prolonging the steroid therapy for longer than 3 weeks further reduces the level of 
uNK cells.  None of these women reported side effects significant enough to stop the 
medication.  The next step was hence to assess if the reduction in uNK cells in the 
pre-implantation endometrium of women with idiopathic RM with 20mg of 
prednsiolone led to an improved pregnancy outcome.   
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A mode of mechanism of how prednisolone may be therapeutic is through 
the function of uNK cells in regulating blood vessel formation.  A recent study 
showed that prednisolone treatment not only reduced uNK cells density, but also 
reduced the number of matured endometrial blood vessels, and decreased some 
angiogenic growth factor expression
124
.  This may modify the endometrial 
environment to one of low oxygen tension that is more favourable for maintaining a 
pregnancy. 
 
 
4.2  Objectives of the trial 
The rationale for carrying out a double blind, RCT of prednisolone use in 
women with idiopathic RM and found to have high uNK cells density (≥5%) was to 
assess if the reduction of uNK cells density with 20mg of prednisolone therapy 
would impact on the subsequent pregnancy outcome.  This trial was intended to 
make progress towards meeting the challenge of diagnosing and treating endometrial 
immune-mediated early pregnancy loss and RM, with the primary aim to investigate 
if prednisolone use during the first trimester of pregnancy was able to reduce the risk 
of miscarriage and improve live birth rates.  
A large trial with adequate power calculation would be needed to show 
significance for an impact in clinical practice.  For this, it was essential to 
demonstrate that women were in support of attending for an endometrial biopsy to 
assess for a potential cause of RM, and their willingness for randomisation, 
potentially to placebo, when pregnant.  Prednisolone was also a medication known to 
have side effects, and it is unclear if women would comply in completing the course 
of treatment.  In view of the above, we conducted the pilot phase of the RCT to 
assess the feasibility of recruitment and randomisation, integrity of trial methodology 
and procedures, including women’s perspective of the trial.  Clinical aims of this 
pilot phase would include live birth rates, miscarriage rates, pregnancy complications 
and acceptability and safety of prednisolone treatment.  This pilot phase should also 
provide results of preliminary data for accurate power calculations for the definitive 
trial.  
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4.3  Methodology 
4.3.1  Overview of pilot trial design (Figure 4.1) 
The trial protocol was designed by my supervisor (SQ) for submission for 
ethical approval and to source for funding.  When funding was available to start the 
trial, I took up post and conducted the trial as the principal investigator, contributing 
to every step in the trial, discussed below.  Women were recruited primarily from 
Liverpool Women Hospital’s RM clinic (tertiary referral centre for Cheshire and 
Merseyside) and an endometrial research clinic (details in section 4.3.3).  Patient 
information leaflets regarding the trial were given or sent to them for consideration 
of their participation in this study when these women were first seen in the RM 
clinic, or if a referral letter to the research clinic was received (Appendix 2).  Women 
willing to participate were encouraged to ring for an appointment 6-9 days after their 
luteinising hormone (LH) surge in a cycle where they have not tried to conceive 
(patient information leaflet advised patients to get an ovulation kit and to use non-
hormonal/barrier contraception).  A trial recruitment clinic was set up in hospital to 
allow me to review women suitable for the trial.  At this appointment, a full history 
was taken and the results of previous investigations noted to ensure that there was no 
cause found for RM.  They were given a questionnaire to assess whether they 
thought they had an endometrial cause to the miscarriages, and their preference to 
medication allocation if they had an option to choose their medication rather than be 
randomised (Appendix 2).  If suitable, consent was obtained to perform an 
endometrial biopsy, which was taken in clinic with a Wallach endocell sampling 
device.  This was stored in formalin prior to being processed for analysis.  
The endometrial biopsy was analysed for uNK cell density in the laboratory 
through immunohistochemistry and image analysis (details in section 4.3.5).  The 
normal range was defined as <5% uNK cells per stromal cell using the upper end of 
the interquartile range of control patients from the preliminary study conducted 
previously.  Results of the uNK cell density were communicated to the women by 
letter and followed up with a telephone consultation.  Those with normal uNK cell 
density were advised to follow standard management, and those with uNK cell 
counts of ≥5% were advised to contact us as soon as they were pregnant to be 
considered for randomisation.  They were reviewed again when pregnant by myself 
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or SQ to ensure they fit all the inclusion criteria and to consent for randomisation 
into the trial.  
Once randomised, women were dispensed a bottle of tablets and advised to 
take four tablets a day for six weeks, then two tablets a day for one week, and one 
tablet a day in the final one week (details in section 4.3.3.2 and 4.3.4).  They were 
also given a chart to remind them of the number of tablets to take each day and 
marked off each day as they took the medication (Appendix 2).  They completed a 
diary and reported any unusual symptoms, hospital admissions or side effects that 
were severe (Appendix 2).  Both we and the women were blinded to the treatment 
allocation.   
After randomisation, women were offered an ultrasound scan every 2 weeks 
for reassurance and clinic consultations to assess side effects of treatment.  At 12 
weeks gestation, women were referred to the hospital of their choice for booking and 
consultant-led antenatal care.  At 14 weeks gestation, they were reviewed again by 
us, and all case report forms (CRF) were collected (Appendix 2).  Completed CRFs 
were given to an independent research administrator who entered the information on 
a database and kept them as confidential trial documentation.  Reports were 
generated to the data monitoring committee (DMC) as necessary.  A routine anomaly 
scan at 20 weeks gestation and growth scans at 28 and 34 weeks gestation were then 
performed in the hospital where the women have booked to deliver.  The final 
follow-up occurred 6 weeks after the delivery of the baby to assess the pregnancy 
and secondary outcomes through a clinic appointment or telephone consultation.  
 
 
 
 
 
 
 
 
 
69 
 
Figure 4.1  Patient flow during trial 
 
 
Referral letter from GP/Recurrent Miscarriage Clinic 
 
 
Patient information leaflet explaining trial sent or given to patient  
 
          Patient to ring for appointment  
       6-9 days after LH surge if  
       interested to participate  
 
STEP 1: SCREENING 
   Take history, and review RM investigations 
 
 
        If known cause of RM  
             Ineligible for trial and for usual care                  
 
If idiopathic RM (no cause found) 
Explain trial again and consent taken for screening 
                              Perform endometrial biopsy 
 
 
Biopsy analysed in laboratory for uNK cells density 
 
 
If uNK <5%      
  Ineligible for trial and for usual care      
If uNK ≥5%  
        Advise woman to contact research team when pregnant 
 
 
 
 
STEP 2: RANDOMISATION 
      Ultrasound scan performed to ensure intrauterine pregnancy  
    2
nd
 step of trial explained and consent taken for randomisation 
Randomise to either prednisolone or placebo 
    
           2 weekly reassurance  
ultrasound scan and assess 
        side effects (if any) 
 
   At 12 weeks refer for booking and consultant-led obstetric care 
At 14 weeks collect side effects diary and completed forms 
                Arrange for routine 20 week anomaly scan 
     Arrange for growth scans at 28 and 34 weeks gestation 
 
 
 
Follow up pregnancy outcome data approximately    
               6 weeks after expected due date 
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4.3.1.1  Inclusion and exclusion criteria 
The inclusion criteria for the trial were: 
- 3 or more consecutive miscarriages with no cause found after routine 
investigations (idiopathic) 
- Age less than 40 years old 
- ≥5% uNK cells density at 6 to 9 days after urinary LH surge 
The exclusion criteria for the trial were: 
- A known cause for recurrent miscarriage:  
o Parental chromosomal abnormalities 
o Uterine anomaly (bicornuate or septate uterus from ultrasound or 
cervical weakness diagnosed at hysteroscopy) 
o Antiphospholipid syndrome (positive anticardiolipin antibody or 
lupus anticoagulant on 2 separate occasion at least 6 weeks apart)  
o Thrombophilia (FVL heterozygous or homozygous mutation, APCR, 
protein C or S deficiency, prothrombin G20210A mutation, 
antithrombin III deficiency) 
o Abnormal thyroid function tests 
- Contraindications to steroid therapy such as: 
o Chronic hypertension on regular treatment 
o Diabetes on regular medication  
o Serious mental health problems requiring psychiatric services 
o Obesity with BMI ≥35 
- Decline consent to randomisation 
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4.3.1.2  Feasibility outcome 
The main outcome for the pilot phase was feasibility of recruitment, assessed by the 
willingness of women with RM to be randomised into either placebo or treatment 
arm of the trial 
 
4.3.1.3  Clinical outcomes  
Secondary outcomes for the trial included: 
- Number of babies born alive after the age of viability (24+0 weeks gestation) 
- First trimester (including number of empty gestational sacs or fetal losses) 
and second trimester miscarriages  
- Results of karyotype of miscarried pregnancies 
- Stillbirths 
- Gestational age at delivery 
- Any fetal abnormality 
- Intrauterine growth restriction (IUGR) defined as birth weight <5th centile 
according to customised birth weight charts 
- Pregnancy complications such as pre-eclampsia or gestational diabetes 
- Side effect of steroids (eg: mood changes, weight gain, increased appetite, 
indigestion, or hyperglycemia) and patient acceptability of medication 
defined as compliance to completing the course of tablets 
 
4.3.2  Sample size calculation   
Advice on pilot and feasibility studies recommended that more than 30 was a 
reasonable number
180
.  Thus, we continued recruiting women for uNK cells density 
analysis and stopped after randomising 40 women.  This was done for pragmatic 
reasons as funding allocation was limited and the randomisation list was stratified to 
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groups of 20.  Results of this pilot phase was intended to assess feasibility of 
recruitment and allow for more accurate power calculation for the definitive trial as 
preliminary power calculations were based on multiple presumptions. 
 
4.3.3  Patient recruitment into the trial 
This trial involved a two-step process where first, women need to fit the 
inclusion criteria for screening, and then further needed to have high uNK cells 
density (≥5%), before they can be considered for randomisation when pregnant.  
Thus, a large group of women need to be recruited for screening as only a small 
proportion of all women screened will eventually be randomised.  Therefore, many 
methods were used in recruitment for screening. 
 
4.3.3.1  Recruitment for screening  
Endometrial Research Clinic 
The endometrial research clinic was established by my supervisor and Chief 
Investigator (CI) of the trial, SQ.  It was designed to review women, with either 
idiopathic RM or idiopathic RIF after ART, for further management.  It was also a 
platform to inform women about relevant research projects and recruit them if they 
wished to participate.  Recruitment for screening into this trial began with women 
from this clinic a few months before I took up this post.  These women were referred 
from all over UK and Europe following national presentations, media publicity 
surrounding the publication of the case report about a successful pregnancy with 
steroid use after 19 consecutive miscarriages
122
 and evidence that prednisolone 
reduces the density of uNK cells in the endometrium
110
.   
 After the commencement of the trial, the endometrial research clinic was 
expanded to a trial recruitment clinic, and operated three times a week on a Monday, 
Wednesday and Friday to review anybody interested in the trial.  This ensured that 
an appointment was always available during the mid-luteal phase (day 6-9 after LH 
surge from urinary testing) of the menstrual cycle for any women who wished to 
have the endometrial biopsy taken and be screened for the trial.   
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Liverpool Women Hospital’s (LWH) Recurrent Miscarriage Clinic 
 Women were also recruited from the LWH’s Recurrent Miscarriage Clinic 
(RMC), the tertiary referral centre for the region.  The referral letter and hospital 
notes of every woman attending the clinic were examined to identify suitable women 
for trial screening.  Approval was obtained from consultants conducting the clinic to 
provide information to these women after clinic consultations.    
 
Trial Website – www.prednisolonetrial.org.uk 
I designed and launched an internet webpage to further improve patient 
recruitment and to provide regular updates and information on the trial (Figure 4.2).  
The availability of a trial website allowed women to have constant access to 
information relating to the trial and links to trial support groups from relevant 
websites such as the Miscarriage Association (MA).  Information available on the 
website included the rationale for the trial, process for recruitment, and contact 
details for women who were interested to participate.  The website was maintained 
until the pilot phase of the trial was completed.  
 
Figure 4.2  Homepage of the trial website 
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The Miscarriage Association (MA) website and forum 
The President of the MA of UK acted as the trial patient representative.  The 
Association showed their support by advertising the trial regularly on their website 
and newsletter.  There was a link from the MA website to the Prednisolone Trial 
website for women to get more information and contact details if they were 
interested to participate.  They also agreed to be independent advisors to women 
during the recruitment phase and throughout the trial.  There was a forum associated 
to RM (not accessible to myself or SQ) to provide support for women who had been 
recruited and those who were thinking of participating in the trial.  The forum also 
allowed for women to discuss the trial confidentially among themselves, with 
support from the MA. 
 
Early Pregnancy Units (EPU) 
The EPU was where many miscarriages are first diagnosed, and a cohort of 
these women may have RM.  In some cases, women request an alternative plan of 
‘what next’.  Thus if suitable, information leaflets about the trial were given to these 
women.  They were not expected to make any decisions, but were welcomed to make 
further enquiries through the contact details on the information leaflet.  Therefore, 
appointments were made to meet up with the person-in-charge of the EPU in all the 
surrounding hospitals in the Northwest to explain about the trial and to leave trial 
leaflets with them.  The EPU in the following hospitals were visited: Warrington 
Hospital, Macclesfield Hospital, Leigh Infirmary, Salford Hope Hospital, North 
Manchester General Hospital, Royal Oldham Hospital, Royal Bolton Hospital, 
Leighton Hospital, Whiston Hospital, Tameside Hospital, Ormskirk Hospital, 
Chester Hospital, Arrowe Park Hospital, and St Mary’s Manchester.  
A Northwest Early Pregnancy Regional Meeting was held annually.  This 
was organised for the 13
th
 of July 2009 and was taken as an opportunity for an 
educational update on NK cells, a chance to inform all the attendees about the 
existence of this RCT, answer any queries relating to it, and to encourage 
recruitment.   
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Media Publicity  
Although there were no intentions for it, there was massive media hype after 
the publication of the case report and journal article about the effect of prednisolone 
in reducing uNK cells.  This was followed by a surge of telephone calls of interest 
from women with idiopathic RM and demonstrated the power of media services.  It 
was inevitable that media publicity became one of the means for informing the 
public about the existence of this RCT.   
SQ presented about the potential use of steroid in idiopathic RM and the 
existence of this on-going RCT in the British Association (BA) Festival of Science 
Conference in September 2008, which was reported as a news article in The Times 
newspaper.  This was followed by an increase in recruitment for screening, and 
October 2008 saw the highest number of women screened per month in the entire 
recruitment period of the pilot phase of this trial.  Similarly a few months later, 
recruitment for screening increased after an appearance of SQ and a trial participant 
on Granada News on ITV, highlighting the importance for more studies into 
treatment for idiopathic RM. 
 
4.3.3.2  Recruitment for randomisation 
Women meeting the inclusion criteria for randomisation had a transvaginal 
ultrasound performed in the trial clinic as soon as possible after a positive pregnancy 
test.  If a viable intrauterine pregnancy between 4-8 weeks gestation was found, then 
a second consent was obtained for randomisation to either 20mg of prednisolone or 
placebo.  20mg was chosen as this was the dose that resulted in a live birth for a 
previous patient
122
, and the dose that demonstrated a reduction in uNK cells density 
in a previous study
110
.  They were then dispensed the tablets accordingly from 
pharmacy and reviewed in the clinic every 2 weeks for reassurance scans.  Tablets 
were taken in the first trimester for 8 weeks after a confirmed pregnancy, as the aim 
was to improve the implantation process which was completed after the first 
trimester.  If the initial ultrasound scan was inconclusive, women had serial serum β-
hCG to exclude an ectopic pregnancy, and were recruited for randomisation only 
after β-hCG results has confirmed an ongoing intrauterine pregnancy.  Prednisolone 
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was tapered off at the end of the treatment regime to allow for the adrenal glands to 
readjust and prevent steroid withdrawal symptoms. 
 
 
4.3.4  Randomisation and Blinding 
4.3.4.1  Sequence generation 
Once consent was obtained, women were assigned consecutive study 
numbers.  A dedicated pharmacist for the trial dispensed the tablets, either the active 
treatment (prednisolone) or placebo to the women according to her study number.  
This study number was paired to a pre-constructed randomisation list by a 
computerised random number generator in blocks of 20.  Stratified sampling was not 
considered in the randomisation process as the population studied were already a 
selected group (uNK cells ≥5%) of women with RM, and sample size was small.  
Stratification would create difficulties in interpreting results as there would be 
smaller numbers in each group, and possibly make recruitment even more difficult.  
The randomisation list was only available to the dedicated pharmacist for the trial.  
 
4.3.4.2  Blinding 
This was designed as a double blinded RCT where both we and women did 
not know whether they were on the active or placebo tablets.  Both prednisolone and 
placebo tablets were similar in size, colour and dispensed in identical packaging.  
The active tablets consisted of 5 mgs of prednisolone (manufactured by Wockhardt 
UK Ltd), and the placebo (manufactured by Quay Pharmaceuticals) was an inert 
substance specially made to be identical to the placebo.  Each bottle given to the 
women were identical and contained 189 tablets of either 5mg prednisolone or 
placebo.   
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4.3.4.3  Mechanism of unblinding 
 
All women randomised in the trial kept a trial ID card where contact details 
of the hospital were available, to get in touch with either the CI or principal 
investigator (PI)  in the event of an emergency where the trial group allocation 
needed to be identified.  The CI or PI could then authorise the pharmacy department 
to unblind the group in severe illness where the attending physician needed to know 
whether the women had been allocated steroids.  The DMC was also able to unblind 
these groups if necessary.    
 
 
4.3.5  Laboratory methods for processing and analysing endometrial biopsies 
The laboratory methods for processing and analysing of uNK cells density 
were already established from previous studies investigating the function of uNK 
cells
107
.  The normal range of uNK cells for our laboratory had also been determined 
to be <5% in a previous study
110
.  Currently, there is no universally accepted method 
for investigating uNK cells although ideally, laboratory methods should be 
standardised.  While I was not involved in the development of the method used to 
analyse uNK cells density, I performed nearly all the laboratory analysis on the 
endometrial samples for the trial, with the assistance of 2 other laboratory personnel. 
 
4.3.5.1  Tissue preparation 
The endometrial biopsy taken from the women was immediately transferred 
to the laboratory to be fixed in formalin.   The specimen was then dehydrated, 
cleared and impregnated with paraffin wax using the automated Shandon Citadel 
1000 processing machine (manufactured by Thermo Electron Corporation, Runcorn, 
UK).  The total processing time was 18¾ hours, and therefore was always run 
overnight.  Processing involved a rotation through these solutions for the duration: 
- 4% formalin in neutral buffer (45 minutes), 60% Ethanol (1 hour), 70% 
Ethanol (1 hour), 90% Ethanol (1 hour), 100% Ethanol (1 hour), 100% 
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Ethanol (1 ½ hours), 100% Ethanol (2 hours), Xylene 1 (1 hour), Xylene 2 (1 
½ hours), Xylene 3 (2 hours), Wax 1 (2 ½ hours), Wax 2 (3 ½ hours) 
The cassette with the endometrial biopsy was then filled with wax, cooled and stored 
as paraffin blocks in the freezer.  
3 µm sections from the paraffin blocks were cut, mounted on APES coated 
glass slides and air-dried overnight.  Each slide consisted of 2 endometrial samples 
from the same women.  The sample on top was for incubating with the antibody for 
analysis, and the sample at the bottom served as a negative control.  They were then 
baked overnight at 37
o
C in racks.  The next day, samples were then dewaxed and 
rehydrated through xylene followed by alcohol in the following manner: 
- Xylene (10 minutes) 
- Xylene (10 minutes) 
- 100% alcohol (5 minutes) 
- 100% alcohol (5 minutes) 
- 90% alcohol (1 minute) 
- 70% alcohol (1 minute)  
The slides in racks were then submerged in water prior to antigen retrieval. 
 
4.3.5.2  Antigen retrieval 
 Heat induced epitope retrieval (HIER) was carried out by boiling the slides in 
citric acid buffer to break any protein cross-links, and unmasking the antigens and 
epitopes in the tissue sections.  The buffer was prepared fresh with 3.15g of citric 
acid in 1500mls of distilled water.  The pH was adjusted to 6 by adding in 2M 
Sodium Hydroxide (NaOH). 
 The citric acid buffer was then boiled in a pressure cooker.  Once the buffer 
was bubbling, the slides were inserted and pressure cooked for 1 minute.  After that, 
they were immediately cooled under running tap water.     
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4.3.5.3  Immunohistochemical staining with CD56 antibody 
 The slides were then transferred to a staining dish and washed in TBS (Tris 
buffered saline) solution prepared either on the day of immunohistochemical staining 
or the day before, for 5 minutes.  TBS was made by mixing 12g Trizma base and 
17.4g Sodium Chloride (NaCl) in 2000mls of distilled water.  The pH was adjusted 
to 7.6 by adding in Hydrochloric Acid (HCl). 
Endogenous peroxidase activity was quenched by incubating the slides in 
0.3% peroxidase block (30% H202 diluted to 1:100 with TBS) for 10 minutes.  
Thereafter, the slides were washed twice (5 minutes x2) in TBS solution.  The 
endometrial specimens on the slides were then circled using a DAKO hydrophobic 
marker to define the staining area containing the antibody.  All slides were then 
washed in TBS for another 5 minutes.  Then, slides were removed from the staining 
dish and placed in a humidified chamber. 
All the antibodies used for incubation were diluted using 0.5% BSA solution 
(10% BSA diluted to 1:20 with TBS).  The primary antibody used to detect uNK 
cells was CD56 (diluted to 1:50, NCL-L-CD56-1B6, Novocastra, Milton Keynes, 
UK).  IgG mouse antibody (diluted to 1:100, MCA928, Serotech, Kidlington, UK) 
was used as the negative control.  A positive control slide from a patient known to 
have high uNK cells, and an IgG mouse negative control was used for every slide 
undergoing immunohistochemistry to ensure no false negative or false positive 
staining.  50l of CD56 antibody was pipetted onto each section on the top, and 50l 
of IgG mouse antibody was pipette onto each section at the bottom (negative 
control), and incubated in the humidified chamber for 60 minutes at room 
temperature.  
 After 60 minutes, the slides were washed twice (5 minutes x2) in TBS 
solution.  Next, a drop of HRP-labelled polymer (supplied with EnVision System 
reagent kit) which was conjugated with secondary antibodies was applied onto the 
sections and incubated for 30 minutes in the humidified chamber at room 
temperature.  The slides were then washed twice (5 minutes x2) again in TBS to 
remove excess polymer.  Staining for CD56 (uNK cells) was completed with 
incubation of sections in 3’3-Diaminobenzidine (DAB) chromagen solution for 10 
minutes at room temperature to give a brown coloured reaction.  After 10 minutes, 
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the slides were then immediately immersed in tap water to stop further reaction.  The 
nuclei were then counterstained with Gill 2 haematoxylin for 90 seconds, and rinsed 
in tap water until clear.  The slides were then dipped in acid alcohol and rinsed again 
under running water until cells were blue.  The intensity of haematoxylin was 
checked, and the slides were re-counterstained if staining was found to be too faint.  
The sections were then dehydrated through alcohol and xylene in the following: 
- 70% alcohol (1 minute) 
- 90% alcohol (1 minute) 
- 100% alcohol (3 minutes) 
- 100% alcohol (3 minutes) 
- Xylene (5 minutes) 
- Xylene (10 minutes) 
Finally, the slides were mounted with Consul mount (Thermo Fisher Scientific).  
The positive control slide was checked under a wet microscope for DAB colour 
development (Figure 4.3).  The slides were then left to dry overnight in a fume hood.  
They were all then checked for adequate staining intensity the next day.  If DAB 
staining was too faint, the endometrial sample was prepared again for repeat staining.  
 
Figure 4.3  DAB staining of CD56 positive uNK cells under the microscope   
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4.3.6  Image analysis for determination of uNK cell density 
The method for image analysis for uNK cells density had also already been 
developed for previous studies on uNK cells.  However, I was involved in the 
validation of digital image analysis for uNK cells density.  Digital image analysis 
was shown to markedly reduce the inter-observer error as compared with manual 
counting
181
.  Thus, a combination of manual and digital counting was used to 
determine uNK cells density for all the samples analysed in the trial.  Digital 
counting was performed by Image J, an image analysis software developed by 
National Institutes of Health (NIH) which is freely available for public use 
(http://www.rsbweb.nih.gov/ij/download.html)
182
.  
UNK cells density was established by averaging the results of 10 images of 
endometrial stained sections for each woman.  Each result was the manual 
calculation of CD56 positive stained cells (uNK cells) in proportion to digital 
calculation of total stromal cells (CD56
+
 and CD56
-
 cells) using the formula:  
             ____Number of uNK cells__        x 100% 
                 Total number of stromal cells 
 
 
4.3.6.1  Image capture and editing 
10 high-powered fields (HPF) (x40 magnification) images were captured 
from different areas along the epithelial edge of the stained endometrial sections for 
analysis.  Images were captured using a Nikon DS-Fi1 digital camera Head 5M 
pixel, and Nikon Eclipse 50-i Microscope with the software NIS-Elements-F, 
developed for Nikon instruments.  All images were captured on the following 
settings: 
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Mode – Normal 
Resolution – 640 x 480 (fast focus) 
          1280 x 960 (quality capture) 
AE lock on 
Exposure – Mode – Auto exposure 
AE comp +1.0 EV - +1.6 EV 
Colour – Contrast – High 
Sharpness – High 
 
 
These images were then edited with Adobe Photoshop CS2 or CS3 (Adobe, 
San Jose, USA).  First, the glandular epithelial cells and blood vessels were removed 
electronically by encircling these structures with the ‘Magic Lasso’ tool and deleted.  
Next, the brown DAB and non-specific background staining were removed by 
selecting them using the ‘Eyedropper’ or ‘Magic Wand’ tool.  The threshold for stain 
intensity and area to be removed were adjusted according to the area and darkness of 
DAB stain in each image, and deleted.  These steps were done to ensure that the 
edited image consisted only of nuclei of stromal cells, which were used as the 
denominator for assessing uNK cells density (Figure 4.4).  
 
4.3.6.2  Counting of uNK and stromal cells 
 Uterine NK cells were manually counted by totalling the number of blue-
stained nuclei surrounded by cytoplasmic brown-stained DAB to the CD56 antibody.  
Positively identified uNK cells were digitally marked with a cross using the ‘point 
picker’ function on Image J, and summed at the end (Figure 4.5).  This was more 
reproducible and accurate as compared with the conventional method of counting 
across the microscope
181
. 
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Figure 4.4  Edited image after removing, glands, blood vessels and DAB 
 
 
 
Figure 4.5  UNK cells marked with a ‘point picker’ 
 
 
84 
 
The counting of total stromal cells was performed using the ‘Analyze 
Particles’ tool in Image J on the edited image of only blue nuclei.  The plugin was set 
at the following parameters for each nucleus to be digitally counted (Figure 4.6): 
Particle size: 36-2250 
Circularity: 0.3-1 
 
This edited image was then merged with the corresponding original image for 
visually checking that outlines of analysed particles matched with cell nuclei, 
clusters of cells were split properly, DAB and background staining were not 
calculated as cells and large cells were not split into multiple cells (Figure 4.7). 
The total stromal cells count was then recorded, and used as the denominator 
for the total uNK cells count obtained manually and applied to the formula above.  
The above steps were repeated 10 times for each woman and averaged, to obtain the 
uNK cells density for that woman.      
Intermittently, the images were double counted by another observer to ensure 
that the uNK results were consistent, especially when there was borderline result.  
For each observer, Bland-Altman plots were produced to ensure that there were no 
systematic differences in uNK or stromal cell counts between observers.   
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Figure 4.6  Edited image of outlines of nuclei digitally counted  
 
 
Figure 4.7  Merged image of nuclei outlines and original image  
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4.3.7  Trial management and monitoring structure   
4.3.7.1  Ethical and Regulatory Issues 
Approval to conduct the trial was granted from the Liverpool Local Research 
Ethics Committee and MHRA.  The trial was included in the National Institute for 
Health Research (NIHR) Clinical Research Portfolio (NIHR CRN ID: 6567) and was 
registered with the European and international clinical trials database (EUDRACT 
No: 2005-003307-36, ISRCTN28090716).  
Apart from the monitoring of pregnancy with ultrasound and side effects of 
medication as described above, any events reported were assessed in terms of their 
seriousness, causality and expectedness.  A serious adverse event or adverse event 
(SAE/AE) report form was completed by the CI or PI and submitted to the relevant 
committees if the side effect was deemed serious (Appendix 2).  If it was a suspected 
unexpected serious adverse reaction (SUSAR), then reporting was expedited 
accordingly 
 
4.3.7.2  Trial management bodies 
A data monitoring committee (DMC) independent of the trial investigators 
was appointed for the trial to provide independent review of unblinded data at agreed 
intervals to ensure that no harm was being caused by the treatment.  Particular 
emphasis was placed upon monitoring the side effects of steroids, fertility rate and 
pregnancy complications.  They also addressed issues such as: 
- Significant problems with trial design or methodology 
- Recruitment rate 
- Patient’s acceptance of the possibility of randomisation to placebo 
The first DMC meeting occurred after 36 women were randomised into the 
trial in May 2010.  The chair of the DMC then reported to the Trial Steering 
Committee (TSC) approximately 2 weeks after the meeting in accordance with 
recommended trial oversight. 
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A TSC and trial management group (TMG) supervised and managed the trial 
and was responsible for approving the core protocol and any subsequent 
amendments.  The TMG met every 4-6 months to discuss:  
- recruitment rate and patient acceptability of the trial 
- side effect of steroids 
- case report forms (CRF) 
- problems arising from the trial 
The TMG reported the above and presented possible solutions to problems or 
strategies to improve recruitment, to the TSC who met when deemed necessary by 
the CI.  The accuracy of CRFs to the case notes were intermittently checked by the 
sponsors of the trial at random.  There was also double entry data management to 
minimise human error.   
 
4.3.8  Data Analysis  
Data was cleaned prior to any analysis.  As this was the feasibility phase of 
the trial, the proportion of women who screened positive with high uNK cells 
density and returned for randomisation into the trial was recorded.  Their willingness 
for randomisation was assessed by the questionnaire and proportion randomised.  
Demographic information for all women screened was tabulated.  Similarly, 
summary statistics for information relating to the allocation groups of women who 
were randomised were tabulated and examined to assess whether both treatment and 
placebo groups were similar. 
Clinical outcomes of live birth rate in each group were expressed as a risk 
ratio with 95% confidence intervals.  Other outcomes such as the rates of 
miscarriage, type of miscarriage (biochemical, sac or fetal loss), karyotype of 
miscarried pregnancies, gestational age at delivery, mode of delivery and pregnancy 
complications were tabulated.  Compliance to medication and side effects of steroids 
were evaluated.  All adverse events were also noted according to allocation group. 
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4.4  Results 
4.4.1  Feasibility of patient recruitment   
In the two year period, a total of 160 women were screened for the trial and 
72 (45%) women had ≥5% uNK cells and were eligible for randomisation.  It was 
not possible to assess the true recruitment rate as information of the trial were widely 
disseminated and it is unknown how many women were approached.  The majority 
of women who attended for screening were informed of the trial through the 
consultant who was in charge of their care for RM, and thus referred to the 
endometrial research clinic.  It was also clear that publicity of the trial through public 
events impacted on the recruitment for screening.  October 2008 saw the highest 
number of women screened per month after publication of a news article in The 
Times which reported on the presentation by SQ about the potential use of steroid in 
idiopathic RM and the existence of the on-going RCT, in the British Association 
(BA) Festival of Science Conference in September 2008 (Figure 4.8).  
About half (78/160, 49%) of women screened were given and completed a 
questionnaire to ask if they think they had the pathology, and if given a choice 
whether they wanted the active medication, placebo or had no preference.  53 (68%) 
women thought they had an endometrial immune cause for the RM, and thus 
attended for assessment.  There was little relationship between the patient’s 
perception of their result and their actual result: 23 of 53 (43%) who thought they 
had high uNK cells density did so and 7 of 17 (41%) who thought they had normal 
uNK cells density did so.   
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Figure 4.8  Number of women screened and randomised each month     
 
 
 
Overall, 85% (66/78) of women wanted prednisolone treatment if they were 
given an option (Figure 4.9).  This finding was not unexpected as these women 
commented on the questionnaire that their desire for a live birth far outweighed side 
effects and potential risk from any empirical treatment.  Of those wanting active 
medication, 27 (41%) were found to have high uNK cells and 18 (67%) were 
randomised.  11 (14%) women had no preference for either group and 4 (36%) were 
found to have high uNK cells.  Of these, 2 (50%) were randomised.  Only one 
woman preferred to have placebo, due to fear of side effects from prednisolone.  She 
was found to have high uNK cells density, and returned for randomisation when 
pregnant.  Thus, the response to randomisation was good (66% overall of women 
eligible for the trial), despite the wish for active treatment in the majority of women 
screened.  
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Figure 4.9  Women’s perspective of the trial 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.1.1  Study population of women screened for the trial 
 160 eligible women were screened for uNK cells density (Table 4.1).  Of 
these, 72 (45%) were found to have ≥5% uNK cells, and were suitable to be 
randomised.  Eighty-eight women were informed of the normal results and 
discharged back to the referring clinician for standard care.  Of the 32 women with 
≥5% uNK cells and not randomised, 14 conceived but declined randomisation and 3 
decided to seek assisted reproduction.  15 women did not contact the clinic again 
pregnant before the trial was stopped (Figure 4.10).  The demographic 
characteristics of women were similar in those screen positive (≥5% uNK) and those 
screen negative.  It was interesting to note that there were no difference in the 
miscarriage rate in women with normal or high levels of uNK cells (Table 4.1).   
 
 
66 (85%) preferred 
steroids 
78 completed questionnaire 
11 (14%) had no 
preference 
1 (1%) preferred 
placebo 
27 (41%) had                            
≥5% uNK cell density 
18 (67%) randomised 2 (50%) randomised 1 (100%) randomised 
4 (36%) had                            
≥5% uNK cell density 
1 (100%) had                            
≥5% uNK cell density 
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Table 4.1  Baseline characteristics of women screened for the trial (N=160)  
Characteristics <5% (N = 88) ≥5% (N = 72) 
Age in years (Mean (SD)) 34 (3.8) 34 (4.5) 
% UNK (Median (Range)) 2.8 (0.4-4.7) 7.1 (5-23) 
Previous live birth                                
(Number of women (%)) 
26 (30%) 15 (21%) 
Number of previous miscarriages  
(Median (range)) 
4 (3-14) 
 
4 (3-15) 
Number of previous fetal loses  
(Median (range)) 
1 (0-5) 1 (0-5) 
Number of previous losses of empty sac 
(Median (range)) 
3 (0-13) 3 (0-12) 
Previous 2
nd
 trimester miscarriage  
(Number of women (%)) 
2 (2.3%) 5 (6.9%) 
Previous cctopic pregnancy 
(Number of women (%)) 
7 (8%) 6 (8.3%) 
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Figure 4.10  Trial flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
160 women with idiopathic RM 
were screened for uNK cells 
density 
72 (45%) found to have ≥5% 
uNK cells density 
 
40 Randomised 
20 Randomised to 
Prednisolone 
20 Randomised to 
Placebo 
88 (55%) found to have <5% 
uNK cells density and were 
ineligible for randomisation 
32 not randomised 
- 14 were pregnant and 
declined randomisation 
- 3 decided for assisted 
reproductive techniques 
(ART) 
- 15 did not contact the clinic 
again 
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4.4.1.2  Study population of women randomised into the trial  
 The baseline characteristics of all women randomised were similar in both 
groups (Table 4.2).  The mean age at randomisation was 33 years, with a mean BMI 
of 26.  The mean uNK cells density for all randomised women was 7.7%.  The 
characteristics of the pregnancy at randomisation were also similar. 
 
4.4.2  Clinical outcomes  
 The live birth rate was 60% in the prednisolone group and 40% in the 
placebo group, but this did not reach statistical significance (RR 1.5, 95% CI 0.79-
2.86) (Table 4.3).  The gestational age at delivery was similar between both groups 
(272 days (prednisolone) and 279 days (placebo)).  Similarly, the mean birth weight 
was comparable (3522g vs 3547g), with no pregnancy complications of IUGR (<5
th
 
centile) or macrosomia.  There were also no reports of gestational hypertension, pre-
eclampsia or gestational diabetes in either group.  There were no adverse fetal 
outcomes.  One baby in the prednisolone group had post-natally detected mild 
hearing problems and one baby in the placebo group had ante-natally detected renal 
tract abnormalities.  Both the admissions to neonatal unit (NNU) were for 
observation.  The baby from the prednisolone group had mild jaundice and 
hypoglycaemia and the baby in the placebo group was treated with antibiotics due to 
the renal tract abnormality.  Both babies were discharged home with the mother.   
There were 8 (40%) miscarriages in the prednisolone group and 12 (60%) 
miscarriages in the placebo group (Table 4.3).  They were all first trimester 
miscarriages, with similar number of biochemical, sac and fetal losses in both 
groups.  Karyotypes of 6 miscarriages were obtained, 3 in each group, and 67% were 
normal.  Products of conception (POC) were not readily available for the other 
miscarriages as most women chose to have either conservative or medical 
management of the miscarriage.   
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Table 4.2  Baseline characteristics of women randomised (N=40) 
 
Patients randomised 
Prednisolone 
(N=20) 
Placebo 
(N=20) 
Total 
(N=40) 
Age in years (Mean (SD)) 34 (4.6) 33 (3.6) 33 (4.1) 
% UNK cells  (Mean (SD)) 8.3 (4.2) 7.2 (3.5) 7.7 (3.8) 
BMI (kg/m
2
) (Mean (SD)) 26.1 (4.3) 25.6 (3.4) 25.8 (3.8) 
Previous live birth (Count (%)) 4 (20) 3 (15) 7 (17.5) 
Number of previous miscarriages 
(Median (Range)) 
4 (3-8) 4 (3-15) 4 (3-15) 
  Fetal Losses (Count (%)) 20 20 40 
     0 10 (50) 5 (25) 15 (37.5) 
     1 4 (20) 8 (40) 12 (30) 
     2 2 (10) 4 (20) 6 (15) 
     > 2 4 (20) 3 (15) 7 (17.5) 
 Biochemical/Sac Losses (Count (%)) 20 20 40 
     0 0 0 0 
     1 2 (10) 2 (10) 4 (10) 
     2 5 (25) 5 (25) 10 (25) 
    >2 13 (65) 13 (65) 26 (65) 
2
nd
 T Misc (Count (%)) 0 2 (10) 2 (5) 
Previous Ectopics (Count (%)) 1 (5) 2 (10) 3 (7.5) 
 
Current pregnancy in trial 20 20 40 
Folic Acid intake 20 19 39 
    -400 mcg 15 17 32 
    -5 mg 5 2 7 
Aspirin intake 4 5 9 
Sac present at randomisation 15 17 32 
FH present at randomisation 3 1 4 
 
 
 
95 
 
Table 4.3  Clinical outcomes of women randomised into the trial 
 
 Prednisolone 
(N = 20) 
Placebo     
(N = 20) 
Relative Risk 
(95% CI) 
Live Birth (%) 12 (60) 8 (40) 1.5 (0.79-2.86) 
Delivery at <37 weeks (%) 1 (8.3) 0 3.00 (0.13-69.52) 
Vaginal Delivery (%) 3 (25) 4 (50) 0.75 (0.19-2.93) 
Caesarean Section Delivery (%) 9 (75) 4 (50) 2.25 (0.83-6.13) 
     - Elective CS 2 1  
     - Emergency CS 7 3  
Birth Weight (g) (mean) 3522 3547 - 
Admission to Neonatal Unit (%) 1 (8.3) 1 (8.3) 1.00 (0.07-14.90) 
Miscarriages (%) 8 (40) 12 (60) 0.67 (0.35-1.27) 
   - Biochemical Loss 2 1  
   - Sac Loss 2 3  
   - Fetal Losses 4 6  
           Normal karyotype 2 2  
           T22 1 1  
   - Pregnancy of unknown 
location 
0 1  
   - Ectopic (tx with methotrexate) 0 1  
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4.4.3  Acceptability of trial medication  
Side effects were more commonly reported in women in the prednisolone 
group compared with the placebo group (Table 4.4).   However, none were severe 
enough for women to stop taking medication and all completed treatment.  Women 
were advised to discontinue treatment when a miscarriage was confirmed.  Despite 
the fact that women were advised to take the tablet early in the morning, the most 
common side effect was insomnia (RR 7, 95% CI 0.9-51.0).  There were no reports 
of bruising or infection.  In the diaries that were kept, 8 women in the prednisolone 
group reported additional side effects.  2 women reported increased appetite, 1 
headache and hallucinations, 1 reported palpitations, 1 reported hirsutism, 1 had 
worsening of her irritable bowel syndrome, and 2 complained of nausea.  In the 
placebo group, 4 complained of additional side effects (2 headache and 2 bloating). 
 
Table 4.4  Side effects profile of women randomised in the trial 
Side effects        
(Count (%)) 
Prednisolone 
(N=20) 
Placebo      
(N=20) 
Relative Risk  
(95% CI) 
Acne 5 (25%) 2 (10%) 2.5 (0.5-11.4) 
Bruising 0 0 - 
Flushing 4 (20%) 3 (15%) 1.3 (0.3-5.2) 
GI problems (Reflux) 5 (25%) 3 (15%) 1.6 (0.4-6) 
Infections 0 0 - 
Insomnia 7 (35%) 1 (5%) 7.0 (0.9-51.0) 
Joint pain 0 2 (10%) 0.2 (0.01-3.9) 
Mood changes 3 (15%) 2 (10%) 1.3 (0.3-8) 
Others  8 (40%) 4 (20%) 2.0 (0.7-5.9) 
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4.4.4  Adverse events 
There were no unexpected events that led to the need for unblinding of trial 
medication.  Both ectopic pregnancies that required methotrexate management were 
reported as serious adverse events and file notes were recorded.  Both completed 
treatment and had no other complications. 
 
4.4.5  Laboratory analysis 
It was reassuring to know that there has been consistently about 40% of 
women with RM that were found to have uNK cells density of ≥5% in different 
cohorts of women with RM recruited for different studies in this laboratory
110
.  This 
demonstrated the reliability and reproducibility of our method of analysis.  We have 
also intermittently performed double counts on random samples to ensure 
consistency in the analysis for the trial.  The mean difference was <0.5% uNK cells 
density between myself and another observer in the laboratory, and there were no 
systematic errors in the analysis (Figure 4.11). 
 
Figure 4.11  Bland-Altman plot of uNK cells density between myself and another 
observer with a mean difference of <0.5%   
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4.4.6  Post-hoc analysis 
It was observed that women who miscarried in the trial appeared to have 
higher uNK cells density, regardless of trial medication (Figure 4.12).  This was 
however not statistically significant (p=0.3) (Figure 4.13). 
 
Figure 4.12  Distribution of uNK cells density of women randomised 
 
 
 
Figure 4.13  UNK cell density and pregnancy outcomes of women on the trial 
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4.5  DISCUSSION    
4.5.1 Feasibility of recruitment and acceptability of trial medication 
This pilot trial has demonstrated that it was possible and acceptable to 
women to conduct a stratification and treatment trial based upon uNK cell density in 
a reasonable time period, allowing for new approaches to the management of RM to 
be developed.  We did not seek for a particular sample size but advice on pilot 
studies recommended that more than 30 was a reasonable number
180
.  Thus, we 
stopped after randomising 40 women for pragmatic reasons as the randomisation list 
was stratified to groups of 20 and funding was limited.  The limitation of funding 
also meant that it was not possible to follow up the obstetric outcomes of all the 
women screened, and important information was lost.   
From the questionnaire that was completed by the women who attended for 
screening, 68% (53/78) thought they had an underlying endometrial immune 
pathology, which could have been the reason for them to participate in screening.  
There were however no correlation between the women’s perception of immune 
pathology and the result of the uNK cell density.  Of those who completed the 
questionnaire, 32 (41%) were screened positive. 84% (27/32) of them desired active 
medication if given an option.  Despite this, the majority (66%) self-referred when 
pregnant and consented to randomisation.  Furthermore, the women in the trial 
travelled from all over the UK and funded their own transport for both the screening 
and randomisation visits.  This showed the women’s commitment and support of a 
study that looked for a test that could identify the subgroup of women where targeted 
treatment could be beneficial.  This concept is analogous to the trend of personalised 
clinical practice, where treatment should be tailored to the individual patient.   
Tertiary referral centres review high numbers of women with RM but many 
of these present with complicated histories, and may not be suitable for inclusion 
into trials.  With the development of national guidance in the management of RM, 
many women with idiopathic RM are now managed in district general hospitals and 
the community.  Thus, recruitment of trials should not solely be targeted at tertiary 
referral centres, but also involve smaller hospitals and GPs.  Health care providers 
also need to support recruitment into trials by avoiding empiric prescribing, 
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especially if women have attended for screening.  A large trial will need extensive 
planning and communication with many centres to encourage participation. 
It was encouraging to find that prednisolone was well accepted, as it was 
important to assess if women will tolerate the side effects of prednisolone for 8 
weeks.  Although side effects were reported, no women stopped the medications 
because of its severity, and all completed treatment.  Compliance may have been 
improved because this treatment was targeted towards a plausible cause of their 
previous miscarriages.  Reassuringly, there were no serious adverse effects or 
SUSAR reported from treatment with prednisolone.  Although the safety of 
prednisolone were only examined in 20 women in this study, there are other 
published studies of its safety profile in the first trimester of pregnancy where 
prednisolone was used to treat asthma, hyperemesis or rheumatoid arthritis
176-178
.  
Furthermore, studies with post-natal follow-up have also not shown complications of 
prednisolone use
178, 179
.  Thus, prednisolone treatment was thought to be safe.       
 
4.5.2  Karyotype of miscarriages  
 The most common cause of miscarriage is chromosomal abnormalities in the 
conception.  These happen in about 70% of all miscarriages
7
.  As discussed in 
previous chapters, endometrial receptivity plays a role in recognising and selecting 
the embryo for implantation
183
.  Thus, karyotype of miscarriage is important in 
making progress towards the management of idiopathic RM.  Therapeutic 
endometrial manipulation should prevent miscarriages of pregnancies with normal 
chromosomes, and not encourage implantation and support pregnancies that have 
genetic abnormalities.  Results of an abnormal karyotype also provide the reason for 
the miscarriage, and helps in counselling the couple.  The development of new 
microarray-based technologies have revealed a much higher rate of chromosomal 
abnormalities than previously thought in the developing embryo,  and when possible, 
should be the method used for assessing genetic abnormalities in all miscarriages
184
.  
Further studies should be targeted towards women with idiopathic RM of normal 
karyotype, where the miscarriage was not due to chromosomal abnormalities. 
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Unfortunately in this trial, results of karyotype were only available for 30% 
of miscarriages.  Reassuringly, the percentage of normal and abnormal karyotype in 
both groups was similar.  Although the numbers were small, this indicated that 
prednisolone therapy was not improving implantation of abnormal pregnancies.  We 
could not determine what type of pregnancy loss prednisolone could potentially 
prevent as the number of losses in each category was too small.  The reason for not 
having many results of karyotype may be that women either had biochemical 
miscarriages, with no tissue for karyotyping; or were counselled towards medical 
and conservative management to avoid general anaesthesia, where complications 
could occur if the trial medication allocation was unknown.  In many occasions, 
women who miscarried in other hospitals or at home did not have POC sent for 
karyotype.  In further studies, the importance of sending POC for karyotyping need 
to be emphasised to both health care providers and women to improve the rate of 
chromosome analysis. 
 
4.5.3  Uterine NK cell density as a screening test  
It is reported in the literature that women with idiopathic RM have live birth 
rates of >70% with supportive care and reassurance scans
37
.  For the uNK cells 
density test to be able to select women who need treatment, the live birth rate in the 
screen positive and placebo group need to be lower than expected in trials involving 
similar women.  In this pilot trial, the overall live birth rate was 50%, and in the 
placebo group, only 40%.  This was significantly lower than the live birth rates in the 
placebo group of other recently published RCTs in women with RM (Table 4.5).  
Furthermore, it was also observed that women who miscarried in the trial appeared 
to have higher uNK cell density, regardless of trial medication (Figure 4.12).  This 
finding, alongside the biological plausibility of the role uNK cells play in 
implantation as discussed in previous chapters, would support raised uNK cells 
density as a clinical marker to identify a subgroup of women with an increased risk 
for adverse pregnancy outcomes for potential treatment.   
It is possible that 5% may not be the accurate threshold of normality, or the 
correct inclusion criteria for randomisation.  There is currently no universally 
accepted normal level of uNK cell density as the method of assessment varies from 
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laboratory to laboratory as discussed in Chapter 3.  5% was determined by using the 
upper end of the interquartile range of control women.  This may not be the best 
method of obtaining a cut-off as this is based on a normal population and not in the 
population of interest, women with RM.  An alternative method would be to obtain 
pregnancy outcomes of all women with untreated idiopathic RM and perform a ROC 
analysis of uNK cells density between the live birth and miscarriage groups to obtain 
an optimal cut-off value.  In the context of a RCT, it would be to randomise all 
women screened when they fell pregnant.  In this alternative study, uNK cells 
analysis would be performed at the end of the study when the pregnancy outcomes 
were known.  This would allow for a ROC analysis to determine the optimum cut off 
for adverse pregnancy outcomes (miscarriage) in the placebo group.  This method 
will improve recruitment as every woman who had an endometrial biopsy taken can 
be randomised, but it may not be ethically right to withhold results of her uNK cells 
density.  This study would involve an entirely different methodology, but if 
adequately powered, may be the best technique to identify the optimal cut-off of 
normality for uNK cells density.  But even though the level of normality is known, 
there is significant cycle-to-cycle variability of uNK cells density which needs to be 
further investigated and addressed in the process of developing uNK cells density as 
a screening test
118
. 
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Table 4.5  Live birth rates in the control group in similar recent RCTs 
 
Authors Year of 
study 
Population 
studied 
Control 
group 
Live birth 
rate in control 
group 
Visser et al
185
 2011 ≥3 RM, 
Idiopathic 
Aspirin 61% 
Stephenson et al
128
 2010 Previous LB 
followed by ≥3 
RM, Idiopathic 
Placebo 63% 
Kaandorp et al
32
 2010 ≥2 RM, 
Idiopathic 
Placebo 67% 
Clark et al
40
 2010 ≥2 RM, 
Idiopathic 
USS 
surveillance 
80% 
Laskin et al
29
 2009 ≥2 RM with APS, 
Thrombophilia or 
ANA  
Aspirin 79% 
El-Zibdeh
186
 2005 ≥3 RM, 
Idiopahtic 
Placebo 71% 
 
 
4.5.4  Laboratory standardisation and analysis 
The method of immunohistochemistry and image analysis to assess uNK 
cells, and the cut-off threshold of 5% was determined and validated from previous 
studies in our laboratory
107, 110, 181
.  The same method of analysis was applied to all 
endometrial samples in a single laboratory in the trial for consistency. 
The mid-luteal phase of the menstrual cycle were assessed through the 
urinary surge of LH as women were advised to use ovulation kits and contacted us 
on the day of ovulation for an appointment 6-9 days later for an endometrial biopsy.  
In the laboratory, these biopsies were further assessed for accuracy of dating 
according to the Noyes criteria
59
.  We could have further improved our accuracy of 
dating through serum progesterone but we considered two methods of assessment of 
mid-luteal phase as adequate.  Women were advised to reuse the ovulation kit and 
reattend if their endometrial biopsy was found not to meet the Noyes criteria for mid-
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secretary phase the first time.  All but 4 (2.5%) women have results of their uNK 
cells density. 
Unfortunately, the current method of analysis was very time consuming.  
Thus, there is a need for an alternative method for image analysis to produce results 
quickly to accommodate the potentially large number of women in a bigger trial or if 
uNK cells test was to be developed as a screening marker for adverse pregnancy 
outcomes.  A more time efficient method for uNK cells analysis will be further 
discussed in Chapter 5.  
 
4.5.5  Mechanism of action of prednisolone 
Prednisolone treatment may improve the live birth rate from 40% to 60% 
(absolute risk reduction of 20%) in this group of women with high uNK cells 
density.  This is a preliminary observation that needs to be interpreted with caution 
as it does not demonstrate efficacy.  The exact mechanism of how prednisolone 
could work in improving outcome is unknown.  It is unlikely through 
immunosuppression as a systematic review of RCTs on IVIG therapy (arguably a 
more powerful immunomodulator compared to prednisolone) in both primary and 
secondary RM, has not shown to be of benefit in improving outcomes
128, 129
.  
Prednisolone reduces the number of uNK cells, and also affects angiogenesis, a 
function of uNK cells, and an important factor in implantation
107, 124, 187
.  This 
mechanism through altering the angiogenic growth factors production of uNK cells 
was thought to be one of the therapeutic effects of prednisolone
124
.  More recently, 
laboratory studies have shown defective decidualisation correlating with uNK cell 
density of >5% and a lack of 11-β hydroxyl steroid dehydrogenase type 1 in stromal 
cells
125
.  11-β hydroxyl steroid dehydrogenase type 1 activates cortisol.  Hence, 
administration of the glucocorticoid prednisolone may overcome this deficit and 
modify the endometrial environment to one more favourable for maintaining a 
pregnancy. 
The dose of 20mg was used as this was the dose that resulted in a live birth in 
a previously published case report
122
, and the dose that demonstrated a reduction in 
uNK cells density after treatment
110
.  It is unclear if this is the optimum dose.  It is 
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also uncertain if the effect of prednisolone on uNK cells and subsequent outcomes 
are dose-dependent.  But, an increase in the dose would need to be balanced with the 
increase in side effects, which can be investigated in a dose finding study.  Efficacy 
of different doses could perhaps be examined by assessing the effect of different 
dosages of prednisolone on uNK cell number and function in the laboratory, prior to 
clinical assessment in influencing pregnancy outcomes.  This could lead to different 
therapeutic dosage of prednisolone for different results of uNK cell density.  
In this trial, prednisolone was only commenced at a positive pregnancy test 
and it is known that the endometrium decidualises in preparation for implantation, 
before any interaction with the blastocyst
188
.  Thus, it was possible that starting 
prednisolone at about 4 weeks gestation was too late, as there was inadequate time to 
modify the endometrium to a presumed more favourable one for implantation.      
Efficacy could be further improved if it was commenced prior to the cycle of 
conception.  However, this could subject the women to repeated cycles of high dose 
prednisolone if they do not conceive easily, which may result in unwanted side 
effects such as immunosuppresion, hypertension or weight gain. 
The endometrium sampled was only a single point in the cycle, and may not 
be representative of every cycle or the cycle when implantation occurred.  As it is 
ethically wrong to sample conception endometrium, any results of the effect of 
prednisolone on endometrium when implantation occurred were extrapolated from 
in-vitro studies of endometrium in a pre-conception cycle, or on deciduas of 
miscarriages.  Therefore, the clinical effect of prednisolone on improving pregnancy 
outcomes is best confirmed or refuted in a clinical trial.    
 
4.5.6  Sample size calculation for a definitive trial  
Preliminary power calculation was based on multiple presumptions informed 
by minimal data.  With the results of this pilot trial, we performed a more precise 
sample size calculation.  The live birth rate of women with uNK cells ≥5% in the 
placebo group was 40% and 60% in the prednisolone group.  This pilot trial has also 
confirmed that about 40% of all women screened had raised uNK cells and of these, 
about 60% of women returned for randomisation.  These proportions would mean 
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that in excess of 890 endometrial biopsies would need to be sampled, to randomise 
214 women (107 in each arm) in the definitive trial to significantly detect the benefit 
of prednisolone with 80% power (α 0.05) (Figure 4.14) (Stats Direct v2.6.8). 
The results from this pilot trial also allowed us to estimate the sample size in 
a definitive trial if the expected benefit of prednisolone in improving live birth rates 
was more or less than anticipated (Table 4.6).  It is important to consider that women 
randomised were only about a quarter (25%) of all women that will need to be 
screened with endometrial biopsies.  Thus, it may not be feasible to recruit the large 
numbers for screening to detect a significant difference if the expected benefit of 
prednisolone was less than this pilot trial.  The most optimistic view would be an 
improvement in live birth rates with prednisolone to one commonly quoted for 
women with idiopathic RM at 70-75% from the rate of 40% live birth in the current 
placebo group.  If the recruitment rate and benefit was equivalent to this pilot trial, it 
would take about 10 years to complete the definitive trial with adequate power.  
However, the recruitment time would shorten in a multi-centre trial. 
 
Figure 4.14  The power calculation for the definitive RCT 
 
    >890 biopsies 
             
 
40% raised uNK cells 
              (357 women) 
 
              
60% agree to trial and randomisation (40/68 in pilot) 
    (214 women) 
   
   
           Placebo  Prednisolone 
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Expected Outcomes:   
                    40% Live births  60% Miscarriages    60% Live births 40% Miscarriages 
                           (43 women)          (64 women)             (64 women)          (43 women) 
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Table 4.6  Numbers needed for randomisation with different expected LB rate       
Expected live birth rate Women needed to be randomised 
Placebo group Prednisolone group 80% Power 90% Power 
40% 50% 816 1078 
40% 55% 374 590 
40% 60% 214 280 
40% 65% 140 180 
40% 70% 98 126 
40% 75% 74 92 
 
  
 
4.6   CONCLUSION 
This pilot trial has demonstrated that it is feasible to conduct screen and treat 
trials of selecting women through an endometrial based investigation for 
randomisation into a double-blind, placebo-controlled trial.  Women were in support 
of a trial where a test is used to select the subgroup of women whom may benefit 
from treatment.  They appear to tolerate the active medication prednisolone well 
with minimal side effects and all completed treatment.  Reassuringly, there were no 
adverse effects from prednisolone.  Support will be needed from both tertiary referral 
centres and health care providers in the community to ensure adequate recruitment to 
meet the sample size needed to assess for a significant difference in the live birth rate 
in a similar trial, prior to consideration for implementation into clinical practice. 
In planning the definitive trial or future trials of similar nature, it is of 
importance that karyotype results are available for all the miscarriages, as therapy is 
aimed at supporting pregnancies of normal chromosomes.  Hence, measures such as 
good communication between centres of the trial and written information to patients 
should be taken to ensure POC are available for cytogenetics analysis.  There should 
also be consistency in the entry into trials to allow for uniformity in starting of trial 
medication. 
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It is still unclear how prednisolone could work in improving pregnancy 
outcomes.  Proposals include regulating angiogenesis, a function of uNK cells and 
an important factor in implantation
107
, or through improving steroid metabolism in 
stromal cells
125
.  Further laboratory studies are needed to explore these different 
mechanisms.  Additional studies could also consider investigating the optimal 
dosage of prednisolone, whether effects are dose dependent, and timing of 
commencing prednisolone.  All these may then path the way for uNK cells density to 
be developed as a clinical marker of endometrial cause of RM. 
Analysis of uNK cells is currently time consuming and will need to be more 
efficient to accommodate the large numbers for screening in a definitive trial.  The 
development of an alternative, quicker method for assessing uNK cells density will 
be discussed in the next chapter. 
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CHAPTER 5: COLOUR DECONVOLUTION AND AREA 
MEASUREMENT AS AN ALTERNATIVE METHOD FOR 
ESTIMATING UTERINE NK CELLS DENSITY 
 
5.1  Introduction 
As described in the previous chapters, there is interest in uNK cells density 
being used as a diagnostic or screening tool for women with RM or other 
reproductive problems.  Unfortunately, the lack of standardisation in the 
methodology between laboratories in the analysis of uNK cells density has made 
comparisons of results between units difficult.   
The current method of assessing uNK cells density in our laboratory, 
described in the last chapter, is by a combination of manually counting the number 
of uNK cells stained positive with DAB staining, divided by the number of total 
stromal cells calculated through the application of ‘particle analysis’ function of 
Image J.  This method of semi-automated image analysis (SAIA) has been validated 
and is reproducible
181
, but was too time consuming.  The feasibility of conducting 
the definitive trial would involve the ability to inform a large number of women in a 
reasonable time whether they were screened positive or negative for suitability of 
randomisation.  The method of uNK analysis should also be easily reproducible and 
standardised to allow for other units to replicate, to permit synthesis and meta-
analysis of results from different departments.  The development of an alternative 
method for uNK cells counting that is quick, reliable and reproducible is needed to 
further develop uNK cells density as a screening test to select women with 
reproductive problems for targeted treatment. 
 
5.1.1  Image J – Colour Deconvolution plug-in and Area Measurement (CDAM) 
Image analysis in IHC by means of different computer assisted image 
processing programmes has been widely used in biologic research
189-191
.  In our 
experience, digital image analysis has shown to be more objective, more 
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reproducible with low inter and intra-observer errors, and served as a good teaching 
tool
181
.  
 Image J, the Java-based, freely available software that has been used in the 
analysis of uNK cells density for the RCT, has other plug-ins contributed by 
different authors that are used in different types of image analysis
182
.  One of the 
plug-in is colour deconvolution (CD), a technique used to separate an image with 
different colour stains into the individual colour component based on the stain 
specific RGB (red, green, blue) absorption
192
.  Vectors for several commonly used 
stains such as Haematoylin and Eosin (H & E), and Haematoxylin and DAB (H 
DAB) have been developed and were freely available for use on Image J.  The H 
DAB vector would be suitable as uNK cells were stained with DAB and all nuclei 
were counterstained with haematoxylin.  Therefore, this plug-in could be used with 
the area measurement (AM) tool as an alternative method to estimate uNK cells 
density.  Although editing of the image was still needed to remove epithelial edge, 
glands and blood vessels from the captured image, there was no need for further 
steps of removing DAB staining, digitally counting the stromal cells and manually 
counting the uNK cells.  Therefore, this method would hopefully be more time 
efficient. 
 
5.1.2  Inconsistency in reporting of uterine NK cells 
There is currently inconsistency in the reporting of uNK cells analaysed 
through IHC.  Clifford et al
108
 reported the number of uNK cells per 10 HPF, and did 
not take into consideration the stromal cells count, which would affect the density.  
Michimata et al
117
 on the other hand reported uNK cells density as uNK cells 
number per CD45
+
 cells and not over all stromal cells.  In our unit, similar to 
Tuckerman et al
109
, uNK cells density were reported as total uNK cells over the total 
of stromal cells.   
 It would be particular useful to standardised the method of analysing and 
reporting uNK cells density, to allow for comparison and reproducibility of uNK 
cells density between  different laboratories.  With Image J being freely available on 
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public domain, and the vector for haematoxylin and DAB set, the method of CDAM 
could potentially be used as a universal method of reporting uNK cell density. 
 
 
5.2  Objective 
The aim was to develop a new method of estimating uNK cell density using 
both the colour deconvolution (CD) and area measurements (AM) function available 
on Image J.  Subsequently, the new method was validated, and assessed for its 
feasibility to be used as a method to quantify uNK cells density in endometrial 
samples from women for the definitive RCT of prednisolone in women with RM and 
high uNK cells, by determining the optimal CDAM cut-off equivalent to the 5% 
uNK cell density with the current combined method.  
 
 
5.3  Methodology 
5.3.1  Sample selection 
Images for analysis were captured from mid-luteal phase endometrial 
biopsies processed from 100 consecutive women who consented for screening into 
the RCT as described in Chapter 4.  Each woman had an average of 10 images taken 
from the stained slide, and thus 997 images were examined with this new method.  
As with any IHC staining procedure, the staining was checked with the positive 
control slide to ensure adequate colour development from DAB.  If it was found to 
be too faintly stained (when compared with the control slide), the process of IHC 
staining was repeated on these samples. 
 After ensuring that this method was feasible, images from 40 women (400 
images) with uNK cells density ranging from 2-16% were randomly selected to test 
for intra and inter-observer errors for this new CDAM method. 
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5.3.2  Preparation of images for analysis 
Images of the selected samples were captured using Eclipsenet software as 
described in the previous chapter and were saved in a compression free format 
(TIFF), and edited prior to being analysed.  First, the background colour was 
changed to white.  Similarly to editing images for the trial, all the epithelial edges, 
glands and blood vessels in the images were removed.  In this study, they were 
removed using the Image J Freehand selection tool (Figure 5.1), rather than using 
Adobe Photoshop CS2 or CS3 as with the SAIA method used in the pilot trial.  Once 
the selected area was surrounded, the mouse button was released and the chosen area 
cleared (Figure 5.2).  The image was ready to be analysed when all the luminal 
epithelium, glands and blood vessels have been removed (Figure 5.3).  
 
Figure 5.1  The freehand selection icon on Image J 
 
 
 
Figure 5.2  The selection of area to be removed prior to image analysis 
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Figure 5.3  The edited image ready for CDAM analysis for uNK cells density 
 
 
 
 
5.3.3  Method for colour deconvolution and area measurement (CDAM) 
The background of the image was ensured to be neutral with respect to colour 
intensity prior to using the CD plug-in.  This was checked by clicking on ‘point 
selection’ (arrow) and ensuring that the RGB values were similar (circled values) 
(Figure 5.4).  Next, the ‘colour deconvolution’ function was selected and built-in 
vectors for haematoxylin and DAB chosen to separate the colours for DAB (brown) 
and haematoxylin (blue).  This resulted in one image of each, corresponding to the 
individual stain and another which was white, and the original image (Figure 5.5).  
The haematoxylin stained image (colour 1) and the DAB stained image (colour 2) 
were individually analysed for area measurements.  An estimate of UNK cell density 
would be the total area occupied by DAB stain of uNK cells (brown), divided by the 
area occupied by stromal cell nuclei (blue).   
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Figure 5.4  Neutralising the background of the image 
 
 
 
 
Figure 5.5  The resulting images after utilising CD function on Image J 
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First, a threshold was applied to the haematoxylin stained nuclei (colour 1). 
This was adjusted to ensure the selection of area matched the original blue stained 
nuclei.  The manual threshold was compared with the auto threshold available in the 
plug-in for 10 women (100 images) and was found to yield similar results.  Thus, the 
auto threshold for haematoxylin was used in the rest of the study and further 
adjustments were not required.  Auto threshold had the benefit of reducing 
subjectivity.  The total area thresholded was measured using the Image J ‘area 
measurement’ (AM) function.  The values for the threshold, total area and area 
fraction were recorded.   
These steps were repeated for the DAB stained image (colour 2).  The 
threshold for this image needed to be adjusted manually as DAB cytoplasmic 
staining was not as clearly demarcated as haematoxylin nuclei staining.  A few 
methods to manually threshold for DAB staining were tested on images from 10 
women (100 images) prior to deciding on the best method that was consistent, 
reproducible, and easily explained to and understood by another user.  The methods 
tried were: 
-  threshold for the brown to match as closely as possible to the DAB 
staining in the original image 
- threshold to ensure that every uNK cell was accounted for, while 
minimising background staining 
- threshold to match the strongest area of brown stain with the DAB 
staining in the original image, regardless of background staining      
The best, most easily taught and understood method was found to be to 
match as closely as possible the threshold brown area to the DAB staining on the 
original image.  The accuracy could be checked by merging the DAB stained image 
with the original image file and checking that the outlines matched the DAB staining 
(Figure 5.6) (steps explained in section 4.3.6.2).   
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Figure 5.6  A correctly measured and matched DAB area  
 
 
 
 
If the merged image did not match well, then, the image was reanalysed by 
using a different threshold.  The total area thresholded for DAB was measured using 
the Image J ‘area measurement’ (AM) function, and values for the threshold, total 
area and area fraction were recorded.   
The final result for this method using CDAM was calculated by dividing the 
DAB total area (brown stain) with the haematoxylin total area (blue stromal nuclei), 
multiplied by 100.  This would be an estimate of the uNK cells density.  
Estimate of % uNK cells density =  __Area of brown in 10 HPF_   X 100 
                  Area of blue in 10 HPF 
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5.3.4  Validation of CDAM method 
 We estimated uNK cells density from 100 consecutive women (997 images) 
that were screened for the trial with the new CDAM method.  The results of the uNK 
cells density from the current SAIA (‘gold standard’) were blinded.  The time taken 
for analysis with CDAM method was recorded. 
The correlation between the results of the current SAIA method and new 
CDAM method was assessed by Pearson’s correlation coefficient.  Repeated analysis 
of images from 40 women (400 images) with a range of uNK cells density that 
spanned across the whole spectrum was done by myself and another independent 
trained observer to assess the reproducibility of the CDAM method.  The repeat 
analysis was done after a period of one week.  The time for analysis of each of these 
samples were recorded.  As both methods required the editing of glands, blood 
vessels and epithelial edge removal, time was recorded for the steps of: 
- Removal of DAB staining 
- Manual counting of uNK cells 
- Digital quantification of total stromal cells with Image J   
The total time was recorded and compared with the time taken for the CDAM 
method.  Mann-Whitney U test was used to compare the differences in the analysis 
time.  From the results of these 400 images, inter and intra observer errors were 
calculated, and Bland-Altman plots were used to evaluate the relationship between 
both methods and between observers.   
Results of raised uNK cells density of ≥5% was used as entry criteria into the 
RCT, as discussed in Chapter 4.  Thus, we needed to determine the optimal CDAM 
cut-off equivalent to the current 5% uNK cells from the SAIA method, for CDAM to 
be used to analyse the images.  We calculated the number of misclassifications 
(classified ‘normal’ with current SAIA method but ‘high’ with CDAM, and vice 
versa) for different percentages with the CDAM.   
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5.4  Results 
5.4.1  Correlation and agreement between current SAIA method and CDAM 
The analysis of 997 images from 100 women showed good rank order 
agreement between both methods of quantifying uNK cells density (r
2
 = 0.92) 
centred around the line of equality (Figure 5.7).  There was also good agreement 
between both methods with no systematic differences in the measurements.  The 
mean difference between both methods was 0.12%, with upper and lower limits of 
agreement (LOA) of 1.5% and -1.7% respectively and no evidence of systematic 
error (Figure 5.8). 
 
 
Figure 5.7  Correlation between CDAM and SAIA     
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Figure 5.8  Bland-Altman plot showing agreement between CDAM and SAIA 
 
 
 
 
 
The mean time taken to provide uNK cells density results for one woman 
(from 10 images) was significantly shorter with the CDAM method, compared with 
the current SAIA method (mean time 10 mins (range 7-13 mins) vs 28 mins (range 
16-47 mins, p<0.0001) (Figure 5.9).  With the SAIA method, there was a great 
variability in the time taken in analysing each sample, largely dependent on the 
density of uNK cells (Table 5.1). 
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Figure 5.9  Chart showing significant difference in time taken for uNK analysis 
 
 
 
Table 5.1  Time taken for each step in uNK cells analysis with the SAIA method   
Steps Mean time taken (range) (mins) 
Remove of DAB 6 mins (3-16) 
Manual counting of uNK cells 12 mins (3-34) 
Digital counting of stromal cells 13 mins (9-20) 
 
 
 
 
 
122 
 
5.4.2  Reproducibility of CDAM method 
Repeated analysis of 400 images from 40 women by myself showed good 
reproducibility with a mean difference of 0.04% and standard deviation of 0.6.  This 
provided an upper LOA of 1.1% and lower LOA of -1.2% (Figure 5.10).  Bland-
Altman plots of the results from both observers showed no systematic differences in 
the method of analysis.  The mean difference was 0.51%, with upper LOA and lower 
LOA of 2.2% and -1.2% respectively (Figure 5.11).  There was also good correlation 
between observers where r
2
 = 0.96 (Figure 5.12).   
 
 
Figure 5.10  Bland-Altman plot showing intra-observer agreement with CDAM 
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Figure 5.11  Bland-Altman plot showing inter-observer agreement with CDAM 
 
 
 
 
 
Figure 5.12  Correlation of uNK cells density (%) between observers with CDAM 
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5.4.3  Validating the new method CDAM as a screening tool  
The total number of misclassifications was compared with different cut-off 
percentage of uNK cells density.  Misclassifications of false positive was defined as 
categorizing the women as having a raised result from CDAM, when her uNK cells 
density test from the SAIA method was normal (<5%), and the definition of false 
negative was defined as categorising the women as having a normal result from 
CDAM, when current SAIA method of uNK cells assessment gave her a raised uNK 
cells result of ≥5%.  The implications of a false negative test would be the women 
missing out from participating in the trial.  Misclassifications were least with 5% as a 
cut-off for high uNK cell density for CDAM, similar to the current SAIA method 
(Table 5.2 and Figure 5.13a,b).  
 
 
Table 5.2  The optimal CDAM cut-off equivalent of the SAIA method 
 
uNK cells 
density cut-off 
with CDAM 
Misclas-
sifications 
False +ve 
(normal 
results with 
SAIA method) 
False –ve 
(missing 
the trial) 
Sensitivity Specificity 
4.5% 8 8 0 100% 87.1% 
5% 6 2 4 89.5% 96.8% 
5.5% 7 2 5 86.8% 96.8% 
6% 11 0 11 71.1% 100% 
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Figure 5.13a  The number of misclassifications at different CDAM cut-offs 
 
 
 
 
Figure 5.13b  The magnified area of interest for misclassifications 
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5.4  Discussion 
The results show that it is possible to use this new method of estimating uNK 
cells density with the ‘colour deconvolution’ and ‘area measurements’ functions on 
Image J.  This concept of utilising area measurements to estimate cell density 
removes the need for manual counting, which may have more errors compared with 
computer aided automated analysis.  It is important to remember that this result is an 
estimation of the uNK cells density according to the area occupied by uNK cells and 
stromal nuclei, and not the exact percentage of uNK cells density.  However, 
validation has shown that the correlation was very strong and results were similar.  
This may be because the cytoplasmic staining of DAB equated to the area occupied 
by the nuclei of cells overall.  As the function of the results was for screening 
women who may have high uNK counts, an estimate of the uNK cells density may 
be adequate.  The estimate of uNK cells density was achieved with a significantly 
faster turnaround compared with the current SAIA method.  In borderline cases, the 
combined method of manually counting uNK cells and digitally calculating stromal 
cells could be used to obtain the exact percentage.  To maintain the standard between 
observers, results from the CDAM method should be intermittently confirmed with 
the SAIA method, to ensure that they remain similar to each other. 
This CDAM method has the advantage of being significantly faster, while 
maintaining similar intraobserver errors of 0.5%, with similar 95% confidence 
intervals.  It is important for the analysis of uNK cells density to be time efficient, if 
this becomes a universally available screening test in the future.  Furthermore, the 
CDAM method was also more cost effective as the whole process involved only the 
utility of Image J, a freely downloadable software, and removed the need to purchase 
specialist image processing programmes such as Adobe photoshop. 
A limitation of this new method is the dependence on the staining intensity of 
the DAB and haematoxylin on uNK cells and nuclei.  However, this holds true for 
any analysis of IHC staining.  Thus, it is vitally important to have a positive control 
slide for each staining run, to check the consistency of stain intensity in each IHC 
cycle.  There are also other variables that affect uNK cells density measurements 
such as number of days since LH surge, fixation method, antibody clone and 
detection system used, depth of endometrium where counting is performed and 
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exclusion of other structures including glands, vessels and clusters.  However, these 
other variables could be standardised between laboratories and quality control is an 
achievable objective.  Similarly to any other analysis and new skills, this method 
would require training.  But, the review of results by a new observer can be readily 
achieved as the threshold results are documented and can be reevaluated and 
reassessed.  
 
 
5.5  Conclusion 
We have shown that this new method of CDAM is a high through-put, 
reliable and accurate estimation of uNK cells density that can be used as the 
alternative method of screening for women with RM for selection into the pilot RCT.  
Apart from utility in the trial, it could potentially be used, subsequent to individual 
validation to the ‘gold standard’ method currently used, for the quantification of 
uNK cells in other studies.   Although this method gives an estimation of uNK cells 
density rather than the exact percentage, results have shown that they are both 
strongly correlated.  If there were uncertainty with the results, then the manual or 
gold-standard method could be used to get the exact percentage to confirm or 
disprove the results.   
Future studies can be designed to further develop a fully automated and 
reliable method for analysis of uNK cells density using this concept.  This will move 
towards a standardised, reproducible method of uNK cells analysis for comparison 
and evaluation of different studies from different institutions, if uNK cells test 
become important for screening in women with RM in the future.  
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CHAPTER 6 – CONCLUSION OF THESIS 
 
6.1  Endometrial pathology in recurrent miscarriage 
 The endometrium is a rich source of cells and cytokines that are involved in 
the essential processes such as implantation of the conception and nurturing of the 
developing fetus for the outcome of a successful pregnancy.  The signalling 
pathways in the endometrium could render the endometrium unreceptive to 
implantation or lead to defective implantation.  Many of these processes are not yet 
fully understood and more studies are needed to comprehend the endometrial 
physiology and pathologies in RM, and hopefully lead to development of further 
treatment for these women.   
Understanding the decidualisation process in the endometrium is difficult as 
it is ethically wrong to obtain endometrium sample at the cycle of implantation for 
that index pregnancy.  Currently, much evidence is extrapolated from studies of 
endometrium prior to the conception cycle or from animal studies.  There is a need to 
further develop invitro models to simulate the decidualisation and implantation 
process to have better understanding of interactions between the embryo and 
endometrium.  Focus could be on endometrial immune cells (uNK cells, 
macrophages and T cells), and stromal cells which are in abundance in the 
endometrium, and their relationship to RM.  Endometrial explants of receptive and 
non-receptive endometrium can also be developed to compare and comprehend 
differences between them.  
Uterine NK cells are the most abundant leucocyte in the endometrium during 
the critical period for implantation and there is evidence for biological plausibility 
that uNK cells play a role in this intricate process.  UNK cells have been shown to 
contribute to the endometrial and decidual environment during menstrual cycles and 
pregnancy.  However, they are difficult to study due to the transient nature and 
cycling of these cells with the menstrual cycle.  But, experiments are improved with 
development in co-culture models.  Further investigations into uNK cells biology, 
their role in angiogenesis and vascular remodelling, including the array and pattern 
of growth factors and cytokines released, and interaction with the other cells in the 
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endometrium is needed.  Much focus has been on their role in reproduction but 
investigations need to also target potential roles of uNK cells in the non-pregnant 
endometrium.  Recent studies have also shown inter-cycle variability in uNK cells 
density which needs to be further explored
118
.  The study was carried out in a small 
number of women with reproductive problems and it needs to be known if this 
variation also exists in the normal population, and whether this variation is consistent 
in every cycle.  The degree of biological variation in women with reproductive 
problems compared to normal fertile women needs further analysis as this may have 
implications to the differences of uNK cell density reported in both these groups of 
women.  The endometrial pipelle biopsy samples the superficial functional layer of 
the endometrium and studies needs to examine differences in the uNK cell density, 
and variation in different layers of the endometrium.  Greater understanding of the 
biology of uNK cells will provide better insight into whether they serve as a marker 
of endometrial immune pathology.     
 
6.2  Clinical implications of results 
Our systematic review, updated to March 2014, found insufficient evidence 
for the association of abnormal uNK cells density with adverse pregnancy outcomes 
in women with RM.  There were only 2 studies that were found to have investigated 
this and they had contradictory results where one study reported that high uNK cells 
were predictive of further miscarriage while the other did not.  There is also 
currently no consensus on the definition of an abnormal test result.  Similarly for 
pNK cell tests, there is still inadequate evidence for its utility as a marker to select 
women with RM for treatment.  This conclusion was echoed in another systematic 
review on NK cells performed by a group in London
163
.  In the feasibility trial, 
women with uNK cells density of more or less than 5% had similar number of 
previous miscarriages, further questioning the meaning of an abnormal test result.  
Therefore, women with RM should not be offered any uNK or pNK cell assessment 
as part of a diagnostic work-up in a clinical setting.  More importantly, they should 
not be offered any treatment based on test results of uNK or pNK cells in an attempt 
for a positive outcome as there is currently no adequately powered, conclusive RCT 
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that has proven efficacious.  Any NK cells analysis and immunotherapy should only 
be performed in the context of clinical research. 
In the pilot trial although 85% of women expressed that they preferred the 
active medication if given a choice, 66% returned voluntarily for randomisation into 
the trial when pregnant.  This demonstrated that women were in favour and in 
support of trials to look for a test that can identify pathology for targeting treatment.  
Hence, they should be encouraged to participate in well-designed research studies 
and be supported throughout these trials, rather than be prescribed empirical 
treatment.  
 
6.3  Feasibility of future clinical trials 
There is a call for ‘a specific assay to diagnose immune-mediated early 
pregnancy loss and a reliable method to determine which women might benefit from 
manipulation of the maternal immune system’52.  This pilot phase assessing patient 
acceptability of the trial has shown that it is feasible to recruit for a ‘screen and treat’ 
trial as the majority of women returned for randomisation despite wanting the active 
medication.  A weakness of this thesis was that the trial was designed before the 
results of our systematic review.  A suggestion of a future trial would be a change in 
methodology to include assessment and analysis of both uNK and pNK cells 
(numbers and activity), and to randomise all women regardless of the NK cell results 
to either prednisolone or placebo when pregnant.  Every woman recruited into the 
trial should be followed up to get details on whether they get pregnant, and if they 
do, what the pregnancy outcome is.  A trial design of this nature would also allow 
one to obtain the optimal cut-off of uNK or pNK cells tests by using the ROC 
analysis to discriminate between outcomes of live birth or miscarriage.  This would 
add to the literature about levels of normality of NK cells which is currently limited.  
Furthermore, it will also show if any of these tests are useful, and if they are, which 
one is ideal.  Reassuringly, there were minimal side effects from prednisolone 
treatment and all completed treatment.  Research should also examine  the 
mechanisms of how prednisolone could exert its effect on the pregnancy outcome.      
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This pilot trial showed that the analysis of uNK cells density was time 
consuming, with a wide variability depending on the uNK density (16-47 minutes).  
For uNK cells test to be developed to allow for a quick turnover of results when 
conducting a large trial, analysis need to be efficient and reliable.  Thus, an 
alternative method for quantifying uNK cells was validated using the freely available 
Image J.  This new CDAM method may also be used as a standardised method for 
the analysis and reporting of uNK cells in other studies, to allow for comparison 
between different institutions. 
 
6.4  Final Conclusion 
 With current progress in the field of medicine, it is difficult to accept that 
more than half of women with RM are informed that there is no explanation for the 
miscarriages, and counseled about the lack of available evidence in most treatments.  
There is good evidence that the endometrium plays an important role in the 
regulation of implantation, with biological plausibility that uNK cells participates in 
this process.  Research should be targeted at further understanding of uNK cell 
distribution, function and regulation.  It is possible that uNK cells function as a 
marker of poor decidualisation, but the definition of normality is first needed.  The 
systematic review on the association of uNK cells and adverse pregnancy outcomes 
revealed insufficient studies with small numbers of women included in each study, 
demonstrating the need for more studies in this field.   
The best verification of effectiveness of treatment is results from adequately 
powered RCTs.  This pilot RCT has demonstrated that women with RM are in 
favour of studies looking for a cause for their condition prior to initiating treatment.  
Although time consuming, it is realistic and feasible to recruit for screen and treat 
trials as suggested above.  This may pave the way towards finding another treatment 
for RM with an endometrial immune cause, and women with RM should be 
encouraged to participate.  Future trials will hopefully be able to confirm or refute 
the role of uNK cells, or pNK cells as a clinically useful marker for screening 
women with RM, and the efficacy of prednisolone as a new treatment option.   
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background: Peripheral natural killer (pNK) and uterine NK (uNK) cells have been associated with reproductive failure. We system-
atically reviewed the literature to assess whether numbers or activity of pNK or uNK cells predicted subsequent pregnancy and outcome.
methods: We searched the electronic MEDLINE database from 1950 to April 2010 for relevant publications by using MeSH terms
‘natural killer cells’, ‘reproduction’ and ‘pregnancy complications’. We included studies that measured pre-pregnancy pNK and uNK cell
numbers or activity in women with recurrent miscarriage (RM) or infertility, and reported subsequent pregnancy outcomes of miscarriage
or failure to conceive after assisted reproductive technology (ART).
results: The search identiﬁed 783 publications and 12 fulﬁlled the inclusion criteria. There were too few women entered into the obser-
vational studies to assess whether high pNK cell percentages or activity predicted subsequent miscarriage in women with idiopathic RM
(numbers: n ¼ 32, OR 17, 95% CI 0.82–350.6, activity: n ¼ 92, OR 2.51, 95% CI 0.16–40.29), or implantation failure (n ¼ 203, OR
1.35, 95% CI 0.28–6.46), or miscarriage in infertile women after ART (n ¼ 79, OR 2.48, 95% CI 0.50–12.32). Similarly, the studies of
uNK cells were not large enough to assess whether abnormal uNK cell density predicted subsequent miscarriage in women with idiopathic
RM (n ¼ 72, OR 1.33, 95% CI 0.16–11.11). None of the uNK cell studies in women with infertility reported pregnancy outcomes dichot-
omized for uNK cell numbers.
conclusions: The prognostic value of measuring pNK or uNK cell parameters remains uncertain. More studies are needed to conﬁrm
or refute the role of NK cell assessments as a predictive test for screening women who may beneﬁt from immunotherapy.
Key words: systematic review / natural killer cells / recurrent miscarriage / infertility / pregnancy outcomes
Introduction
Immunological mechanisms have been thought to play a role in repro-
ductive problems such as recurrent miscarriage (RM) (deﬁned as three
or more consecutive miscarriages), infertility and implantation failure.
This implies that a successful pregnancy involves maternal adaptation
of the immune response to the semi-allogenic developing embryo.
Natural killer (NK) cells are part of the innate immune system, and
are found in both peripheral blood and endometrium. Although both
peripheral NK (pNK) and uterine NK (uNK) cells express the surface
antigen CD56, pNK cells are phenotypically and functionally different
from uNK cells and ,10% of pNK cells resemble uNK cells
(Moffett-King, 2002). Furthermore 90% of pNK cells are CD56dim
and CD16+ whereas 80% of uNK cells are CD56bright and CD162
(Nagler et al., 1989; King et al., 1991).
Peripheral NK cells (CD56dim) have been demonstrated to show
signiﬁcant cytotoxic activity with well-established antiviral and anti-
neoplastic functions, while uNK cells have little cytotoxic activity,
but are a rich source of cytokines, particularly angiogenic ones, with
possible roles in regulation of trophoblast invasion and angiogenesis
(Bulmer and Lash, 2005; Dosiou and Giudice, 2005). A high pro-
portion of peripheral NK cells may not reﬂect the condition of the
endometrium where implantation occurs and the mechanism of how
these cells can be associated with miscarriage is unclear. In contrast
large numbers of uNK cells appear in the mid-secretory phase
although the mechanism is still not known. There are two theories:
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recruitment from pNK cells which subsequently differentiate in the
uterine microenvironment into uNK cell phenotype through a series
of organized processes, or uNK cells come from the in utero prolifer-
ation and differentiation of stem cells or endogenous NK cells in the
endometrium (Bulmer and Lash, 2005; Kitaya et al., 2007). The
former theory is the rationale for testing pNK cells although the
latter is the more widely held view. In contrast to pNK cells, uNK
cells are resident in the endometrium and constitute 70% of endo-
metrial leucocytes, the most predominant leucocyte population
during the time of implantation and early pregnancy (Bulmer et al.,
1991). They are adjacent to fetal trophoblast cells in the maternal–
fetal interface and express receptors such as killer-cell
immunoglobulin-like receptor (KIR), immunoglobulin-like transcript-2
(ILT2) and NKG2, for fetal trophoblast antigens, human leucocyte
antigen-C (HLA-C), HLA-E and HLA-G (Moffett-King, 2002). Thus,
pNK and uNK cells have different surface antigens, functions and
receptors and hence, should be considered separate entities.
There have been a series of case–control studies reporting an
association between pNK cell numbers (Kwak et al., 1995; Ntrivalas
et al., 2001; Yamada et al., 2003) or activity (Aoki et al., 1995;
Shakhar et al., 2003) with RM, as well as some studies that have
shown no difference in pNK cells parameters between RM and con-
trols (Emmer et al., 2000; Souza et al., 2002; Wang et al., 2008). Simi-
larly, there have been case–control studies reporting an association
between uNK cells and RM (Clifford et al., 1999; Quenby et al.,
1999, 2005; Tuckerman et al., 2007), but others, that have included
women with only two miscarriages, have failed to ﬁnd this association
(Michimata et al., 2002; Shimada et al., 2004).
There is also inconsistency in the association of pNK cells and uNK
cells with infertility. Some groups have found an association of pNK
cells and infertility (Beer et al., 1996; Matsubayashi et al., 2001; Ntri-
valas et al., 2001) while some have not (Vujisic et al., 2004). Likewise
for uNK cells, one group has reported an association with infertility
(Ledee-Bataille et al., 2005) and another has found no difference
(Matteo et al., 2007).
Evidence for a causative role for NK cells test in reproductive pro-
blems would be considerably improved if the tests of pre-pregnancy
NK cell numbers or activity predicted subsequent pregnancy
outcome. Thus, our aim was to perform a systematic review of the
current literature to ascertain the relationship between pre-pregnancy
NK cell tests results and outcomes of miscarriage, live births or
implantation failure in women with RM or infertility requiring assisted
reproductive technology (ART).
Materials and Methods
Data sources
We searched the electronic MEDLINE database through OvidSP from
1950 to April 2010 for published literature in all languages. The MeSH
terms ‘natural killer cells’, ‘reproduction’ and ‘pregnancy complications’
were exploded. To identify relevant citations about NK cells, we used
terms ‘CD56’, ‘uterus’, ‘uterine’, ‘endometrial’, ‘decidual’ and ‘peripheral’,
in addition to ‘NK cells’. Search terms such as ‘abortion/miscarriage’,
‘ectopic pregnancy’, ‘fetal death’, ‘fertilization’, ‘insemination’, ‘live birth’,
‘pregnancy’, ‘pregnancy outcome’ and ‘stillbirth’, in relation to pregnancy
outcomes were under the MeSH tree of ‘reproduction’ and ‘pregnancy
complications’, to retrieve all papers relevant to NK cells and reproductive
outcomes. The search was then limited to humans and females. Advice
was sought from the Trials search coordinator of the Cochrane Collabor-
ation Pregnancy and Childbirth Group with regards to the development of
the search strategy protocol, who advised on the terminology and
methods of searching. The Trials search coordinator was not involved in
the study selection of the articles, or data extraction.
The abstracts for all the citations were retrieved and assessed for their
suitability for inclusion. Papers that were published in other languages all
had abstracts in English. Original articles of abstracts where relevance
could not be judged from the abstract alone were obtained for detailed
analysis. Additionally, the reference lists of the publications identiﬁed
were examined for possible studies not included in the initial search.
Study selection
Review articles, letters and studies with no pregnancy outcomes reported
were excluded after reading the abstracts. This review also excluded
studies that reported on treating women with immunotherapy such as pre-
dnisolone or intravenous immunoglobulin (IVIG) as prednisolone reduces
both uNK (Quenby et al., 2005) and pNK (Thum et al., 2008) cells and
IVIG alters pNK cell parameters (Morikawa et al., 2001b), which may
either positively or negatively affect the pregnancy outcome, and distort
the results of this review. Furthermore, these treatments are still exper-
imental without evidence from methodologically sound randomized con-
trolled trials (RCTs).
Inclusion criteria were studies that identiﬁed NK cells using the CD56
marker, either CD56+, CD56bright or CD56dim, the CD69 activation
marker or NK cells activity measured by Chromium51 release cytotoxicity
assay, and investigated women with RM (deﬁned as two or more consecu-
tive miscarriages) or women with infertility seeking ART.
Two reviewers (A.T. and S.Q.) read through all the papers selected for
detailed evaluation. Study quality was assessed using The Guidelines
Manual 2009 published by National Institute for Health and Clinical
Excellence (NICE). Information was obtained for the inclusion and exclu-
sion criteria of women in the study, the source and method of analysing
NK cells, the percentage/number and activity levels of NK cells, the
level of normality of NK cells in the unit, and pregnancy outcomes.
Publications were divided into four groups according to the source of
NK cells and type of reproductive failure: pNK cells test in RM, pNK
cells test in infertility, uNK cells test in RM and uNK cells test in infertility.
Pregnancy outcomes of implantation failure (deﬁned as no positive preg-
nancy test after ART), miscarriage ,24 weeks gestation, live births or
implantation success (positive pregnancy test) leading to either miscarriage
of ,24 weeks gestation or live births were collected for women in all
these groups. Data were extracted from texts, tables and graphs of
each of the included studies. Original data in our unit were re-examined
by classifying the pregnancy outcomes according to the cut-off of 5%, pub-
lished in a later article (Quenby et al., 2005). When appropriate,
meta-analyses were performed using Review Manager (RevMan) Version
5.0 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collabor-
ation 2008) on studies reporting pregnancy outcomes according to prede-
termined cut-offs for normality of NK cell parameters in similar patient
groups. In the presence of signiﬁcant heterogeneity, random effects have
been used to pool the results. The results were reported according to
the Meta-analysis of Observational Studies in Epidemiology (MOOSE)
Guidelines (Stroup et al., 2000).
Results
There were altogether 783 citations identiﬁed. Seven hundred and
eighty were from the search terms mentioned above and three
were from the assessment of reference lists of these publications.
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There were no non-English language publications that were found to
be relevant to this review. The selection process leading to the
included publications in the review are presented in Fig. 1. After
reading the abstracts, 756 articles were excluded and 27 full text
articles regarding pNK and uNK cells were retrieved for evaluation.
After detailed analysis, 15 publications were excluded: three were
letters, 6 did not report relevant outcomes (Kwak et al., 1995; Ntri-
valas et al., 2001; Michou et al., 2003; Putowski et al., 2004; Matteo
et al., 2007; Thum et al., 2007), 4 reported on studies using the
same group of women for slightly different aspects of NK cells
(Emmer et al., 1999; Yamada et al., 2001; Morikawa et al., 2001a;
Thum et al., 2004) and 2 reported immunotherapy use in some
women (Coulam et al., 1995; Beer et al., 1996). A total of 12 publi-
cations met the criteria for analysis. There were seven studies report-
ing on pNK cells (Table I), and six studies reporting on uNK cells
(Table II), as one study investigated both pNK and uNK cells. Five
publications reporting on pNK cells and two publications on uNK
cells presented pregnancy outcomes, dichotomized into groups of
high and normal levels of NK cell parameters, established from
controls, as described in Tables I and II.
Only three studies (Lachapelle et al., 1996; Quenby et al., 1999;
Tuckerman et al., 2007), all investigating uNK cells, ﬁt the deﬁnition
of idiopathic RM where women were included after three consecutive
miscarriages with no causes for the miscarriages found after routine
investigations in their hospital. Three studies on pNK cells (Aoki
et al., 1995; Emmer et al., 2000; Yamada et al., 2003) and one
study on uNK cells (Michimata et al., 2002) included women after
only two miscarriages, and one (Yamada et al., 2003) included
women with known associations of RM such as endocrine disorders,
antiphospholipid syndrome (APS) and thrombophilia. The group for
infertility included all women who underwent IVF treatment, regard-
less of the cause for infertility, apart from one study (Ledee-Bataille
et al., 2005), which included women after three cycles of implantation
failure.
Peripheral NK cells
All studies on pNK cells used ﬂow cytometry to investigate the
numbers of pNK cells as a percentage of lymphocytes or leucocytes
depending on the panel of monoclonal antibodies used to identify
these cells, or 51Cr release cytotoxicity assay to assess NK cells
activity.
There were three studies (Aoki et al., 1995; Emmer et al., 2000;
Yamada et al., 2003) investigating pNK cells (number or activity) in
women with RM, but only two studies included women with idiopathic
RM (Aoki et al., 1995; Emmer et al., 2000). Emmer et al. (2000)
reported pregnancy outcomes in relation to both number and activity
of NK cells. It is likely that the same women were tested for both par-
ameters and, therefore, these results were not pooled to avoid double
counting. When the results of the different studies were pooled, there
was signiﬁcant heterogeneity between the studies with I2 ¼ 85%.
Therefore, random effects were used. High pNK cell numbers or
activity did not predict miscarriage in a subsequent pregnancy in
women with idiopathic RM as the meta-analysis of these studies did
not reach statistical signiﬁcance, although positive OR were found
(n ¼ 22, OR 17, 95% CI 0.82–350.60; n ¼ 92, OR 2.51 95% CI
0.16–40.29; Fig. 2).
Of the four studies (Fukui et al., 1999; Matsubayashi et al., 2005;
Thum et al., 2005; Baczkowski and Kurzawa, 2007) that investigated
pNK cells in women with infertility, two (Matsubayashi et al., 2005;
Thum et al., 2005) reported outcomes of implantation failure after
ART, dichotomized into high and normal levels of pNK cells, but
used different parameters of pNK cell numbers and activity. High
pNK cell parameters did not predict subsequent implantation failure
(n ¼ 203, OR 1.35, 95% CI 0.28–6.46; Fig. 3). The same two
studies (Matsubayashi et al., 2005; Thum et al., 2005) also reported
outcomes of miscarriage after implantation success, and the effect of
abnormal pNK cell test results on the risk of subsequent miscarriage
after implantation success was also uncertain as the meta-analysis
was not statistically signiﬁcant (n ¼ 79, OR 2.48, 95% CI 0.50–12.32;
Figure 1 The selection process of the included studies.
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Fig. 4). There was again signiﬁcant heterogeneity with I2 of 84%
between studies reporting implantation failure and I2 of 46% for
studies reporting miscarriage after implantation success, in women
with infertility.
The other two studies (Fukui et al., 1999; Baczkowski and Kurzawa,
2007) that investigated women with infertility, did not report preg-
nancy outcomes according to a predetermined cut-off of normality.
Fukui et al. (1999) reported no difference in pre-pregnancy pNK
cells number and activity between women who failed to get pregnant
and those who became pregnant after ART, and between miscarriage
and live birth in those who were pregnant after ART. Baczkowski and
Kurzawa (2007) also found no difference in the percentage of pNK
cells in these two groups of women.
uNK cells
All the samples in the studies were timed from the LH surge as uNK
cells population vary throughout the menstrual cycle: scanty in the
proliferative phase then increasing in numbers after ovulation and
through the secretary phase (Bulmer and Lash, 2005). Thus, the mid-
.............................................................................................................................................................................................
Table I Included studies investigating peripheral NK cells (seven studies).
Study n Inclusion criteria Method of
analysis
Results
Recurrent miscarriage
Aoki et al. (1995) 68 ≥2 miscarriages;
idiopathic RM
51Cr release assay Higher % NK activity in patients who miscarried
Normal range—,41.8% NK activity determined by the mean +1 SD of
47 healthy controls with no history of miscarriages with pregnancy
outcomes reported according to normal range
Emmer et al. (2000) 142 ≥2 miscarriages;
idiopathic RM
Flow cytometry,
51Cr release assay
Normal range—,12% NK cells taken from publications by other groups
and ,322 lytic units for NK cells activity (no mention of how this was
obtained) with pregnancy outcomes reported according to normal range
Yamada et al. (2003) 113 ≥2 miscarriages;
all RM
Flow cytometry,
51Cr release assay
Higher % NK cells in miscarriage of normal karyotype and biochemical
pregnancy compared with live birth
Normal range—,16.4% CD56+ cells and ,46% NK activity
determined by ROC curve for optimal discrimination between
miscarriage (normal karyotype or biochemical pregnancy) and live birth
Infertility
Fukui et al. (1999) 85 NK
cells
Patients undergoing
IVF
Flow cytometry % NK cells
297 NK
activity
51Cr release assay Pre-IVF cycle—No difference in % NK cell and subpopulation in women
with infertility who failed to get pregnant and those who became
pregnant after ART
% NK cell activity
Pre-IVF cycle—No difference in % NK cell activity in women with
infertility who failed to get pregnant and those who became pregnant
after ART, and between miscarriage and live birth in those who were
pregnant
No normal range reported
Thum et al. (2005) 138 Patients undergoing
IVF
Flow cytometry No difference in % NK cell and NK cell subpopulation in women with
infertility who failed to get pregnant and those who became pregnant
after ART, and between miscarriage and live birth in those who were
pregnant
Normal range—,12% taken from publications by other groups with
pregnancy outcome reported according to this normal range
Matsubayashi
et al. (2005)
94 Patients undergoing
IVF
51Cr release assay Higher % NK cell activity in women with infertility who failed to get
pregnant and those who became pregnant after ART
No difference in % NK cell activity between miscarriage and live birth in
those who were pregnant
Normal range—,44% as determined by the mean +1 SD of 94
healthy, age-matched controls with pregnancy outcomes reported
according to normal range
Baczkowski and
Kurzawa (2007)
58 Patients undergoing
IVF
Flow cytometry No difference in % NK cell in women with infertility who failed to get
pregnant and those who became pregnant after ART
No normal range reported
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luteal biopsy examines the endometrium in the implantation window
of a non-conception cycle.
Four studies (Quenby et al., 1999; Michimata et al., 2002; Ledee-
Bataille et al., 2004; Tuckerman et al., 2007) investigating uNK cells
used immunohistochemistry of frozen or parafﬁn ﬁxed sections with
antibodies to CD56 to identify NK cells staining, and two studies
(Lachapelle et al., 1996; Fukui et al., 1999) used enzymatic digestion
of endometrium and then ﬂow cytometry to identify C56bright or dim
cells. uNK cells results were presented either as an absolute count
of NK cells per 3 (Ledee-Bataille et al., 2004) and 10 high power
ﬁelds (Michimata et al., 2002) or as a percentage of total stromal
cells (Quenby et al., 1999; Tuckerman et al., 2007). There were no
.............................................................................................................................................................................................
Table II Included studies investigating uNK cells (six studies).
Study n Inclusion criteria Method of analysis Results
Recurrent miscarriage
LaChapelle et al.
(1996)
20 ≥3 miscarriages;
idiopathic RM
Flow cytometry No difference in % total NK cells in women with miscarriage and ongoing
pregnancy
No normal range reported
Quenby et al.
(1999)
22 ≥3 miscarriages;
idiopathic RM
Immunohistochemistry Higher % NK cells in women with miscarriage compared with LB
Normal range—,5% determined by 75th percentile of 18 control women
who were attending for sterilization with two or more pregnancies and no
miscarriages
Michimata et al.
(2002)
17 ≥2 miscarriages;
idiopathic RM
Immunohistochemistry No difference in number of NK cells/10 high power ﬁelds in women with
miscarriage and LB
No normal range reported
Tuckerman et al.
(2007)
87 ≥3 miscarriages;
idiopathic RM
Immunohistochemistry No difference in % NK cells in women with miscarriage and LB
Normal range—,13.8% determined by the 90th percentile of 10 control
women with regular menstrual cycle not on hormonal contraception
Infertility
Fukui et al. (1999) 76 Patients undergoing
IVF
Flow cytometry No difference in % NK cells in women with infertility who failed to get
pregnant and those who became pregnant after ART; and between
miscarriage and LB in those who were pregnant
Higher subpopulation of %CD56bright NK cells in women who had LB
compared with miscarriage
No normal range reported
Ledee-Bataille et al.
(2004)
15 ≥3 IVF cycles
failures
Immunohistochemistry No difference in number of NK cells/100x ﬁelds in natural IVF cycle in
women with infertility who failed to get pregnant and those who b
ecame pregnant after ART
No normal range reported
Figure 2 Odds of miscarriage with high pre-pregnancy peripheral NK cell parameters in women with idiopathic RM.
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studies that reported pregnancy outcomes according to uNK cells
activity.
There were four studies investigating uNK cells in women with idio-
pathic RM but only two (Quenby et al., 1999; Tuckerman et al., 2007)
reported pregnancy outcomes according to high and normal levels of
uNK cells. A meta-analysis, with high heterogeneity (I2 ¼ 69%), found
that uNK cell density did not predict pregnancy outcome (n ¼ 72, OR
1.33, 95% CI 0.16–11.11; Fig. 5). The two studies that did not report
dichotomized pregnancy outcomes found no differences in mean per-
centage of uNK cells in women who subsequently miscarried and
those who had live births.
Two studies (Fukui et al., 1999; Ledee-Bataille et al., 2004), differing
in study design to each other, investigated uNK cells in women with
infertility, and both did not report pregnancy outcomes according to
a predetermined cut-off of normality. One included women who
underwent IVF treatment and reported NK cells as a percentage of
lymphocytes. The other included women with implantation failure
after three cycles of IVF, and reported NK cells as mean absolute
numbers in three 100x ﬁelds. Both report no differences in uNK
cells between women who failed to get pregnant and who became
pregnant after ART. However, the study by Fukui et al. (1999)
which analysed NK cells by ﬂow cytometry, showed a higher percen-
tage of the subpopulation CD56bright NK cells in women who had live
births compared with women who miscarried.
Discussion
This systematic review did not demonstrate that abnormal pNK and
uNK cell parameters predicted adverse pregnancy outcomes of mis-
carriage or implantation failure, in women with RM or infertility. The
Figure 3 Odds of implantation failure after ART with high levels of pre-pregnancy peripheral NK cell parameters in women with infertility.
Figure 4 Odds of miscarriage (after implantation success from ART) with high levels of pre-pregnancy peripheral NK cell parameters in women with
infertility.
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observational studies were individually and collectively underpowered
to answer this important question. Assuming that, irrespective of the
reason for NK testing, women with a normal NK cell count have mis-
carriage rate of around 30%, one would expect an increase in miscar-
riage rate by at least 10% (33% increase) when NK cells are high. At
least 376 women per group would have to be followed until delivery
(752 in total) to test this hypothesis with 80% power (a ¼ 5%). This is
considerably more than the largest individual study available, which
investigated 126 women (Thum et al., 2005). There was also signiﬁ-
cant heterogeneity between studies in terms on inclusion criteria,
methodology of NK cells analysis and outcome measurements.
Peripheral NK cells
It has been postulated that uNK cells originate from pNK cells, which
subsequently differentiate in the uterine microenvironment into the
uNK cell phenotype (Kitaya et al., 2007). Testing for pNK cells
involves venous blood sampling at any time during the menstrual
cycle as they have not been shown to ﬂuctuate throughout the
cycle (Pantazi et al., 2010), or with sampling in pregnancy. All
studies used ﬂow cytometry, the best method to analyse and quantify
lymphocyte subsets (Dosiou and Giudice, 2005). Investigations have
been reported in the pre-pregnancy period, during pregnancy or on
the day of embryo transfer in infertility patients undergoing ART.
However, only results from investigations done prior to pregnancy
were analysed in this study as the prespeciﬁed aim of the study was
to assess the association of pre-pregnancy NK testing and subsequent
pregnancy outcomes.
All three studies of pNK cells and RM included women after only
two miscarriages which does not ﬁt the ESHRE (European Society
of Human Reproduction and Embryology) deﬁnition of RM (Farquhar-
son et al., 2005). Yamada et al. (2003) and Emmer et al. (2000) inves-
tigated both pNK cells number and activity, while Aoki et al. (1995)
only studied pNK activity. Emmer et al. (2000) and Aoki et al.
(1995) both studied women with idiopathic RM whereas Yamada
et al. (2003), the study with the largest sample size in these group,
included women with known associations of RM such as endocrine
disorders, APS and thrombophilia. Although they reported that high
pNK cells number and activity predicted subsequent biochemical mis-
carriage and miscarriage of normal karyotype, more than half of the
women investigated had another possible contributing factor to their
miscarriage, creating potential bias in the results.
There is also signiﬁcant heterogeneity between studies which is not
surprising given potentially important differences in the analysis and
interpretation. The determination for the cut-off of normality in differ-
ent studies was through different methods with different control
groups. Emmer et al. (2000) used ,12% pNK cell numbers as
normal range set by Beer et al. (1996) with no explanation of how
this level was calculated. Yamada et al. (2003) used ,16.4% pNK
cell numbers and ,46% pNK cells activity as the normal range deter-
mined by receiver operating characteristic (ROC) curve for optimal
discrimination between miscarriage (normal karyotype or biochemical
pregnancy) and live birth. However, Aoki et al. (1995) set ,41.8%
pNK cells activity measurement as normal range determined by the
mean +1 SD of 47 healthy controls with no history of miscarriages
and Emmer et al. (2000) set ,322 lytic units as normal with no
mention of how this was obtained. The inconsistency was also seen
in studies of women with infertility where Matsubayashi et al. (2005)
determined ,44% pNK activity as normal range with controls,
although age-matched, not all of proven fertility, whilst Thum et al.
(2005) used ,12% pNK cell numbers as set by Beer et al. (1996).
Therefore, it is clear that there is a lack of a commonly accepted
normal range for pNK cells number and activity, or generally accepted
type of pNK cells testing. In addition, there were also differences in IVF
protocols in different units and the deﬁnition for implantation failure or
success was not mentioned in some studies (Matsubayashi et al., 2005;
Baczkowski and Kurzawa, 2007).
It is also known that pNK cells increase signiﬁcantly with stress and
exercise and this was not taken into account when blood was taken
for investigation (Benschop et al., 1998; Timmons and Cieslak,
2008). Furthermore, the value of an abnormal test for pNK cells
activity is also unknown as it may be a reﬂection of a transient
stress response at the time of blood withdrawal, or a representation
Figure 5 Odds of miscarriage with high levels of pre-pregnancy uNK cell numbers in women with idiopathic RM.
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of the response to other stresses in daily life (Shakhar et al., 2006). It is
unclear if these phenomena exist for uNK cells.
uNK cells
Testing of uNK cells involves an endometrial biopsy that can only be
carried out in the pre-pregnancy period. Immunohistochemistry was
the method used in most of the studies of uNK cells. This is more
time consuming than ﬂow cytometry but it reveals the location of
the uNK cells (Bulmer et al., 1991). Analysis using ﬂow cytometry
involves digesting the tissue, and thereby potentially losing cells and
antigens. Furthermore, it needs a large sample of endometrium that
may be difﬁcult to obtain in some women.
The evidence for the association between preimplantation uNK cell
density and miscarriage in a subsequent pregnancy is limited. Two
studies reported no difference in uNK cell density between women
who subsequently miscarried and those who had live births while
two other studies reported pregnancy outcomes according to high
and normal uNK cell density had contradictory results (Quenby
et al., 1999; Tuckerman et al., 2007). The studies that reported no
difference in uNK cell density were different to each other and are
not comparable. Michimata et al. (2002) included women after
two miscarriages and used immunohistochemistry for analysis while
LaChapelle et al. (1996) included women with three miscarriages
and analysed NK cells using ﬂow cytometry.
There was again considerable heterogeneity between the two
studies that reported dichotomized pregnancy outcomes. Similarly
to pNK cell parameters, the normal ranges were obtained with differ-
ent control women. Quenby et al. (1999, 2005) used ,5% uNK cells
as a normal range based on the upper quartile of 18 control women
while Tuckerman et al. (2007) deﬁned ,13.8% as normal determined
by the 90th percentile of 10 control women. For analysis, Quenby
et al. (1999) used frozen sections and pressure cooker for antigen
retrieval while Tuckerman et al. (2007) used waxed embedded speci-
mens and microwave for antigen retrieval. Furthermore, uNK cells are
not evenly distributed through the tissues and their density varies
depending on where the cells are counted. One study counted cells
near the epithelial edge (Quenby et al., 1999) and the other at
random, including deeper into the section (Tuckerman et al., 2007).
Both studies investigating uNK cells in women with infertility
reported no difference in uNK cell density and percentage between
women who failed to get pregnant and those who became pregnant
after ART. However, the population of women in both studies was
different as Fukui et al. (1999) included all women undergoing ART
while Ledee-Bataille et al. (2004) included women without pregnancies
after three cycles of ART. In addition, the method of analysis was
different where one employed ﬂow cytometry and the other immuno-
histochemistry. Thus, the studies are not comparable enough to draw
conclusions about the implications of uNK cells tests in women with
infertility.
Despite the lack of clinical evidence, there is a biological plausibility
for a role for uNK cells in reproductive failure. uNK cells are most
numerous in the implantation window and in early pregnancy
(Bulmer and Lash, 2005), and they are adjacent to and interact with
extravillous trophoblast cells (Moffett-King, 2002). Different uNK
cell populations have been found in the deciduas of normal and mis-
carried early pregnancy (Quack et al., 2001). Furthermore, uNK
cells have been shown to regulate angiogenesis (Hanna et al., 2006;
Kalkunte et al., 2009; Quenby et al., 2009), an important factor in
implantation, and trophoblast cells express antigens that are recog-
nized by the receptors on uNK cells, resulting in changes during
the implantation process which may affect pregnancy outcome
(Hiby et al., 2010).
Conclusions
This review suggests that the prognostic value of measuring pNK and
uNK cell numbers or activity remains uncertain as these parameters
have not been shown to be associated with subsequent pregnancy
outcome. This ﬁnding is similar to that of the many conditions that
have been associated with RM such as thrombophilia and structural
uterine anomalies, none of which have been shown to predict preg-
nancy outcome.
This may be because of the disappointingly small number of studies
reporting clinical outcomes on small numbers of women. The inclusion
criteria were also inappropriate in studies that investigated women
after only two miscarriages. Furthermore, there is still no consensus
on what an abnormal NK cell test result is, as the normal ranges in
different studies are derived from different controls. There is a need
for more studies investigating pNK and uNK cells population and func-
tion in women with reproductive problems. Ideally, future studies
should be prospective, with appropriate inclusion criteria and have a
standardized methodology of analysing and reporting pNK and uNK
test results. Sample size should also be calculated to avoid lack of
power in the study.
Before the availability of results from these larger, more methodo-
logically sound evaluations of prognostic value or RCTs of therapeutic
modalities on speciﬁcally selected women with potential immunologi-
cal pathology, women with reproductive problems should not be
offered NK testing in routine clinical practice, and prescribed empirical
immunotherapy, without clear evidence of beneﬁt. An alternative
would be to counsel them about the lack of available evidence, and
encourage them to participate in well-designed studies, to conﬁrm
or refute the role of NK cells as a clinically useful marker for screening.
We echo the Cochrane review on immunotherapy for RM that quotes
‘a speciﬁc assay to diagnose immune-mediated early pregnancy loss
and a reliable method to determine which women might beneﬁt
from manipulation of the maternal immune system are urgently
needed’ (Porter et al., 2006).
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Abstract
Background: Idiopathic recurrent miscarriage is defined as 3 consecutive pregnancy losses with
no contributing features found on investigations. At present there are no treatments of proven
efficacy for idiopathic recurrent miscarriage. Uterine natural killer (uNK) cells, the most
predominant leucocyte in the endometrium are adjacent to foetal trophoblast cells and thought to
be involved in implantation. The exact mechanisms of how uNK cells affect implantation are not
clear but are probably through the regulation of angiogenesis. Multiple studies have shown an
association between high density of uterine natural killer cells and recurrent miscarriage. We have
shown that prednisolone reduces the number of uNK cells in the endometrium. The question
remains as to whether reducing the number of uNK cells improves pregnancy outcome.
Methods: We propose a randomised, double-blind, placebo controlled trial of prednisolone with
a pilot phase to assess feasibility of recruitment, integrity of trial procedures, and to generate data
to base future power calculations. The primary aim is to investigate whether prednisolone therapy
during the first trimester of pregnancy is able to improve live birth rates in patients with idiopathic
recurrent miscarriage and raised uNK cells in the endometrium. Secondary outcomes include
conception rate, karyotype of miscarriage, miscarriages (first and second trimester), stillbirths,
pregnancy complications, gestational age at delivery, congenital abnormality and side effects of
steroids. The trial has 2 stages: i) screening of non-pregnant women and ii) randomisation of the
pregnant cohort. All patients who fit the inclusion criteria (<40 years old, ≥3 consecutive
miscarriages with no cause found and no contraindications to prednisolone therapy) will be asked
to consent to an endometrial biopsy in the mid-luteal phase to assess their levels of uNK cells.
Women with high levels of uNK cells (≥5%), will be randomised to either prednisolone or placebo
when a pregnancy is confirmed. Follow-up includes 2 weekly ultrasound scans in the first trimester,
an anomaly scan at 20 weeks gestation, growth scans at 28 and 34 weeks gestation and a postnatal
follow-up at 6 weeks.
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Recurrent miscarriage (RM) is defined as the loss of 3 or
more consecutive pregnancies and is a stressful condition
for both patients and clinicians alike. It affects about 1%
of all fertile couples trying to conceive [1,2]. Despite a
wide range of investigations, no apparent cause is found
in more that 50% of cases and they are categorized as idi-
opathic recurrent miscarriage [2,3]. Apart from supportive
care in a dedicated early pregnancy unit with regular reas-
surance scans and psychological support, empirical treat-
ment in this group of women is not recommended [1,4].
Immunomodulation therapies such as steroids, intrave-
nous immunoglobulin (IVIG), 3rd party donor cell
immunization, paternal cell immunization and trophob-
last membrane infusion have been proposed with con-
flicting evidence as to their efficacies. A meta-analysis of
trials evaluating IVIG, 3rd party donor cell immunization,
paternal cell immunization and trophoblast membrane
infusion found no evidence of a beneficial effect over pla-
cebo in preventing further miscarriages [5]. Porter et al
concluded that "a specific assay to diagnose immune-
mediated early pregnancy loss and a reliable method to
determine which women might benefit from manipula-
tion of the maternal immune system are urgently needed"
[5]. This trial is intended to make progress towards meet-
ing the challenge of diagnosing and treating immune-
mediated early pregnancy loss.
Uterine Natural Killer Cells
The putative association of recurrent miscarriage and
immunological phenomenon has been present for many
years. Natural killer (NK) cells which form part of the
innate immune system are found in peripheral blood and
in the endometrium. Although sharing some similar
properties, peripheral and uterine natural killer (uNK)
cells are unique cell types with distinct antigenic features
and functional markers. UNK cells in peripheral circula-
tion differ in many respects to those in the endometrium
[6-8]. It is the intensity of CD56 antigen expression and
the lack of two typical NK cell markers - CD16 and CD 57
antigens, that differentiate uterine from peripheral NK
cells. Around 80% of uNK cells are CD56bright and CD16-
whereas 90% of peripheral NK cells show opposite char-
acteristics; they are CD56dim and CD16+ [7,9].
Uterine NK cells are the most predominant leucocytes in
the endometrium and their density varies throughout the
menstrual cycle. UNK cell density increases in number
towards the mid-luteal phase and peaks in early preg-
nancy if implantation occurs [8]. UNK cells accumulate as
a dense infiltrate at the implantation site near stromal
cells, glands, blood vessels and trophoblast cells in early
pregnancy [7]. In-vitro studies have also shown that
extravillous trophoblast and uNK cells interaction occurs
[10]. These interactions may have an effect on trophoblast
invasion. However, more recent evidence points to the
role of uNK cells as one of controlling angiogenesis [11].
Embryo implantation and early pregnancy development
occur in a relatively hypoxic environment (2-3% O2) [12].
Inappropriate blood flow to the intervillous space has
been associated with oxidative stress damage to the devel-
oping placenta and thus miscarriage [13]. UNK cell den-
sity in women with recurrent miscarriage was found to be
positively correlated with endometrial angiogenesis and
uterine artery blood flow [14]. A similar positive correla-
tion was also found in women with unexplained recurrent
failure of in-vitro fertilisation (IVF) [15]. Thus, we have
proposed that increased uNK cell density is associated
with increased number of spiral arteries which may lead
to inappropriate blood flow to the developing foetal-pla-
cental unit causing oxidative stress and consequent mis-
carriage [14].
Uterine NK cells and Recurrent Miscarriage
Increased density of uNK cells in pre-implantation
endometrium has been found in women with RM com-
pared to fertile controls [16-19]. However, there are also
studies that have shown no difference in the population
of uNK cells in patients with RM and controls but these
included women with only 2 consecutive miscarriages
[20,21]. Whether high numbers of uNK cells in the mid-
luteal phase predict subsequent miscarriage is controver-
sial. One study suggested that they do [17] but a more
recent slightly larger study refuted this [19]. However,
both studies were small in number and were retrospec-
tively analysed.
Studies on normal and miscarried early pregnancy decid-
uas have also implicated uNK cells in the aetiology of idi-
opathic RM [22,23].
The effect of prednisolone on uNK cells
UNK cells express both glucocorticoid and ER-β receptors
[24]. Thus, therapeutic manipulation of these cells may be
possible. Prednisolone was chosen as the steroid for
manipulation as it is metabolised by the placenta and very
little of the drug reaches the fetus [25]. One woman with
significantly raised uNK cells had 17 miscarriages and was
given 5 mg of prednisolone pre-conceptually. She had a
further 2 miscarriages and then had 20 mgs of pred-
nisolone once a day both pre-conceptually and in early
pregnancy. On this regime, she had a live birth [26].
Next, a prospective study was carried out with 20 mg pred-
nisolone from day 1 to day 21 of the menstrual cycle
which demonstrated a reduction in uNK cells in the pre-
implantation endometrium of patients with idiopathic
RM [18]. This study, carried out in Liverpool investigated
85 women with RM and 18 women with 2 or more nor-Page 2 of 7
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phase endometrial biopsy. The normal range of uNK cells
was defined using the upper end of the inter-quartile
range for the 18 control women. Thus, women with more
than 5% uNK cells per stromal cell were considered to
have high levels. 32 women with RM had high levels of
uNK cells and 29 agreed to take 20 mg prednisolone for 3
weeks and have a second biopsy. In 23 women, the
number of uNK cells decreased. The reduction in uNK cell
density was significant with a mean level of 14% before
treatment to 9% after treatment (p = 0.0004, CI 2.3-12).
Furthermore, 3 women requested a third biopsy after a
further month of prednisolone and in each case, the uNK
cells level had fallen further suggesting that prolonging
the steroid therapy for longer than 3 weeks further reduces
the level of uNK cells. None of these women reported side
effects significant enough to stop the medication.
Aims of trial
The primary aim of this trial is to investigate whether
prednisolone therapy during the first trimester of preg-
nancy is able to reduce the risk of miscarriage and
improve live birth rates in patients with idiopathic RM
and raised uNK cells in the endometrium.
Primary Outcome
The primary outcome is the number of babies born alive.
Secondary Outcomes
They will include:
- Conception rate
- First and second trimester miscarriages
- Number of losses of empty gestation sacs and foetal
losses
- Karyotype of miscarried pregnancies
- Stillbirths
- Intrauterine growth restriction (IUGR) defined as birth
weight below the 5th centile according to customised birth
weight charts
- Pregnancy complications such as pre-eclampsia or gesta-
tional diabetes
- Gestational age at delivery
- Foetal abnormality
- Side effect of steroids (eg: mood changes, weight gain,
increased appetite, indigestion, avascular necrosis of the
hip, hypertension or hyperglycemia)
Methodology
Design
This will be a randomised, double-blind, placebo control-
led trial with an initial pilot phase to assess feasibility of
recruitment and randomisation. Women are recruited
from Liverpool Women's Hospital's recurrent miscarriage
clinic which is the tertiary referral centre for the region and
an endometrial research clinic. Referrals for the research
clinic are from all over UK and Europe following media
publicity surrounding the publication of the case report
about a successful pregnancy with steroid use after 19 con-
secutive miscarriages [26] and national presentations.
When these women are first seen in the RM clinic, or if a
referral letter to the research clinic is received, patient
information leaflets regarding the trial are given or sent to
them for consideration of their participation in this study
(Figure 1). Women willing to participate are encouraged
to ring for an appointment 6-9 days after their luteinising
hormone (LH) surge in a cycle where they have not tried
to conceive (patient information leaflet advises patients to
get an ovulation kit and to use contraception). At this
appointment, a full history is taken and the results of pre-
vious investigations noted to ensure that there is no cause
found for RM. The trial is then explained further and con-
sent obtained to perform a transvaginal scan and an
endometrial biopsy.
The endometrial biopsy is then taken and the sample
fixed in formalin, processed and embedded in paraffin
wax. 3 μm sections are prepared and stained for CD56
using immunohistochemistry. A positive control slide
from a patient known to have high uNK cells and an IgG
mouse negative control is used for every slide undergoing
immunohistochemistry to ensure no false negative or
false positive staining. Next, 10 high-powered fields from
different areas along the epithelial edge of the sample are
selected and photographed. Then, the glandular epithelial
cells and blood vessel are removed electronically. Subse-
quently, the number of CD56 positive and negative cells
in each field are counted using image analysis software.
Image analysis has markedly reduced the inter-observer
error as compared with manual counting [27]. For each
observer, Bland-Altman plots were produced to ensure
that there were no systematic differences in uNK or stro-
mal cell counts between observers. The inter- and intra-
observer co-efficients of variation were 12.2 (SD 6.53)
and 6.8 (SD 4.29) respectively. The normal range was
defined as <5% uNK cells per stromal cell using the upper
end of the interquartile range of control patients from a
previous study [18]. The positive and negative predictivePage 3 of 7
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Results of the uNK cell counts are communicated to the
women by letter with a follow up telephone consultation.
Those with normal uNK cell density are advised to follow
standard management. Those with uNK cell counts of
≥5% are advised to contact the research team as soon as
they are pregnant to be considered for randomisation.
Inclusion Criteria
- 3 or more consecutive miscarriages with no cause found
(idiopathic)
- Less than 40 years old
- ≥5% uNK cells at day LH +6 to +9
Exclusion Criteria
- Known cause for recurrent miscarriage: antiphospholi-
pid syndrome (positive anticardiolipin antibody or lupus
anticoagulant on 2 separate occasion at least 6 weeks
apart), thrombophilia (factor V Leiden mutation, APCR
resistance, protein C or S deficiency, prothrombin
G20210A mutation, antithrombin III deficiency), abnor-
mal thyroid function tests, parental balanced transloca-
tion or uterine anomaly (known subseptate uterus or
cervical weakness diagnosed at hysteroscopy).
- Contraindications to steroid therapy: hypertension, dia-
betes, mental health problems or obesity with BMI >35
- Decline consent to randomisation
Randomisation and blinding
Women meeting the inclusion criteria are scanned after a
positive pregnancy test. If a viable intrauterine pregnancy
between 4-8 weeks gestation is found, then a second con-
sent is obtained for randomisation to either prednisolone
or placebo. Once consent if obtained, women are given
consecutive study numbers then sent to pharmacy. A ded-
icated pharmacist then allocates to the treatment or pla-
cebo group the women using her study number. This
study number allocation is performed by using a ran-
domisation list that was pre-constructed with a computer-
ised random number generator in blocks of 20. All
women are given a pack of tablets by the pharmacist and
advised to take 4 tablets for 6 weeks, 2 tablets for 1 week
and 1 tablet for 1 week. Both prednisolone and placebo
tablets are similar in size and colour and dispensed in
identical packaging. The active tablets consist of 5 mgs of
prednisolone and the placebo is an inert substance spe-
cially made to be identical to the placebo. Women are also
given a chart that tells them how many tablets to take each
day and instructions to mark off each day they take the
study medication. They are then asked to return this chart
to the investigators at 14 weeks gestation so that compli-
ance is monitored. Thus, both the trial investigators and
women are blind to the treatment allocation.
Case report forms (CRF) are then completed and given to
an independent research administrator who enters the
information on a database and keeps them as confidential
trial documentation. The research administrator will gen-
erate reports to the data monitoring committee (DMC) as
necessary.
All women participating in the trial are given a trial ID
card where contact details of the hospital are available to
get in touch with either the chief investigator (CI) or prin-
cipal investigator (PI) in the event of an emergency where
the trial group allocation needs to be identified. The CI or
PI will then authorise the pharmacy department to
unblind the group only if severe illness occurs and the
attending physician needs to know whether the women
had been allocated steroids. The DMC will also be able to
unblind these groups if necessary.
Patient flow during trialFigure 1
Patient flow during trial.
Referral letter from GP/Recurrent Miscarriage Clinic 
Patient information leaflet explaining trial sent or given to patient  
         Patient to ring for appointment  
       6-9 days after LH surge if  
       interested to participate  
STEP 1: SCREENING 
   Take history, and review RM investigations 
      If known cause of recurrent miscarriage  
          Ineligible for trial and for usual care                  
If idiopathic recurrent miscarriage (no cause found) 
Explain trial again and consent taken for screening 
                            Perform endometrial biopsy 
Biopsy analysed in laboratory for uNK cells count 
If uNK <5%      
 Ineligible for trial and for usual care      
??????????  
      Advise woman to contact research team when pregnant 
STEP 2: RANDOMISATION 
      Ultrasound scan performed to ensure intrauterine pregnancy  
    2nd step of trial explained and consent taken for randomisation 
Randomise to either prednisolone or placebo 
   
          2 weekly reassurance  
ultrasound scan and assess 
        side effects (if any) 
   At 12 weeks refer for booking and consultant-led obstetric care 
At 14 weeks collect side effects diary and completed forms 
                Arrange for routine 20 week anomaly scan 
     Arrange for growth scans at 28 and 34 weeks gestation 
Follow up pregnancy outcome data approximately    
               6 weeks after expected due date Page 4 of 7
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After randomisation, women will be offered a 2 weekly
ultrasound scan for reassurance and a clinic consultation
to assess side effects of treatment. This will be done by ask-
ing them about side effects, reviewing the side effect diary,
and measuring the blood pressure until 12 weeks gesta-
tion. If hypertension or any significant side effects
occurred, they will be asked to stop the medication. Any
side effects reported will be assessed in terms of their seri-
ousness, causality and expectedness. If the event was
deemed serious, a serious adverse event or adverse event
(SAE/AE) report form will be completed by the CI or PI
and submitted to the relevant committees. If it was a sus-
pected unexpected serious adverse reaction (SUSAR), then
reporting will be expedited accordingly.
At 12 weeks gestation, women are referred to the hospital
of their choice for booking and consultant-led antenatal
care. At 14 weeks gestation, they are reviewed again and
all the CRF are collected. A routine anomaly scan at 20
weeks gestation and growth scans at 28 and 34 weeks ges-
tation will then be arranged. Another telephone follow-up
consultation will be arranged 6 weeks after the delivery of
the baby to assess the pregnancy and secondary outcomes.
Safety considerations
Prednisolone is commonly used to treat medical condi-
tions in pregnancy and has been given in the first trimester
to women with asthma [28], rheumatoid arthritis [29]
and hyperemesis gravidarum [30] with minimal side
effects. It is metabolised by the placenta to inactive pred-
nisone and thus only about 10% of active drug reaches the
foetus [25]. Although there are concerns of possible com-
plications of intrauterine growth restriction and an associ-
ation with cleft palate from animal studies, more recent
studies, even with postnatal follow-up, have not shown
such complications with prednisolone use [30,31].
Sample size calculation
Preliminary power calculation was based on multiple pre-
sumptions informed by minimal data. The live birth rate
on placebo, is assumed from a previous study where 12
women with >5% uNK cells conceived and 6 subse-
quently miscarried (50%) [17]. We believe an increase in
pregnancy success from 50% to 79% would be clinically
important. At present, there is an 80% pregnancy rate in
the RM clinic in LWH. Thus, to reach statistical signifi-
cance, 68 women will need to be recruited in each group
(80% power, 5% 2-sided alpha). Assuming a 70% accept-
ance rate, we will need to ask 136 women to be ran-
domised. Assuming an 80% conception rate after the
biopsy and a 35% rate of high uNK cells, 694 patients
with idiopathic RM will need to be recruited for endome-
trial biopsies (Figure 2). The current on-going pilot study
can confirm the presumptions made above and provide
more information to perform a definitive power calcula-
tion in the future.
Data Analysis
Data analysis will be performed on an intention to treat
basis using a data analysis plan that will be finalised
before data analysis starts. The outline of the data analysis
plan is as follows.
Power calculation diagramFigure 2
Power calculation diagram.Page 5 of 7
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The results of the trial, including patient flow during the
trial, will be reported in accordance with the guidelines
from the CONSORT (Consolidated Standards of Report-
ing Trials) statement [32].
Analysis will proceed in the following steps:
1. Summary statistics for demographic information
relating to the allocation groups will be tabulated. The
data will be examined to determine the extent to
which the treatment and placebo groups are similar.
2. The primary outcome will be assessed. The live birth
rate in each group will be expressed as a risk ratio with
95% Confidence Intervals. Statistical significance will
be calculated using the Fisher's exact test. A signifi-
cance value of p < 0.05 will be considered significant.
3. Secondary outcomes will be assessed. The rates of
miscarriage, type of miscarriage (sac loss or fetal loss),
karyotype of miscarried pregnancies, conception rate,
gestational age at delivery and pregnancy complica-
tions will be tabulated. For dichotomous categorical
variables, risk ratios and 95% Confidence Intervals
will be calculated. For other categorical variables, a
chi-squared test will be performed. For continuous
variables, non-parametric tests will be used
4. Pre-specified subgroup analyses will include com-
parisons of women with primary and secondary recur-
rent miscarriage.
5. Adverse events. All adverse events will be tabulated
according to allocation group.
6. Trial process measures. The following will be tabu-
lated: how women come to know of the trial, the rate
of acceptance for screening and randomisation, pro-
portion of women who screened high for uNK cells
and compliance to medication will be evaluated.
Trial Management and Monitoring Structure
Ethical and Regulatory Issues
Approval to conduct the trial has been granted from the
Liverpool Local Research Ethics Committee.
The trial is included on the National Institute for Health
Research (NIHR) Clinical Research Portfolio (NIHR CRN
ID: 6567) and is registered with European and interna-
tional clinical trials database (EUDRACT No: 2005-
003307-36, ISRCTN28090716). MHRA approval was also
granted.
Patient Acceptability and Consent
The trial has been discussed with the President of the Mis-
carriage Association, as the patient representative. We
were advised that women who have had recurrent miscar-
riages would be suitable to be randomised to a placebo.
The Miscarriage Association have also agreed to be inde-
pendent advisors to women during the recruitment phase
and throughout the trial. Additionally, women are
informed that if a miscarriage occurred while they are on
the trial, they can choose to have prednisolone in the sub-
sequent pregnancy with the understanding that this is yet
to be proven as an effective treatment.
Women who fit the inclusion criteria will be informed
about the objectives of the study and be given written
information about it. They will then have time to consider
the trial and contact the investigators for a consultation
appointment when they ovulate if interested to partici-
pate. Consent will be obtained by the trial investigators
prior to screening for levels of uNK cells. A separate con-
sent for randomisation into the study is taken when the
woman is found to have raised uNK cells and is pregnant.
Data Monitoring Committee (DMC)
A data monitoring committee (DMC) independent of the
trial investigators has been appointed for the trial to pro-
vide independent review of unblinded data at agreed
intervals to ensure that no harm is being cause by the
treatment. The first DMC meeting will be planned for after
20 patients have been randomised into the trial and
passed 14 weeks gestation. Particular emphasis will be
placed upon monitoring the side effect of steroids, fertility
rate and pregnancy complications.
This committee will also address issues such as:
- Significant problems with trial design or methodology
- Recruitment rate
- Patient's acceptance of the possibility of randomisation
to placebo
The chair of the DMC will report to the Trial Steering
Committee (TSC) approximately 2 weeks after each meet-
ing in accordance with recommended trial oversight.
Steering and Management Committees
A trial steering committee (TSC) and trial management
group (TMG) have been formed to supervise and manage
the trial. The TSC will be responsible for approving the
core protocol and any subsequent amendments. The TMG
will meet every 4-6 months to discuss:
- the recruitment rate and patient acceptability of the trialPage 6 of 7
(page number not for citation purposes)
Trials 2009, 10:102 http://www.trialsjournal.com/content/10/1/102- side effect of steroids
- data collection forms
- potential problems arising from the trial
The TMG will report the above and present any possible
solutions to problems or strategies to improve recruit-
ment to the TSC who will meet when deemed necessary
by the Chief Investigator.
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